Page last updated: 2024-08-26

bismuth and clarithromycin

bismuth has been researched along with clarithromycin in 306 studies

Research

Studies (306)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	89 (29.08)	18.2507
2000's	73 (23.86)	29.6817
2010's	78 (25.49)	24.3611
2020's	66 (21.57)	2.80

Authors

Authors	Studies
de Boer, WA; Tytgat, GN	1
Börsch, G; Labenz, J	1
Coll, I; Espinós, JC; Forné, M; Garau, J; Tresserra, F; Viver, JM	1
Burette, A; Glupczynski, Y	1
Gad, A; Unge, P	1
Cuccurullo, F; Di Iorio, P; Laterza, F; Mezzetti, A; Neri, M; Seccia, G; Susi, D	1
al-Assi, MT; Genta, RM; Graham, DY; Lew, GM; Ramirez, FC	1
Nasu, M	1
Ramírez Ramos, A	1
Boixeda, D; Gisbert, JP; Martín de Argila, C; Monés, J; Mur Villacampa, M; Sáinz Samitier, R	1
Fennerty, MB; Vakil, N	1
Treiber, G	1
Unge, P	1
Caucheteur, B; De Koster, E; Deltenre, M; Jonas, C; Otero, J	1
Gabryelewicz, A	1
Ciociola, AA; McSorley, DJ; Peterson, WL; Sykes, DL; Webb, DD	1
Webb, DD	1
Dammann, HG	1
Hackelsberger, A; Malfertheiner, P	1
Freston, JW; Murphy, K; Taylor, JL; Zagari, M	1
Axon, AT; Ireland, A; Rooprams, PD; Smith, MJ	1
Peterson, WL	1
Drumm, B; Durnin, M; Goggin, N; Moriarty, S; Rowland, M; Walsh, D	1
Damianos, AJ; McGarrity, TJ	1
Lee, SD; Lin, HJ; Lo, WC; Perng, CL; Wang, K	1
Angeletti, S; Annibale, B; Bordi, C; Delle Fave, G; Malagnino, F; Mancino, C; Marignani, M	1
Kim, MJ; Michener, R; Triadafilopoulos, G	1
Danziger, LH; Meyer, JM; Pendland, SL; Ryu, S	1
Hoffman, JS	1
Hogan, J; Krasner, N; Lombard, M; Purkayastha, SK; Tan, WC	1
Bardhan, KD; Dallaire, C; Duggan, AE; Eisold, H	1
Bisso, G; Caroli, M; Celle, G; Mansi, C; Mela, GS; Mele, MR; Olivieri, A; Saggioro, A; Savarino, V; Termini, R; Tosatto, R; Vigneri, S	1
Hamilton, MR; Pounder, RE; Sercombe, JC; Williams, MP	1
Barnett, JL; Chey, WD; DelValle, J; Elta, GH; Fisher, L; Hasler, WL; Nostrant, T; Scheiman, JM	1
Cervantes Bustamante, R; Cuevas, S; Mata Rivera, N; Oyervides Garcia, I; Ramirez Mayans, JA; Zamora Davila, E; Zarate Mondragón, FE	1
Malfertheiner, P; Mégraud, F	1
Keller, JJ; Rauws, EA; Tytgat, GN; van der Hulst, RW	1
Emami, S; Estrada, R; Laine, L; Trujillo, M	1
Minocha, A; Srinivasan, R	1
Donnelly, C; McDowell, S; McLaren, A; Williamson, R	1
Bazzoli, F; Pozzato, P	1
Dixon, JS; Mills, JG; Pipkin, GA; Wood, JR	1
Fennerty, MB	1
Berg, DE; Blaser, MJ; Dubois, A; Fiala, N; Heman-Ackah, LM; Perez-Perez, GI	1
Pipkin, GA; Williamson, R; Wood, JR	2
Bardhan, KD; Jahnsen, J; Lotay, N; Marcelino, M; Roberts, PM; Wurzer, H	1
Scheen, AJ	1
Scott, BB	1
Battaglia, G; Benvenuti, ME; Del Bò, N; Di Mario, F; Donisi, PM; Leandro, G; Pasini, M; Pasquino, M; Vianello, F; Vigneri, S	1
Calvet Calvo, X	1
Bazzoli, F; Cardelli, A; Catalano, FA; Giglio, A; Lami, F; Olivieri, A; Pilotto, A; Pozzato, P; Roda, E; Scarpulla, G; Spadaccini, A; Susi, D; Tosatto, R; Zagari, M	1
Crobach, LF; Geraedts, AA; Kolkman, JJ; Nicolai, JJ; Oudkerk Pool, M; Tan, TG; Timmerman, RJ; Van Der Laan, J; Van Kleef, WA; Wolff, AA	1
de Boer, WA; Haeck, PW; Mulder, CJ; Otten, MH	1
Bazzoli, F; Cannizzaro, O; D'Angelo, A; Ederle, A; Fossi, S; Gerace, G; Iaquinto, G; Olivieri, A; Pozzato, P; Reina, G; Ricciardiello, L; Roda, E; Scarpulla, G; Spadaccini, A; Tosatto, R; Zagari, M	1
Armuzzi, A; Cammarota, G; Cannizzaro, O; Cianei, R; Cuoco, L; Fedeli, G; Fedeli, P; Gasbarrini, A; Gasbarrini, G; Papa, A; Tursi, A	1
Bentivegna, C; Brogna, A; Catalano, F; Catanzaro, R; Cipolla, R; Condorelli, G	1
Di Matteo, G; Dobrilla, G; Dodero, M; Fina, P; Fratton, A; Iaquinto, G; Loriga, P; Marchi, S; Marzio, L; Muratori, R; Olivieri, A; Pacini, D; Saggioro, A; Savarino, V; Spinelli, P; Tosatto, R; Zamboni, G	1
Kleibeuker, JH; Kooy, A; Thijs, JC; van der Wouden, EJ; van Zwet, AA	1
Chan, FK; Cheng, AF; Chung, SC; Lee, YT; Leung, WK; Ling, TK; Sung, JJ; Yung, MY	1
Ciociola, AA; Heath, A; Lanza, FL; McSorley, DJ; Sontag, SJ; Sykes, DL	1
Borody, TJ	1
Coudron, PE; Stratton, CW	2
Howden, CW; Hunt, RH	1
Bardhan, KD; Duggan, AE; Gudjonsson, H; Hoie, O; Kliebe-Frisch, C; Kristensen, ES; Pipkin, GA; Schuetz, E	1
Biagini, R; Bilardi, C; Bisso, G; Celle, G; Mansi, C; Mele, MR; Pivari, M; Savarino, V; Termini, R; Vigneri, S; Zentilin, P	1
Chua, AB; Cutler, A; Ding, RP; Goh, KL; Kandasami, P; Mazlam, MZ; Raj, SM	1
Anderson, SY; El-Zimaity, HM; Graham, DY; Hoffman, J; Osato, MS; Qureshi, W	1
Kleibeuker, JH; Kooy, A; Thijs, JC; Van der Wouden, EJ; Zwet, AA	1
Blanchard, J; Boden, J; Ermak, T; Georgakopoulos, K; Giannasca, P; Gray, H; Hill, J; Ingrassia, J; Kleanthous, H; Lee, CK; Monath, TP; Soike, K; Tibbitts, T; Weltzin, R	1
Ashktorab, H; Hinds, T; Jagtap, J; Kim, KS; Scott, VF; Smoot, DT	1
Cave, DR; Hoffman, JS; Katz, LM	1
Cutler, A; Vakil, N	1
McSorley, DJ; Perschy, TB; Schwartz, HI; Sorrells, SC	1
Cross, R; Grimley, CE; Illing, RC; Lismore, JR; Loft, DE; Nwokolo, CU; O'sullivan, M; Penny, A; Shebani, M	1
Bravo, LE; Correa, P; DeLany, JP; Mera, R; Realpe, JL	1
Neiger, R; Schmassmann, A; Seiler, G	1
Bardhan, KD; Farley, A; French, PC; Paré, P; Roberts, PM; Romãozinho, JM	1
Chan, FK; Cheng, AF; Chung, SC; Lee, YT; Leung, WK; Ling, TK; Suen, R; Sung, JJ; Wu, JC	1
Angeles Arpa, M; Bermejo, F; Boixeda, D; García Arata, I; García Plaza, A; Gisbert, JP; Jesús Higes, M; Martín de Argila, C; Nieves Rincón, M	1
Dagalp, K; Kadayifci, A; Kilinc, R; Uygun, A	1
Carpio, D; Gisbert, JL; Gisbert, JP; Grávalos, RG; Marcos, S; Pajares, JM	1
Mach, T; Zahradnik-Bilska, J	1
Aoyama, N; Kasuga, M; Kita, T; Komada, F; Okumura, K; Shirakawa, K; Tanigawara, Y	1
Borda, F; Domínguez, E; Gisbert, JP; Sainz, R	1
Kerr, TG; Lambert, JR; Midolo, PD; Tee, W	1
Armuzzi, A; Cammarota, G; Cannizzaro, O; Cianci, R; Gasbarrini, A; Gasbarrini, G; Papa, A; Pastorelli, A	1
Armuzzi, A; Cammarota, G; Cannizzaro, O; Cianci, R; Gasbarrini, A; Gasbarrini, G; Gentiloni, N; Ojetti, V; Pastorelli, A; Pirozzi, G	1
Anti, M; Armuzzi, A; Branca, G; Candelli, M; Canducci, F; Fadda, G; Fedeli, G; Gasbarrini, A; Gasbarrini, G; Ojetti, V; Pastorelli, A; Pola, P; Torre, ES	1
Chan, FK; Chung, SC; Ling, TK; Suen, R; Sung, JJ; Wu, JC	1
Brousal, A; Kearney, DJ	1
Ballardini, G; Boni, F; Bortoli, A; Colombo, E; Minoli, G; Spinzi, GC; Venturelli, R	1
Armuzzi, A; Gasbarrini, A; Gasbarrini, G; Ghirlanda, G; Ojetti, V; Pitocco, D; Pola, P; Silveri, NG	1
Bisson, S; Bojarski, C; Epple, HJ; Fromm, M; Kirstein, FW; Riecken, EO; Schulzke, JD	1
Fox, JG; Marini, RP; McColm, AA; Taylor, NS; Williamson, R; Yan, L	1
Bilardi, C; Bisso, G; Borgonovo, G; Borro, P; De Salvo, L; Dulbecco, P; Mansi, C; Pivari, M; Raffaella Mele, M; Savarino, V; Tessieri, L; Vigneri, S; Zentilin, P	1
De Boer, WA; Jansen, JB; Van Oijen, AH; Verbeek, AL	1
Castellote, J; Porta, F	1
Calvet, X; Gabriel, R; Gisbert, JP; González, L; Pajares, JM; Roqué, M	1
Buzás György, M; Illyés, G; Székely, E; Széles, I	1
Bentivegna, C; Branciforte, G; Brogna, A; Catalano, F; Catanzaro, R; Cipolla, R	1
Chiba, N	1
Cabezudo, JG; Ducóns, J; Gomollon, F; Guirao, R; Montoro, M; Santolaria, S	1
Mégraud, F; Roberts, P; Williamson, R	1
Chan, CK; Chu, KM; Fung, FM; Hu, WH; Lai, KC; Lam, SK; Lau, GK; Leung, SY; Wang, WH; Wong, BC; Wong, WM; Yuen, MF; Yuen, ST	1
De Boer, WA; Jansen, JB; Janssen, MJ; Van Oijen, AH; Verbeek, AL	1
Chejfec, G; O'Connell, S; Schnell, T; Seidel, J; Sonnenberg, A; Sontag, SJ	1
Belmonte, A; Cavaliere, C; Ciliberto, E; Fiocca, R; Frandina, C; Giglio, A; Luzza, F; Pallone, F; Saccà, N; Trimboli, V	1
Andriulli, A; Annese, V; Niro, GA; Perri, F; Quitadamo, M; Villani, MR	1
Hopkins, RJ	1
Gisbert, JL; Gisbert, JP; Marcos, S; Pajares, JM	2
Chiba, N; Hunt, RH; Thomson, AB	1
Bardhan, KD; Mitchell, TR; Morris, P; Morton, D; Perry, MJ; Roberts, PM; Rowland, A; Sanders, DS; Thompson, M	1
Bayerdörffer, E; Graham, DY; Miehlke, S	1
Daroch, F; García, A; González, C; Kawaguchi, F; Rivera, N; Solar, H; Vega, E	1
Bujanda, L; Cosme, A; Iriondo, C; Muñoz, C; Sánchez, A; Santos, A	1
Beales, IL	1
Burm, M; Faigel, D; Fennerty, MB; Kelly, C; Magaret, N; Peterson, W	1
Doulgeroglou, V; Kamberoglou, D; Patra, E; Polymeros, D; Sanidas, I; Savva, S; Tzias, V	1
De Francesco, V; Faleo, D; Hassan, C; Ierardi, E; Morini, S; Panella, C; Zullo, A	1
Artikis, V; Georgopoulos, SD; Karatapanis, S; Ladas, SD; Mentis, A; Raptis, SA; Spiliadi, C; Triantafyllou, K	1
Ohkusa, T; Sato, N	1
Gisbert, JP; Pajares, JM	1
Coyle, W; Dunteman, T; Nemec, R; Sullivan, B	1
Bago, J; Bevanda, M; Bilić, A; Halle, ZB; Jandrić, D; Kućisec, N; Strinić, D; Tomić, M	1
Kullavanijaya, P; Tangkijvanich, P; Thong-Ngam, D; Treeprasertsuk, S; Wisedopas, N	1
Farup, PG; Høie, O; Lange, OJ; Tholfsen, J; Torp, R; Wetternus, S	1
Hopkins, RJ; Meyer, JM	1
Chehter, EZ; Eisig, JN; Hashimoto, C; Laudanna, AA; Silva, FM	1
Azagra, R; Calvet, X; Gené, E; Gisbert, JP	1
Laine, L	1
Bästlein, E; Bayerdörffer, E; Haferland, C; Jacobs, E; Kirsch, C; Lehn, N; Miehlke, S; Neumeyer, M; Papke, J; Schneider-Brachert, W; Stolte, M; Vieth, M	1
Barkun, A; Chiba, N; Cockeram, A; Dallaire, C; Fallone, C; Farley, A; Nicholls, B; Simms, L; Veldhuyzen van Zanten, S	1
Balatsinou, C; Caldarella, MP; Cuccurullo, F; Di Bonaventura, G; Lapenna, D; Laterza, F; Milano, A; Neri, M; Piccolomini, R	1
Bianchi Porro, G; Cucino, C; Parente, F	1
Candelli, M; Franceschi, F; Gasbarrini, G; Mettimano, M; Migneco, A; Montebelli, R; Ojetti, V; Savi, L; Specchia, L	1
de Boer, WA; Kuipers, EJ; Kusters, JG	1
Calvet, X; Gené, E; Güell, M; Montserrat, A; Vergara, M	1
Candelli, M; Carloni, E; Cazzato, A; Di Campli, C; Fini, L; Gasbarrini, A; Gasbarrini, G; Nista, EC; Pignataro, G; Zocco, MA	1
Filik, L; Köksal, AS; Odemiş, B; Ozden, A; Parlak, E; Sahin, B; Saşmaz, N; Ulker, A; Yolcu, OF	1
Calvet, X; Gisbert, JP; Gonzalez, L	1
Almeida, JR; Campos, LT; Guerrazzi, F; Lorena, SL; Mesquita, MA; Montes, CG; Zeitune, JM	1
Pan, Y; Xiao, SD; Zhang, L; Zheng, Q	1
Donovan, JL; Egger, M; Harvey, IM; Harvey, RF; Lane, JA; Murray, LJ; Nair, P; Noble, S	1
Benito, LM; Bermejo, F; Bory, F; Castro-Fernández, M; Cosme, A; Ducons, J; Fernández-Bermejo, M; Gisbert, JP; Lamas, E; López-Rivas, L; Olivares, D; Pabón, M; Pérez-Aisa, A	1
Akarca, US; Aydin, A; Musoğlu, A; Onder, GF; Tekin, F; Tunçyürek, M	1
Lule, GN	1
Lee, KH; Tam, YH; Yeung, CK	1
Altintaş, E; Sezgin, O; Tataroğlu, C; Uçbilek, E	1
Pistiolas, D; Robotis, J; Rokkas, T; Sechopoulos, P	1
Choe, YH; Choi, J; Jang, JY; Kim, JS; Kim, KM; Park, HY	1
Arvanitakis, SN; Ashorn, M; Bontems, P; Cadranel, S; Canani, RB; Casswall, T; Celinska-Cedro, D; De Giacomo, C; Drumm, B; Gandullia, P; Gómez, MJ; Gottrand, F; Kalach, N; Oderda, G; Pehlivanoglu, E; Ravelli, A; Roggero, P; Roma, E; Romano, C; Rutigliano, V; Shcherbakov, P; Urruzuno, P	1
Bagci, S; Ilgan, S; Kadayifci, A; Safali, M; Uygun, A	1
Buzás, GM; Széles, I	1
Cakal, B; Kiliç, ZM; Köksal, AS; Kuran, S; Nadir, I; Ozin, YO; Sahin, B	1
Ran, ZH; Shen, J; Tong, JL; Xiao, SD	1
Balkarli, A; Baştürk, A; Cerçi, S; Senol, A; Songür, Y	1
Kandulski, A; Malfertheiner, P; Selgrad, M	1
Chey, WD; Higgins, PD; Luther, J; Moayyedi, P; Schoenfeld, PS; Vakil, N	1
Demir, M; Gokturk, HS; Ozturk, NA; Serin, E; Yilmaz, U	1
Choe, YH; Chung, IS; Kim, HS; Kim, JI; Kim, JJ; Kim, N	1
Hibi, T; Nishizawa, T; Suzuki, H	1
Demir, M; Göktürk, S; Oztürk, NA; Serin, E; Yilmaz, U	1
Huang, X; Li, Y; Shi, R; Yao, L; Zhang, G	1
Gao, XZ; Liu, F; Qiao, XL; Song, WC; Wang, XF	1
Malfertheiner, P	1
Bytzer, P; Dahlerup, JF; Eriksen, JR; Jarbøl, DE; Rosenstock, S; Wildt, S	1
Astegiano, M; Cisarò, F; De Angelis, C; Pellicano, R; Rizzetto, M; Saracco, G	1
Chuah, SK; Hsu, PI; Tsay, FW; Wu, DC	1
Bari, Z; Fakheri, H; Hosseini, V; Taghvaei, T	1
Buzás, GM	1
Liang, X; Liu, W; Lu, H; Sun, Q; Xiao, S; Xu, X; Zhang, W; Zheng, Q	1
Anderson, GL; Baker, LH; Bravo, LE; Chey, WD; Correa, P; Crowley, JJ; Dominguez, RL; Ferreccio, C; Goodman, GE; Greenberg, ER; Herrero, R; Lazcano-Ponce, EC; Martínez, ME; Meza-Montenegro, MM; Morgan, DR; Peña, EM; Peña, R; Salazar-Martínez, E; Sexton, R; Torres, J; Valdivieso, M	1
Gisbert, JP; Marin, AC; McNicholl, AG	1
Graham, DY; Lee, YC; Wu, MS	1
Abbas, Z; Awan, S; Hamid, S; Jafri, F; Jafri, W; Naz, S; Usman, MW; Yakoob, J	1
Ecker, T; Krieger, T; Leandro, G; Malfertheiner, P; Venerito, M	1
Jang, JY; Jung, HK; Kim, CG; Kim, SG; Lee, H; Lee, HL; Lee, YC; Shin, ES; Shin, WG	1
Doğan, Z; Ergül, B; Filik, L; Sarikaya, M	1
Ateş, Y; Avşar, E; Aytuğ, N; Bektaş, A; Bölükbaş, C; Dinçer, D; Ellidokuz, E; Erzin, Y; Güliter, S; Kaymakoğlu, S; Kocakaya, O; Onuk, MD; Poturoğlu, S; Taşan, G; Tiftikçi, A; Türkay, C; Yıldırım, B; Yılmaz, U	1
Bazzoli, F; Calvet, X; Fallone, C; Fischbach, L; Ford, AC; Forman, D; Gisbert, JP; Khan, KJ; Leontiadis, GI; Moayyedi, P; Oderda, G; Tse, F; Yuan, Y	1
Graham, DY; Liou, JM; Wu, JY	1
Heo, J; Jeon, SW	1
Aisa, AP; Barrio, J; Castro-Fernández, M; Cosme, A; Fernández-Bermejo, M; Gisbert, JL; Gisbert, JP; Marcos, S; Marín, AC; McNicholl, AG; Modolell, I; Molina-Infante, J; Rodrigo, L	1
Malfertheiner, P; Selgrad, M	1
Lv, ZF; Wang, B; Wang, H; Wang, YH; Xie, Y; Xiong, HF; Yang, Y	1
Mahachai, V; Siramolpiwat, S; Srinarong, C; Vilaichone, RK; Wongcha-um, A	1
Mahachai, V; Prapitpaiboon, H; Vilaichone, RK	1
Bai, P; He, L; Li, Y; Lin, S; Qian, J; Song, Z; Wang, Y; Xue, Y; Zhang, J; Zhou, L	1
Annibale, B; Calabrese, C; Caselli, M; Di Mario, F; Farinati, F; Gasbarrini, G; Gullini, S; Ierardi, E; Luzza, F; Maconi, G; Ojetti, V; Pretolani, S; Romano, M; Rugge, M; Savio, A; Stockbrugger, R; Zagari, RM	1
Chen, Q; Graham, DY; Liang, X; Liu, W; Lu, H; Xiao, S; Zhang, W	1
Birk, JW; Senatore, FJ; Wilmot, J	1
Asilturk, Z; Basyigit, S; Hokkaomeroglu, M; Kefeli, A; Nazligul, Y; Sapmaz, F; Uzman, M; Yeniova, AO	1
Aslan, M; Basyigit, S; Kefeli, A; Kefeli, TT; Tanas, O; Yeniova, AO	1
Bai, P; He, L; Song, Z; Xue, Y; Zhang, J; Zhou, L	1
Hwang, JC; Kang, JK; Kim, JH; Kim, SS; Lee, KM; Lim, SG; Park, RW; Shin, SJ; Yoon, D	1
Arnold, CA; Coss, E; Cryer, B; Doern, CD; Dunbar, KB; Lam-Himlin, DM; Mitui, M; Okwara, C; Park, JY; Thung, I; Valasek, MA	1
Dore, MP; Graham, DY	1
Chiba, N; Fallone, CA; Fischbach, L; Gisbert, JP; Hunt, RH; Jones, NL; Leontiadis, GI; Marshall, JK; Moayyedi, P; Render, C; van Zanten, SV	1
Oberhofer, E	1
Amorena, E; Campillo, A; Kutz, M; La Iglesia, M; Ostiz, M	1
Atherton, J; Axon, AT; Bazzoli, F; El-Omar, EM; Gasbarrini, A; Gisbert, JP; Graham, DY; Hunt, R; Kuipers, EJ; Malfertheiner, P; Megraud, F; Moayyedi, P; O'Morain, CA; Rokkas, T; Rugge, M; Selgrad, M; Suerbaum, S; Sugano, K	1
Chey, WD; Howden, CW; Leontiadis, GI; Moss, SF	1
Chen, H; Hao, B; Su, J; Zhang, G; Zhang, W; Zhou, X	1
Boyle, B; Brennan, D; Buckley, M; Crotty, P; Doyle, M; Farrell, R; Hussey, M; Kevans, D; Malfertheiner, P; McNamara, D; Megraud, F; Nugent, S; O'Connor, A; O'Morain, C; Smith, S; Weston, S	1
Gisbert, JP; Marin, AC; McNicholl, AG; Nyssen, OP	1
Hu, Y; Lu, NH; Zhu, Y	1
Akay, S; Akpinar, Z; Unsal, B	1
Ang, D; Ang, TL; Chew, CA; Lye, TF	1
Ang, TL; Aung, MM; Chakravuth, O; Chotivitayatarakorn, P; Fock, KM; Goh, KL; Graham, D; Harnsomburana, P; Kositchaiwat, C; Lee, YC; Leelakusolvong, S; Leow, A; Mahachai, V; Mairiang, P; Maneerattanaporn, M; Mya, SM; Pisespongsa, P; Pittayanon, R; Rani, A; Rasachak, B; Rojborwonwitaya, J; Sansak, I; Sollano, JD; Sugano, K; Syam, AF; Treeprasertsuk, S; Trong Quach, D; Vannarath, S; Vilaichone, RK; Wiwattanachang, O; Yamaoka, Y	1
Chen, Y; Ke, L; Li, CJ; Liang, J; Ni, Z; Shang, L; Shi, YQ; Zhang, D; Zhang, LH; Zhu, SH	1
Bellesia, A; De Francesco, V; Palma, R; Panetta, C; Pontone, S; Serviddio, G; Zullo, A	1
Hong, JB; Lu, NH; Luo, LY; Shu, X; Xie, C; Xie, Y; Ye, JF; Zhu, Y; Zhu, ZH	1
Bazzoli, F; Eusebi, LH; Rabitti, S; Zagari, RM	1
Abanades-Tercero, M; Andrés Esteban, EM; Blanco-González, JJ; Jordán-Castro, JA; Muñoz-Gómez, P; Valle-Muñoz, J	1
Coşkun, DÖ; Deniz, K; Gürsoy, Ş; Özbakir, Ö; Yagbasan, A; Yücesoy, M	1
Chan, EW; Chen, L; Cheung, KS; Graham, DY; Leung, WK; Wong, AYS; Wong, ICK; Wong, IOL; Yeung, KF	1
Chen, Y; Du, Y; Li, Y; Liu, D; Lv, N; Pan, X; Wang, H; Wang, J; Wu, K; Xie, Y; Xu, J; Zeng, Z; Zhang, G	1
Chen, Q; Liang, X; Liu, W; Long, X; Lu, H; Yu, L	1
Robotis, J; Rokkas, T; Tsiodras, S	1
Chen, S; Liu, D; Lu, H; Lv, N; Wang, J; Xie, Y; Zeng, Z; Zhang, L; Zhang, Z; Zhu, Z	1
Cai, T; Tang, D; Wang, F; Yao, Y; Yuan, L; Yue, C	1
Chen, PY; Kuo, YT; Liou, JM; Wu, MS	1
Azmi, AN; Goh, KL; Graham, DY; Leow, AH; Loke, MF; Vadivelu, J	1
Bastón-Rey, I; Calviño-Suárez, C; de la Iglesia-García, D; Domínguez-Muñoz, JE; Macías-García, F; Nieto-García, L	1
Cai, Y; Dai, N; Du, Q; Hu, WL; Kao, JY; Kim, JJ; Si, JM; Zhang, YW; Zheng, WF	1
Chung, WC; Kim, YJ; Ko, SW; Lee, SJ	1
Andreev, DN; Dicheva, DT; Maiev, IV; Partzvania-Vinogradova, EV; Yurenev, GL	1
Chen, Y; Li, J; Liu, L; Lu, B; Wang, J	1
Fei, GJ; Guo, T; Li, JN; Li, XQ; Li, Y; Qian, JM; Shu, HJ; Wang, Q; Wu, X	1
Ji, C; Li, L; Li, Y; Liu, J; Sun, Y; Wang, T; Yang, X; Zuo, X	1
Alcedo, J; Alekseenko, S; Alonso-Galan, H; Barrio, J; Bordin, DS; Bujanda, L; Caldas, M; Coba, C; Dominguez-Jimenez, JL; Donday, MG; Fadeenko, G; Fernandez, MC; Gisbert, JP; Gonzalez-Cordero, PL; Hinojosa, J; Ilchishina, T; Lasala, JP; Lucendo, A; McNicholl, AG; Megraud, F; Modolell, I; Molina-Infante, J; Moreno, NF; Nuñez, O; Nyssen, OP; O'Morain, C; Perez-Aisa, Á; Ruiz-Zorrilla Lopez, R; Santaella, I; Sarsenbaeva, AS; Shvetz, O; Varela, P; Vologzhanina, L; Voynovan, I; Zakharova, NV; Zaytsev, O	1
Fallone, CA; Malfertheiner, P; Moss, SF	1
Chen, Q; Chen, Y; Gao, H; Graham, DY; Ji, Y; Li, D; Liang, X; Liu, M; Liu, W; Long, X; Lu, H; Song, Y; Sun, Y; Xu, B; Xu, G; Yu, L; Zhang, W; Zhao, Y	1
Argueta, EA; Moss, SF	1
de Andrés, E; Gómez Hernando, C; Gómez Rodríguez, R; Muñoz Gómez, P; Sierra Bernal, C; Valle Muñoz, J	1
Abrams, G; Adolfsson, E; Agarwal, PK; Akkan, AG; Al Alhareth, NS; Alves, VGL; Armentano, R; Bahroos, E; Baig, M; Baldridge, KK; Barman, S; Bartolucci, C; Basit, A; Bertoli, SV; Bian, L; Bigatti, G; Bobenko, AI; Boix, PP; Bokulic, T; Bolink, HJ; Borowiec, J; Bulski, W; Burciaga, J; Butt, NS; Cai, AL; Campos, AM; Cao, G; Cao, Y; Čapo, I; Caruso, ML; Chao, CT; Cheatum, CM; Chelminski, K; Chen, AJW; Chen, C; Chen, CH; Chen, D; Chen, G; Chen, H; Chen, LH; Chen, R; Chen, RX; Chen, X; Cherdtrakulkiat, R; Chirvony, VS; Cho, JG; Chu, K; Ciurlino, D; Coletta, S; Contaldo, G; Crispi, F; Cui, JF; D'Esposito, M; de Biase, S; Demir, B; Deng, W; Deng, Z; Di Pinto, F; Domenech-Ximenos, B; Dong, G; Drácz, L; Du, XJ; Duan, LJ; Duan, Y; Ekendahl, D; Fan, W; Fang, L; Feng, C; Followill, DS; Foreman, SC; Fortunato, G; Frew, R; Fu, M; Gaál, V; Ganzevoort, W; Gao, DM; Gao, X; Gao, ZW; Garcia-Alvarez, A; Garza, MS; Gauthier, L; Gazzaz, ZJ; Ge, RS; Geng, Y; Genovesi, S; Geoffroy, V; Georg, D; Gigli, GL; Gong, J; Gong, Q; Groeneveld, J; Guerra, V; Guo, Q; Guo, X; Güttinger, R; Guyo, U; Haldar, J; Han, DS; Han, S; Hao, W; Hayman, A; He, D; Heidari, A; Heller, S; Ho, CT; Ho, SL; Hong, SN; Hou, YJ; Hu, D; Hu, X; Hu, ZY; Huang, JW; Huang, KC; Huang, Q; Huang, T; Hwang, JK; Izewska, J; Jablonski, CL; Jameel, T; Jeong, HK; Ji, J; Jia, Z; Jiang, W; Jiang, Y; Kalumpha, M; Kang, JH; Kazantsev, P; Kazemier, BM; Kebede, B; Khan, SA; Kiss, J; Kohen, A; Kolbenheyer, E; Konai, MM; Koniarova, I; Kornblith, E; Krawetz, RJ; Kreouzis, T; Kry, SF; Laepple, T; Lalošević, D; Lan, Y; Lawung, R; Lechner, W; Lee, KH; Lee, YH; Leonard, C; Li, C; Li, CF; Li, CM; Li, F; Li, J; Li, L; Li, S; Li, X; Li, Y; Li, YB; Li, Z; Liang, C; Lin, J; Lin, XH; Ling, M; Link, TM; Liu, HH; Liu, J; Liu, M; Liu, W; Liu, YP; Lou, H; Lu, G; Lu, M; Lun, SM; Ma, Z; Mackensen, A; Majumdar, S; Martineau, C; Martínez-Pastor, JP; McQuaid, JR; Mehrabian, H; Meng, Y; Miao, T; Miljković, D; Mo, J; Mohamed, HSH; Mohtadi, M; Mol, BWJ; Moosavi, L; Mosdósi, B; Nabu, S; Nava, E; Ni, L; Novakovic-Agopian, T; Nyamunda, BC; Nyul, Z; Önal, B; Özen, D; Özyazgan, S; Pajkrt, E; Palazon, F; Park, HW; Patai, Á; Patai, ÁV; Patzke, GR; Payette, G; Pedoia, V; Peelen, MJCS; Pellitteri, G; Peng, J; Perea, RJ; Pérez-Del-Rey, D; Popović, DJ; Popović, JK; Popović, KJ; Posecion, L; Povall, J; Prachayasittikul, S; Prachayasittikul, V; Prat-González, S; Qi, B; Qu, B; Rakshit, S; Ravelli, ACJ; Ren, ZG; Rivera, SM; Salo, P; Samaddar, S; Samper, JLA; Samy El Gendy, NM; Schmitt, N; Sekerbayev, KS; Sepúlveda-Martínez, Á; Sessolo, M; Severi, S; Sha, Y; Shen, FF; Shen, X; Shen, Y; Singh, P; Sinthupoom, N; Siri, S; Sitges, M; Slovak, JE; Solymosi, N; Song, H; Song, J; Song, M; Spingler, B; Stewart, I; Su, BL; Su, JF; Suming, L; Sun, JX; Tantimavanich, S; Tashkandi, JM; Taurbayev, TI; Tedgren, AC; Tenhunen, M; Thwaites, DI; Tibrewala, R; Tomsejm, M; Triana, CA; Vakira, FM; Valdez, M; Valente, M; Valentini, AM; Van de Winckel, A; van der Lee, R; Varga, F; Varga, M; Villarino, NF; Villemur, R; Vinatha, SP; Vincenti, A; Voskamp, BJ; Wang, B; Wang, C; Wang, H; Wang, HT; Wang, J; Wang, M; Wang, N; Wang, NC; Wang, Q; Wang, S; Wang, X; Wang, Y; Wang, Z; Wen, N; Wesolowska, P; Willis, M; Wu, C; Wu, D; Wu, L; Wu, X; Wu, Z; Xia, JM; Xia, X; Xia, Y; Xiao, J; Xiao, Y; Xie, CL; Xie, LM; Xie, S; Xing, Z; Xu, C; Xu, J; Yan, D; Yan, K; Yang, S; Yang, X; Yang, XW; Ye, M; Yin, Z; Yoon, N; Yoon, Y; Yu, H; Yu, K; Yu, ZY; Zhang, B; Zhang, GY; Zhang, H; Zhang, J; Zhang, M; Zhang, Q; Zhang, S; Zhang, W; Zhang, X; Zhang, Y; Zhang, YW; Zhang, Z; Zhao, D; Zhao, F; Zhao, P; Zhao, W; Zhao, Z; Zheng, C; Zhi, D; Zhou, C; Zhou, FY; Zhu, D; Zhu, J; Zhu, Q; Zinyama, NP; Zou, M; Zou, Z	1
Liu, W; Liu, Y; Wang, X; Wang, Y; Zhu, J	1
Arenas, A; Camargo, MC; Echeverría, A; Fuentes-López, E; Harris, P; Jorquera, A; Lavanderos, M; Maquilón, S; Pizarro, M; Quiñones, L; Ríos, C; Riquelme, A; Rojas, L; Sandoval, M; Sepúlveda, R; Serrano, C	1
Jin, Z; Li, Y; Lin, D; Lin, L; Meng, F; Pan, J; Shi, Z; Wu, J; Yang, N; Zhang, J; Zhou, Q	1
Huang, Y; Jiang, Y; Tang, Z; Wang, Y; Yan, W; Ye, Z; Zhang, Y; Zhou, Y	1
Cogdill, AG; Guevara, B	1
Alcaide, N; Areia, M; Ariño, I; Axon, T; Barrio, J; Bordin, D; Boyanova, L; Brglez Jurecic, N; Bujanda, L; Buzas, G; Bytzer, P; Caldas, M; Capelle, L; Castro-Fernández, M; Dominguez-Cajal, M; Garre, A; Gasbarrini, A; Gisbert, JP; Goldis, A; Huguet, JM; Jonaitis, L; Kunovský, L; Kupcinskas, L; Lamy, V; Leja, M; Lerang, F; Lucendo, A; Marcos Pinto, R; María Botargues Bote, J; Mégraud, F; Milosavljevic, T; Modolell, I; Niv, Y; Nyssen, OP; O'Morain, C; Ortuño, J; Pérez Lasala, J; Pérez-Aisa, Á; Perona, M; Phull, P; Przytulski, K; Rodrigo-Sáez, L; Rokkas, T; Romero, PM; Shvets, O; Simsek, I; Tepes, B; Tonkic, A; Venerito, M; Voynovan, I	1
Avallone, L; Bazzoli, F; Compare, D; Dallio, M; Federico, A; Granata, L; Gravina, AG; Loguercio, C; Martorano, M; Miranda, A; Mucherino, C; Nardone, G; Priadko, K; Romano, L; Romano, M; Romiti, A; Romito, MR; Sgambato, D; Tuccillo, C; Zagari, RM	1
Bordin, DS; Embutnieks, YV; Megraud, F; Nyssen, OP; O Morain, C; Perez-Gisbert, J; Voynovan, IN	1
Huang, Y; Lu, J; Lu, X; Miao, S; Sun, H; Wang, Y; Wu, J; Ye, Z; Zhou, Y	1
Calvo, PL; Cisarò, F; Pizzol, A	1
Bazzoli, F; Frazzoni, L; Fuccio, L; Marasco, G; Zagari, RM	1
Abbas, Z; Asim, M; Baqai, K; Laique, N; Samejo, SA	1
Hu, JN; Ji, CR; Ji, R; Li, LX; Li, YQ; Li, YY; Lin, MJ; Liu, J; Qiao, C; Qu, JY; Zuo, XL	1
Chang, YL; Hsu, PI; Kim, SE; Liou, WS; Shiu, SI; Tu, YK; Tung, YC; Wu, MF; Yang, JC; Yeh, HZ	1
Hu, F; Liu, Y; Teng, G; Wang, H; Wang, W; Wu, T	1
Arslan, M; Balamtekin, N; Günal, A	1
Mukhopadhyay, AK; Nandi, SP; Saxena, A	1
Niu, Z; Song, Z; Suo, B; Tian, X; Xue, Y; Zhou, L	1
Cho, SJ; Choi, J; Chung, H; Chung, SJ; Kim, JL; Kim, SG; Lee, A	1
Brglez Jurecic, N; Espada Sanchez, M; Gisbert, J; Mégraud, F; O'Morain, C; Perez Nyssen, O; Tepes, B; Tepes, K	1
Ahn, JY; Choi, KD; Gong, EJ; Jung, HY; Jung, KW; Kim, DH; Lee, GH; Lee, JH; Na, HK; Pih, GY; Song, HJ	1
Bozic, J; Bukic, J; Jukic, I; Leskur, D; Modun, D; Rusic, D; Seselja Perisin, A; Vukovic, J	1
Graham, DY; Howden, CW	1
Han, MH; Hwang, JY; Jeon, SW; Kim, C; Kwon, YH; Lee, JE; Nam, SY; Park, JH; Seo, AN	1
Alsamman, MA; Argueta, EA; D'Agata, EMC; Moss, SF	1
Li, Q; Liu, H; Rao, W; Tian, QJ; Xie, M; Zang, YJ; Zhang, B; Zhang, Q	1
Chung, WC; Kim, DB; Kim, YJ	1
Chen, Y; Deng, X; Hou, X; Shi, Z; Ye, H; Yuan, H; Zhang, X	1
Choi, IJ; Kim, CG; Kim, YI; Lee, JY; Park, B; Park, JY	1
Hu, J; Ji, C; Ji, R; Li, Y; Lin, B; Lin, M; Liu, J; Qi, Q; Qiao, C; Qu, J; Wan, M; Zuo, X	1
Chang, EJ; Chang, YW; Jang, JY; Kim, JW; Moon, JC; Oh, CH; Shin, GY	1
Lee, YC; Liou, JM; Wu, MS	1
Bhatia, S; Chung, H; Huh, KY; Kim, YK; Lee, S; Nakaya, R; Takanami, Y; Yu, KS	1
Cha, JM; Jeon, JW; Kwak, MS; Yoon, JY	1
Ang, D; Ang, TL; Lim, KW; Tan, M; Wong, YJ; Yih Wong, AS	1
Alcedo, J; Amador, J; Bujanda, L; Calvet, X; Castro-Fernández, M; Fernández-Salazar, L; Gené, E; Gisbert, JP; Lanas, Á; Lucendo, AJ; Molina-Infante, J; Nyssen, OP; Pérez-Aisa, A; Puig, I	1
Arcidiacono, PG; Armuzzi, A; Bazzoli, F; Biagi, F; Cannizzaro, R; Cavestro, GM; Ciacci, C; Dajti, E; Frazzoni, L; Marasco, G; Monica, F; Peralta, S; Radaelli, F; Romano, M; Zagari, RM	1
Cho, JH; Jin, SY; Park, S	1
Areia, M; Barrio, J; Beglinger, C; Bordin, D; Boyanova, L; Bujanda, L; Buzas, GM; Bytzer, P; Caldas, M; Capelle, L; Castro-Fernandez, M; Doulberis, M; Fernandez-Salazar, L; Gasbarrini, A; Gisbert, JP; Goldis, A; Huguet, JM; Jonaitis, L; Jurecic, NB; Kunovský, L; Kupčinskas, J; Lamy, V; Lanas, A; Lasala, JP; Leja, M; Lerang, F; Lucendo, AJ; Marcos-Pinto, R; Marlicz, W; Megraud, F; Milivojevic, V; Molina-Infante, J; Morain, CO; Niv, Y; Nyssen, OP; Ortuño, J; Pérez Aísa, Á; Phull, P; Puig, I; Rodrigo, L; Rokkas, T; Sarsenbaeva, AS; Shvets, O; Simsek, I; Smith, S; Tepes, B; Tonkić, A; Vaira, D; Venerito, M; Vologzhanina, L; Voynovan, I	1
Baik, GH; Bang, CS; Jang, HJ; Kae, SH; Kim, HY; Kim, J; Lee, SP; Lim, H; Seo, SI; Shin, WG; Yang, YJ	1
Hubscher, E; Jacob, R; Pelletier, C; Shah, S; Vinals, L; Yadlapati, R	1
Continisio, A; D'Abramo, FS; Di Leo, A; Ierardi, E; Losurdo, G; Piazzolla, M; Pricci, M; Rima, R	1
Daugule, I; Leja, M; Lielause, A; Park, JY; Paršutins, S; Poļaka, I; Rūdule, A; Sjomina, O; Stonāns, I; Vangravs, R	1
Mladenova, I	1
Gou, LZ; Han, TY; Li, XL; Lin, YM; Wang, C; Xu, HM; Yi, GR; Yu, Y; Yun, JW; Zhang, DK	1
Choe, Y; Kim, BW; Kim, JS; Kim, MJ; Na, SY	1
Iakovenko, AV; Ivanov, AN; Soluyanova, IP; Strokova, TV; Vasilyev, NN; Yakovenko, EP	1
Kim, GH; Lee, MW	1
He, XJ; Huang, XY; Li, DL; Li, DZ; Liu, G; Wang, W; Wang, XL	1
Chen, J; Ding, S; Li, T; Liu, Y; Shao, F; Wang, L; Xie, L; Zhang, Z; Zhou, C; Zhou, S; Zhu, B; Zhu, J	1
A Katouah, H; Acker, M; Al Hadi, R; Ali, M; Alserihi, R; Alyami, J; Alzahrani, E; Amirazodi, M; Amrillah, T; Andreassen, OA; Ardiccioni, C; Ask, H; Atzori, C; Ayorech, Z; Azambuja, JH; Azmi, R; Badem, S; Balci, AB; Bali, H; Baranova, NS; Barantsevich, ER; Barocci, S; Bauer, RJ; Bauermeister, JA; Bazhenova, TA; Biagetti, G; Bigdeli, F; Bonar, EE; Bouloumis, T; Bu, Y; Cai, Z; Cakiroglu, B; Canetto, SS; Cao, J; Caucci, S; Cerbo, I; Chen, C; Chen, J; Chen, Q; Chen, Y; Cheng, B; Cheng, X; Chinappi, M; Choya, A; Cicconardi, F; Cipolletta, S; Colasurdo, G; Costabile, BK; Coughlin, LN; Crippa, P; D'Agostino, M; D'Annessa, I; Daryanoosh, F; Das, R; Davey Smith, G; Davidson, BR; Davies, NM; Davis, TME; Davis, WA; de Rivas, B; Demir, D; Deng, Z; Dhanya, TM; Di Marino, D; Divya, KM; Dong, N; Drinkwater, JJ; Ekholuenetale, M; El-Bindary, AA; El-Bindary, MA; El-Desouky, MG; Elsayed, H; Ema, K; Endraswari, PD; Entilli, L; Ettl, T; Eyado, A; Fan, X; Fang, W; Farina, M; Florimbio, AR; Fowobaje, KR; Gaeini, A; Gao, XM; Gao, Y; Ghaemi, R; Ghelardi, E; Gilmutdinov, IF; Gochicoa-Rangel, L; Goncu, MT; Gözüküçük, R; Grammatikopoulos, P; Gu, Y; Guan, ZJ; Gucu, A; Guldberg, R; Gungor, O; Guo, W; Gutiérrez-Ortiz, JI; Guzmán-Boulloud, N; Guzmán-Valderrábano, C; Głuszko, A; Hama, A; Hamada, M; Han, J; Hashimoto, T; Havdahl, A; Hayashita, T; He, X; Helgeland, Ø; Hinck, AP; Hinck, CS; Holtzapple, M; Hou, Y; Howe, LD; Hu, B; Hu, H; Huang, L; Huang, Z; Hughes, AM; Hussain, G; Ibidoja, OJ; Ichikawa, D; Imber, C; Islam, MR; Iype, S; Jaber, J; Jacobs, R; Jafry, AT; Ji, L; Ji, X; Jiang, L; Jiang, Y; Jie, HFM; Jie, HM; Johansen, MP; Johansson, S; Juan, LX; Juan, W; Kahraman, N; Kallinger, I; Kang, H; Karakulova, YV; Kärmer, T; Kataoka, S; Kato, K; Kawashima, N; Kazim, AH; Khalil, MR; Kitazawa, H; Klimesova, YM; Kojima, S; Kose, M; Kostakis, ID; Koushkie Jahromi, M; Krishna, GA; Krizova, D; La Teana, A; Lan, K; Li, J; Li, JZ; Li, M; Li, R; Li, S; Li, Y; Li, Z; Liu, H; Liu, J; Liu, KG; Liu, L; Liu, Q; Liu, T; Liu, X; Lomachenko, KA; López-Fonseca, R; Ludwig, N; Luo, A; Luo, L; Luo, Y; Lupetti, A; M El-Metwaly, N; Ma, K; Maemura, R; Magnus, P; Manakin, YV; Mancia, F; Mashood, LO; Matsumoto, K; Mehrabi, A; Meier, JK; Mekonnen, Y; Mencarelli, D; Menzo, S; Mikagi, A; Mironov, VS; Misawa-Suzuki, T; Miwata, S; Mizuta, Y; Mohanan, PV; Mondal, J; Morici, P; Morita, K; Morozzo Della Rocca, B; Morris, T; Morsali, A; Morzhukhina, MV; Motta, S; Muramatsu, H; Naidu, R; Narita, A; Narita, K; Nasralla, D; Nemcokova, M; Netukova, M; Nishikawa, E; Nishio, N; Niu, X; Niu, Y; Njølstad, P; Notarstefano, V; Nugroho, MA; Nørgård, BM; Okuno, Y; Olokede, O; Ong, SP; Osailan, A; Ouyang, Z; Ozyazicioglu, AF; Pan, F; Parui, A; Paul, R; Pavoni, E; Payne, TE; Peng, X; Pérez-Padilla, R; Perta, N; Peter, SC; Pierantoni, L; Pietrowska, M; Pissanou, T; Pollok, JM; Prasetio, A; Putra, FS; Qiang, C; Qiao, L; Qutob, HMH; Raptis, DA; Razzo, BM; Reichborn-Kjennerud, T; Reichert, TE; Remigio-Luna, A; Rexha, J; Rivani, E; Rizzato, C; Romagnoli, A; Rossolini, GM; Sa, LY; Saad, RA; Sakaguchi, H; Salesi, M; Salsabilla, Z; Sanderson, E; Sanderson, P; Savitha, DP; Schulz, D; Seker, IB; Selvaganapathy, PR; Sha, D; Shah, SF; Shaikhomar, OA; Sharma, D; Shi, C; Shi, P; Shrotri, A; Sidiq, DH; Simonov, SV; Singh, AK; Song, C; Song, T; Spanier, G; Spoerl, S; Staropoli, A; Statsenko, ME; Steinhauer, S; Stosic, A; Studeny, P; Sugaya, T; Sun, S; Sun, X; Sunbul, SA; Supandi, AR; Suzuki, K; Suzuki, Y; Szczepański, MJ; Takahashi, Y; Taniguchi, R; Tao, Y; Tesli, M; Thirión-Romero, I; Tong, D; Trucchi, E; Tsuchido, Y; Turchetti, C; Turkina, SV; Turner, AW; Uldbjerg, N; Vinale, F; Wakamatsu, M; Walton, MA; Wang, C; Wang, Q; Wang, W; Wang, Y; Wang, Z; Wehberg, S; Wei, ZL; Wen, B; Whiteside, TL; Whittingham, MS; Widodo, ADW; Widłak, P; Wright, AI; Wu, H; Wu, Y; Wu, YL; Xiang, LG; Xiao, G; Xie, B; Xie, L; Xin, H; Xiong, J; Xiong, X; Xu, C; Xu, S; Yagubskii, EB; Yakushev, IA; Yang, H; Yang, J; Yao, J; Yao, ZX; Ye, J; Yerneni, SS; Yirgu, A; Yoshida, N; Yoshida, T; Young, SD; Yu, DN; Yuksel, A; Zac, J; Zac, S; Zarifkar, AH; Zhai, Y; Zhang, F; Zhang, H; Zhang, JW; Zhang, L; Zhang, Q; Zhang, X; Zhang, Y; Zhao, D; Zhao, J; Zhao, M; Zheng, D; Zheng, J; Zhou, G; Zhou, H; Zhu, P; Zhu, T; Zhu, Y; Zimmerman, MA; Zou, X	1
Bair, MJ; Chang, CY; Chen, CC; Chen, CY; Chen, MJ; Chen, PY; Chiu, MC; Chou, CK; El-Omar, EM; Fang, YJ; Hsu, YC; Hu, WH; Jiang, XT; Kuo, CC; Lee, JY; Lin, JT; Liou, JM; Luo, JC; Shun, CT; Tsai, MH; Tseng, CH; Wu, MS; Yang, TH; Yu, CC	1
Niu, Z; Ren, X; Song, Z; Suo, B; Tian, X; Xue, Y; Zhou, L	1
Love, BL; Yunusa, I	1
Dang, YN; Gao, X; Li, LR; Li, WJ; Li, X; Qian, HS; Xu, XB; Yang, Z; Yuan, L; Zhang, GX; Zhang, M; Zhang, WF	1
Ding, YM; Duan, M; Han, ZX; Kong, QZ; Li, YQ; Li, YY; Lin, BS; Lin, MJ; Liu, J; Mu, YJ; Wan, M; Wang, J; Wang, ST; Zhang, WL; Zuo, XL	1
Chua, EG; Gao, X; Han, X; Lai, B; Marshall, BJ; Tay, CY; Wang, X; Wei, X; Yu, X; Zhang, X	1
Chen, HW; Liu, JJ; Lu, Y; Peng, X; Su, PZ; Wan, Y; Yao, JY; Yu, J; Zhang, M; Zhi, M	1
Fan, LL; Guo, Y; He, P; Hu, J; Lan, CH; Liu, YX; Mei, H; Pan, J; Su, NY; Sun, WJ; Wang, XW; Zhang, DK; Zou, PY	1
Ding, YM; Li, YY	1
Chan, P; Cheung, K; Deng, Z; Han, S; Li, K; Li, Y; Luo, X; Lyu, T; Ni, L	1
Chen, S; Dong, Q; Liu, Y; Shen, W; Shi, Y	1
Du, Q; Li, Y; Liao, O; Liu, X; Lou, G; Wang, Y; Wu, H; Wu, Y; Ye, J	1
Bae, JH; Jo, HH; Kim, EY; Kwon, JG	1
Ang, TL; Aye, TT; Basir, DN; Lee, YY; Luu, MN; Mahachai, V; Miftahussurur, M; Quach, DT; Sollano, JD; Vannarath, S; Vilaichone, RK; Vutha, K	1
Eiamsitrakoon, T; Graham, DY; Mahachai, V; Ratana-Amornpin, S; Sanglutong, L; Siramolpiwat, S	1
Cho, KB; Jung, HR; Kim, SW; Lee, JW; Lee, JY; Lee, YJ; Park, M	1

Reviews

67 review(s) available for bismuth and clarithromycin

Article	Year
The best therapy for Helicobacter pylori infection: should efficacy or side-effect profile determine our choice? Scandinavian journal of gastroenterology, 1995, Volume: 30, Issue:5 Topics: Amoxicillin; Anti-Bacterial Agents; Bismuth; Clarithromycin; Clinical Trials as Topic; Drug Resistance, Microbial; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans; Metronidazole; Omeprazole; Organometallic Compounds; Randomized Controlled Trials as Topic; Tetracycline	1995
Helicobacter pylori: the place of the new macrolides in the eradication of the bacteria in peptic ulcer disease. Infection, 1995, Volume: 23 Suppl 1 Topics: Anti-Bacterial Agents; Bismuth; Clarithromycin; Drug Resistance, Microbial; Drug Therapy, Combination; Female; Gastritis, Atrophic; Helicobacter Infections; Helicobacter pylori; Humans; Hydrogen-Ion Concentration; Male; Omeprazole; Peptic Ulcer; Treatment Outcome; Uncoupling Agents	1995
Antibacterial therapy of Helicobacter pylori-associated peptic ulcer disease: a new strategy. The Swedes go for it. Journal of clinical gastroenterology, 1994, Volume: 19, Issue:1 Topics: Amoxicillin; Anti-Ulcer Agents; Bismuth; Clarithromycin; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans; Omeprazole; Peptic Ulcer	1994
[Helicobacter pylori infections]. Nihon Naika Gakkai zasshi. The Journal of the Japanese Society of Internal Medicine, 1993, Mar-10, Volume: 82, Issue:3 Topics: Amphotericin B; Bismuth; Clarithromycin; Drug Resistance, Microbial; Gastritis; Helicobacter Infections; Helicobacter pylori; Humans; Peptic Ulcer; Tetracyclines	1993
[Treatment of Helicobacter pylori infection: current status]. Revista de gastroenterologia del Peru : organo oficial de la Sociedad de Gastroenterologia del Peru, 1995, Volume: 15 Suppl 1 Topics: Antacids; Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; Clarithromycin; Drug Administration Schedule; Helicobacter Infections; Helicobacter pylori; Humans; Omeprazole; Time Factors	1995
The influence of drug dosage on Helicobacter pylori eradication: a cost-effectiveness analysis. The American journal of gastroenterology, 1996, Volume: 91, Issue:2 Topics: Amoxicillin; Antacids; Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; Clarithromycin; Cost-Benefit Analysis; Drug Therapy, Combination; Duodenal Ulcer; Helicobacter Infections; Helicobacter pylori; Humans; Imidazoles; Omeprazole; Penicillins; Regression Analysis; Stomach Ulcer; Tetracycline; Time Factors	1996
Review of Helicobacter pylori eradication regimens. Scandinavian journal of gastroenterology. Supplement, 1996, Volume: 215 Topics: Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; Clarithromycin; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Histamine H2 Antagonists; Humans; Omeprazole	1996
[How to eradicate Helicobacter pylori in 1995? Critical review of available treatments]. Gastroenterologie clinique et biologique, 1996, Volume: 20, Issue:1 Pt 2 Topics: Amoxicillin; Antacids; Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; Clarithromycin; Drug Therapy, Combination; Helicobacter Infections; Humans; Omeprazole; Penicillins; Ranitidine	1996
Critical evaluation of the treatment of peptic ulcer diseases associated with Helicobacter pylori infection. Journal of physiology and pharmacology : an official journal of the Polish Physiological Society, 1996, Volume: 47, Issue:1 Topics: Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; Clarithromycin; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans; Metronidazole; Peptic Ulcer; Tetracyclines; Tinidazole	1996
[Helicobacter pylori eradication: triple therapy versus dual therapy]. Fortschritte der Medizin, 1996, Feb-10, Volume: 114, Issue:4 Topics: Amoxicillin; Anti-Ulcer Agents; Bismuth; Clarithromycin; Clinical Trials as Topic; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans; Metronidazole; Omeprazole; Peptic Ulcer; Tetracycline; Tinidazole; Treatment Outcome	1996
A risk-benefit assessment of drugs used in the eradication of Helicobacter pylori infection. Drug safety, 1996, Volume: 15, Issue:1 Topics: Amoxicillin; Anti-Bacterial Agents; Bismuth; Clarithromycin; Drug Therapy, Combination; Dyspepsia; Helicobacter Infections; Helicobacter pylori; Histamine H2 Antagonists; Humans; Nitroimidazoles; Omeprazole; Penicillins; Peptic Ulcer; Proton Pump Inhibitors; Risk Assessment; Tetracyclines	1996
Pharmacoeconomic comparison of treatments for the eradication of Helicobacter pylori. Archives of internal medicine, 1997, Jan-13, Volume: 157, Issue:1 Topics: Anti-Bacterial Agents; Bismuth; Clarithromycin; Clinical Trials as Topic; Cost-Benefit Analysis; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans; Metronidazole; Monte Carlo Method; Organometallic Compounds; Patient Compliance; Proton Pump Inhibitors; Recurrence; Salicylates; Tetracycline; Treatment Outcome	1997
The role of antisecretory drugs in the treatment of Helicobacter pylori infection. Alimentary pharmacology & therapeutics, 1997, Volume: 11 Suppl 1 Topics: Amoxicillin; Antacids; Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; Clarithromycin; Drug Synergism; Drug Therapy, Combination; Enzyme Inhibitors; Helicobacter Infections; Helicobacter pylori; Histamine H2 Antagonists; Humans; Hydrogen-Ion Concentration; Metronidazole; Omeprazole; Penicillins; Proton Pump Inhibitors	1997
Treatment strategies for Helicobacter pylori infection. American family physician, 1997, Volume: 55, Issue:8 Topics: Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; Clarithromycin; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans; Metronidazole; Omeprazole; Organometallic Compounds; Penicillins; Peptic Ulcer; Protein Synthesis Inhibitors; Salicylates; Tetracycline	1997
Treatment of Helicobacter pylori infection: a review of the world literature. Helicobacter, 1996, Volume: 1, Issue:1 Topics: Amoxicillin; Antacids; Bismuth; Clarithromycin; Drug Administration Schedule; Drug Resistance, Microbial; Drug Therapy, Combination; Enzyme Inhibitors; Gastritis; Helicobacter Infections; Helicobacter pylori; Humans; Metronidazole; Omeprazole; Proton Pump Inhibitors; Smoking; Tetracycline; Treatment Outcome	1996
Therapy of H. pylori infection. Journal of physiology and pharmacology : an official journal of the Polish Physiological Society, 1997, Volume: 48 Suppl 4 Topics: Antacids; Anti-Bacterial Agents; Anti-Ulcer Agents; Antitrichomonal Agents; Bismuth; Clarithromycin; Clinical Trials as Topic; Drug Administration Schedule; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans; Omeprazole; Ranitidine; Tinidazole	1997
Ranitidine bismuth citrate plus clarithromycin for the eradication of H. pylori. Journal of physiology and pharmacology : an official journal of the Polish Physiological Society, 1997, Volume: 48 Suppl 4 Topics: Anti-Bacterial Agents; Bismuth; Clarithromycin; Clinical Trials as Topic; Drug Synergism; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Histamine H2 Antagonists; Humans; Ranitidine	1997
New options in Helicobacter pylori eradication: efficacy, resistance and synergy. Scandinavian journal of gastroenterology. Supplement, 1998, Volume: 225 Topics: Anti-Bacterial Agents; Bismuth; Clarithromycin; Drug Resistance, Microbial; Drug Synergism; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Histamine H2 Antagonists; Humans; Ranitidine	1998
[Treatment of Helicobacter pylori infections]. Gastroenterologia y hepatologia, 1998, Volume: 21, Issue:4 Topics: Amoxicillin; Antacids; Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; Clarithromycin; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans; Metronidazole; Omeprazole; Penicillins; Tetracycline; Time Factors	1998
Review article: one-week clarithromycin triple therapy regimens for eradication of Helicobacter pylori. Alimentary pharmacology & therapeutics, 1998, Volume: 12, Issue:9 Topics: Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; Clarithromycin; Helicobacter Infections; Helicobacter pylori; Humans; Proton Pump Inhibitors; Ranitidine	1998
[Helicobacter pylori infection. The Spanish consensus report. The Spanish Consensus Conference Group]. Revista espanola de enfermedades digestivas, 1999, Volume: 91, Issue:11 Topics: Amoxicillin; Antacids; Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; Clarithromycin; Duodenal Ulcer; Duodenitis; Gastrectomy; Helicobacter Infections; Helicobacter pylori; Histamine H2 Antagonists; Humans; Lymphoma, B-Cell, Marginal Zone; Organometallic Compounds; Penicillins; Proton Pump Inhibitors; Ranitidine; Stomach Neoplasms; Stomach Ulcer	1999
Review article: treatment of Helicobacter pylori infection with ranitidine bismuth citrate- or proton pump inhibitor-based triple therapies. Alimentary pharmacology & therapeutics, 2000, Volume: 14, Issue:8 Topics: Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; Clarithromycin; Drug Resistance, Microbial; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans; Nitroimidazoles; Penicillins; Proton Pump Inhibitors; Ranitidine; Treatment Outcome	2000
Helicobacter pylori eradication: proton pump inhibitor vs. ranitidine bismuth citrate plus two antibiotics for 1 week-a meta-analysis of efficacy. Alimentary pharmacology & therapeutics, 2000, Volume: 14, Issue:9 Topics: Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; Clarithromycin; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans; Nitroimidazoles; Proton Pump Inhibitors; Randomized Controlled Trials as Topic; Ranitidine	2000
Ranitidine bismuth citrate. Canadian journal of gastroenterology = Journal canadien de gastroenterologie, 2001, Volume: 15, Issue:6 Topics: Amoxicillin; Anti-Ulcer Agents; Bismuth; Clarithromycin; Drug Therapy, Combination; Helicobacter pylori; Humans; Peptic Ulcer; Ranitidine	2001
Treatment of Helicobacter pylori infection. Seminars in gastrointestinal disease, 2001, Volume: 12, Issue:3 Topics: Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; Clarithromycin; Drug Resistance; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans; Metronidazole; Proton Pump Inhibitors; Tetracycline	2001
[Proton pump inhibitor-based quadruple therapy regimen for Helicobacter pylori infection]. Nihon rinsho. Japanese journal of clinical medicine, 2002, Volume: 60 Suppl 2 Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Benzimidazoles; Bismuth; Clarithromycin; Drug Therapy, Combination; Enzyme Inhibitors; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Metronidazole; Omeprazole; Proton Pump Inhibitors; Rabeprazole; Tetracycline	2002
Review article: Helicobacter pylori "rescue" regimen when proton pump inhibitor-based triple therapies fail. Alimentary pharmacology & therapeutics, 2002, Volume: 16, Issue:6 Topics: Amoxicillin; Anti-Bacterial Agents; Anti-Infective Agents; Bismuth; Clarithromycin; Drug Resistance, Microbial; Drug Therapy, Combination; Enzyme Inhibitors; Helicobacter Infections; Histamine H2 Antagonists; Humans; Metronidazole; Patient Care Planning; Penicillins; Proton Pumps; Ranitidine; Recurrence	2002
Triple vs. quadruple therapy for treating Helicobacter pylori infection: a meta-analysis. Alimentary pharmacology & therapeutics, 2003, May-01, Volume: 17, Issue:9 Topics: Amoxicillin; Antacids; Anti-Bacterial Agents; Bismuth; Clarithromycin; Ditiocarb; Drug Resistance, Bacterial; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans; Metronidazole; Proton Pump Inhibitors; Randomized Controlled Trials as Topic; Tetracycline	2003
Is it time for quadruple therapy to be first line? Canadian journal of gastroenterology = Journal canadien de gastroenterologie, 2003, Volume: 17 Suppl B Topics: Amoxicillin; Antacids; Anti-Infective Agents; Bismuth; Clarithromycin; Clinical Trials as Topic; Drug Therapy, Combination; Duodenal Ulcer; Helicobacter Infections; Helicobacter pylori; Humans; Metronidazole; Peptic Ulcer; Proton Pump Inhibitors; Randomized Controlled Trials as Topic; Time Factors	2003
Treatment options for patients with Helicobacter pylori infection resistant to one or more eradication attempts. Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver, 2003, Volume: 35, Issue:8 Topics: Amoxicillin; Anti-Bacterial Agents; Anti-Infective Agents; Anti-Ulcer Agents; Bismuth; Clarithromycin; Drug Resistance, Multiple, Bacterial; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans; Metronidazole; Proton Pump Inhibitors; Ranitidine	2003
Sequential therapy; a new treatment for Helicobacter pylori infection. But is it ready for general use? Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver, 2004, Volume: 36, Issue:5 Topics: Amoxicillin; Anti-Bacterial Agents; Anti-Infective Agents; Anti-Ulcer Agents; Bismuth; Clarithromycin; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans; Metronidazole; Proton Pump Inhibitors; Ranitidine; Tetracycline	2004
Treatment of H. pylori infection: a review. Current medicinal chemistry, 2005, Volume: 12, Issue:4 Topics: Amoxicillin; Animals; Anti-Bacterial Agents; Bismuth; Clarithromycin; Fluoroquinolones; Furazolidone; Helicobacter Infections; Helicobacter pylori; Humans; Macrolides; Ofloxacin; Polypharmacy; Ranitidine; Rifabutin	2005
Systematic review and meta-analysis: proton pump inhibitor vs. ranitidine bismuth citrate plus two antibiotics in Helicobacter pylori eradication. Helicobacter, 2005, Volume: 10, Issue:3 Topics: Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; Clarithromycin; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans; Nitroimidazoles; Proton Pump Inhibitors; Randomized Controlled Trials as Topic; Ranitidine	2005
Sequential therapy vs. standard triple therapies for Helicobacter pylori infection: a meta-analysis. Journal of clinical pharmacy and therapeutics, 2009, Volume: 34, Issue:1 Topics: Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; Clarithromycin; Drug Administration Schedule; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans; Omeprazole; Proton Pump Inhibitors; Ranitidine; Tinidazole; Treatment Outcome	2009
Helicobacter pylori: diagnosis and treatment. Current opinion in gastroenterology, 2009, Volume: 25, Issue:6 Topics: Amoxicillin; Bismuth; Clarithromycin; Drug Resistance, Bacterial; Drug Therapy, Combination; Fluoroquinolones; Helicobacter Infections; Helicobacter pylori; Humans; Metronidazole; Ofloxacin; Practice Guidelines as Topic; Proton Pump Inhibitors; Rifabutin; Treatment Failure	2009
Empiric quadruple vs. triple therapy for primary treatment of Helicobacter pylori infection: Systematic review and meta-analysis of efficacy and tolerability. The American journal of gastroenterology, 2010, Volume: 105, Issue:1 Topics: Amoxicillin; Antacids; Anti-Bacterial Agents; Anti-Infective Agents; Bismuth; Clarithromycin; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans; Metronidazole; Outcome Assessment, Health Care; Patient Compliance; Practice Guidelines as Topic; Proton Pump Inhibitors; Randomized Controlled Trials as Topic; Tetracycline	2010
Helicobacter pylori eradication therapy. Future microbiology, 2010, Volume: 5, Issue:4 Topics: Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; Clarithromycin; Drug Resistance, Bacterial; Guidelines as Topic; Helicobacter Infections; Helicobacter pylori; Humans; Levofloxacin; Metronidazole; Ofloxacin; Proton Pump Inhibitors; Ranitidine; Tetracycline; Treatment Failure; Treatment Outcome	2010
Advantages of Moxifloxacin and Levofloxacin-based triple therapy for second-line treatments of persistent Helicobacter pylori infection: a meta analysis. Wiener klinische Wochenschrift, 2010, Volume: 122, Issue:13-14 Topics: Anti-Infective Agents; Aza Compounds; Bismuth; Clarithromycin; Drug Administration Schedule; Drug Resistance, Multiple, Bacterial; Drug Therapy, Combination; Fluoroquinolones; Gastritis; Helicobacter Infections; Helicobacter pylori; Humans; Levofloxacin; Moxifloxacin; Ofloxacin; Proton Pump Inhibitors; Quinolines; Randomized Controlled Trials as Topic; Recurrence; Retreatment	2010
Diagnosis and treatment of Helicobacter pylori infection. Danish medical bulletin, 2011, Volume: 58, Issue:4 Topics: Amoxicillin; Anti-Bacterial Agents; Antidiarrheals; Bismuth; Clarithromycin; Denmark; Drug Therapy, Combination; Dyspepsia; Helicobacter Infections; Helicobacter pylori; Humans; Lymphoma, B-Cell, Marginal Zone; Metronidazole; Organometallic Compounds; Peptic Ulcer; Proton Pump Inhibitors; Salicylates; Stomach Neoplasms; Tetracycline	2011
A new look at anti-Helicobacter pylori therapy. World journal of gastroenterology, 2011, Sep-21, Volume: 17, Issue:35 Topics: Amoxicillin; Anti-Infective Agents; Bismuth; Clarithromycin; Drug Resistance, Bacterial; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans; Levofloxacin; Metronidazole; Ofloxacin; Tetracycline	2011
[Helicobacter pylori - 2012]. Orvosi hetilap, 2012, Sep-09, Volume: 153, Issue:36 Topics: Algorithms; Antacids; Anti-Bacterial Agents; Bismuth; Clarithromycin; Drug Resistance, Microbial; Drug Therapy, Combination; Emigrants and Immigrants; Endoscopy, Gastrointestinal; Europe; Helicobacter Infections; Helicobacter pylori; Humans; Hungary; In Situ Hybridization, Fluorescence; Levofloxacin; Ofloxacin; Peptic Ulcer; Polymerase Chain Reaction; Stomach Neoplasms	2012
A review of rescue regimens after clarithromycin-containing triple therapy failure (for Helicobacter pylori eradication). Expert opinion on pharmacotherapy, 2013, Volume: 14, Issue:7 Topics: Amoxicillin; Anti-Bacterial Agents; Bismuth; Clarithromycin; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Resistance, Bacterial; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans; Levofloxacin; Metronidazole; Ofloxacin; Proton Pump Inhibitors; Treatment Failure	2013
Meta-analysis of bismuth quadruple therapy versus clarithromycin triple therapy for empiric primary treatment of Helicobacter pylori infection. Digestion, 2013, Volume: 88, Issue:1 Topics: Anti-Bacterial Agents; Bismuth; Clarithromycin; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans; Metronidazole; Proton Pump Inhibitors; Tetracycline	2013
Optimum duration of regimens for Helicobacter pylori eradication. The Cochrane database of systematic reviews, 2013, Dec-11, Issue:12 Topics: Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; Clarithromycin; Drug Administration Schedule; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans; Nitroimidazoles; Proton Pump Inhibitors; Quinolones	2013
Evidence-based recommendations for successful Helicobacter pylori treatment. Expert review of gastroenterology & hepatology, 2014, Volume: 8, Issue:1 Topics: Amoxicillin; Anti-Bacterial Agents; Bismuth; Clarithromycin; Drug Therapy, Combination; Evidence-Based Medicine; Helicobacter Infections; Helicobacter pylori; Humans; Proton Pump Inhibitors; Treatment Outcome	2014
Optimal treatment strategy for Helicobacter pylori: era of antibiotic resistance. World journal of gastroenterology, 2014, May-21, Volume: 20, Issue:19 Topics: Amoxicillin; Bismuth; Clarithromycin; Drug Administration Schedule; Drug Resistance, Bacterial; Helicobacter Infections; Helicobacter pylori; Humans; Levofloxacin; Microbial Sensitivity Tests; Polymerase Chain Reaction; Proton Pump Inhibitors; Treatment Outcome	2014
Helicobacter pylori. Current opinion in gastroenterology, 2014, Volume: 30, Issue:6 Topics: Anti-Bacterial Agents; Bismuth; Clarithromycin; Drug Resistance, Bacterial; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans; Levofloxacin; Metronidazole; Proton Pump Inhibitors; Stomach Neoplasms	2014
Review: efficacy and safety of hybrid therapy for Helicobacter pylori infection: a systematic review and meta-analysis. Helicobacter, 2015, Volume: 20, Issue:2 Topics: Amoxicillin; Anti-Infective Agents; Bismuth; Clarithromycin; Drug Therapy, Combination; Helicobacter Infections; Humans; Metronidazole; Proton Pump Inhibitors; Randomized Controlled Trials as Topic; Treatment Outcome	2015
Helicobacter pylori treatment: Still a work in progress. Postgraduate medicine, 2016, Volume: 128, Issue:1 Topics: Amoxicillin; Antacids; Anti-Bacterial Agents; Bismuth; Clarithromycin; Drug Administration Schedule; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans; Practice Guidelines as Topic; Proton Pump Inhibitors; Treatment Outcome	2016
Helicobacter pylori therapy: a paradigm shift. Expert review of anti-infective therapy, 2016, Volume: 14, Issue:6 Topics: Amoxicillin; Anti-Infective Agents; Bismuth; Clarithromycin; Drug Resistance, Bacterial; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans; Metronidazole; Practice Guidelines as Topic; Proton Pump Inhibitors; Standard of Care; Treatment Outcome	2016
The Toronto Consensus for the Treatment of Helicobacter pylori Infection in Adults. Gastroenterology, 2016, Volume: 151, Issue:1 Topics: Adult; Amoxicillin; Anti-Infective Agents; Bismuth; Canada; Clarithromycin; Drug Administration Schedule; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans; Levofloxacin; Metronidazole; Proton Pump Inhibitors; Tetracycline	2016
Efficacy and Safety of Quinolone-Containing Rescue Therapies After the Failure of Non-Bismuth Quadruple Treatments for Helicobacter pylori Eradication: Systematic Review and Meta-Analysis. Drugs, 2017, Volume: 77, Issue:7 Topics: Amoxicillin; Antacids; Bismuth; Clarithromycin; Drug Therapy, Combination; Fluoroquinolones; Helicobacter Infections; Helicobacter pylori; Humans; Levofloxacin; Moxifloxacin; Proton Pump Inhibitors; Quinolones	2017
Novel and Effective Therapeutic Regimens for Frontiers in cellular and infection microbiology, 2017, Volume: 7 Topics: Amoxicillin; Anti-Bacterial Agents; Bismuth; Clarithromycin; Drug Resistance, Bacterial; Drug Therapy, Combination; Furazolidone; Helicobacter Infections; Helicobacter pylori; Humans; Levofloxacin; Metronidazole; Mutation; Prevalence; Probiotics; Proton Pump Inhibitors; Pyrroles; Rifabutin; Sulfonamides; Tetracycline; Tetracycline Resistance	2017
Helicobacter pylori management in ASEAN: The Bangkok consensus report. Journal of gastroenterology and hepatology, 2018, Volume: 33, Issue:1 Topics: Amoxicillin; Anti-Bacterial Agents; Bismuth; Clarithromycin; Consensus; Drug Resistance, Bacterial; Drug Therapy, Combination; Fluoroquinolones; Follow-Up Studies; Gastritis; Helicobacter Infections; Helicobacter pylori; Humans; Japan; Metronidazole; Proton Pump Inhibitors; Taiwan; Tetracycline; Thailand; Treatment Outcome; United States	2018
Treatment of Helicobacter pylori infection: A clinical practice update. European journal of clinical investigation, 2018, Volume: 48, Issue:1 Topics: Anti-Bacterial Agents; Bismuth; Clarithromycin; Drug Administration Schedule; Drug Combinations; Drug Resistance, Bacterial; Gastritis; Helicobacter Infections; Helicobacter pylori; Humans; Practice Guidelines as Topic; Proton Pump Inhibitors; Randomized Controlled Trials as Topic; Treatment Failure	2018
Toward population specific and personalized treatment of Helicobacter pylori infection. Journal of biomedical science, 2018, Oct-02, Volume: 25, Issue:1 Topics: Algorithms; Anti-Bacterial Agents; Bismuth; Clarithromycin; Drug Resistance, Microbial; Helicobacter Infections; Helicobacter pylori; Humans; Levofloxacin; Models, Theoretical	2018
Bismuth supplements as the first-line regimen for Helicobacter pylori eradication therapy: Systemic review and meta-analysis. Helicobacter, 2019, Volume: 24, Issue:2 Topics: Antacids; Anti-Bacterial Agents; Bismuth; Clarithromycin; Drug Resistance, Bacterial; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans; Treatment Outcome	2019
Reconciliation of Recent Helicobacter pylori Treatment Guidelines in a Time of Increasing Resistance to Antibiotics. Gastroenterology, 2019, Volume: 157, Issue:1 Topics: Amoxicillin; Antacids; Anti-Bacterial Agents; Bismuth; Canada; Clarithromycin; Drug Resistance, Bacterial; Drug Therapy, Combination; Europe; Helicobacter Infections; Helicobacter pylori; Humans; Levofloxacin; Metronidazole; Microbial Sensitivity Tests; Practice Guidelines as Topic; Proton Pump Inhibitors; Rifabutin; Tetracycline; United States	2019
Proceedings. Mathematical, physical, and engineering sciences, 2019, Volume: 475, Issue:2227 Topics: Acetylcholine; Acinetobacter baumannii; Actinobacteria; Action Potentials; Adalimumab; Adaptation, Physiological; Adipates; Administration, Oral; Adolescent; Adrenal Glands; Adsorption; Adult; Aged; Aged, 80 and over; Aging; AIDS-Related Opportunistic Infections; Aldosterone; Amino Acids; Ammonia; Amoxicillin; AMP-Activated Protein Kinases; Animals; Antacids; Anti-Bacterial Agents; Antineoplastic Agents; Antirheumatic Agents; Apgar Score; Area Under Curve; ARNTL Transcription Factors; Arterial Pressure; Arthritis, Juvenile; Athletes; Attention; Biodegradation, Environmental; Biofilms; Biofuels; Biological Therapy; Biomass; Biomimetic Materials; Bioreactors; Birth Weight; Bismuth; Blood Flow Velocity; Bone and Bones; Brain Injuries, Traumatic; Calcium; Calcium Channels; Capsaicin; Carbon; Carcinoma, Hepatocellular; Cardiomegaly, Exercise-Induced; Cartilage; Cartilage, Articular; Case-Control Studies; Catalysis; Cats; CD4-Positive T-Lymphocytes; CD8-Positive T-Lymphocytes; Cell Death; Cell Differentiation; Cell Line, Tumor; Cell Membrane; Charcoal; Chemokine CCL2; Child; Child, Preschool; Chondrogenesis; Chronic Disease; Circadian Clocks; Circadian Rhythm Signaling Peptides and Proteins; Clarithromycin; Coccidioides; Coccidioidomycosis; Cognitive Behavioral Therapy; Coinfection; Color; Coloring Agents; Computer Simulation; Computers, Molecular; Consensus; Corticosterone; Cyclic AMP Response Element-Binding Protein; Cytochrome P-450 Enzyme System; Death, Sudden, Cardiac; Density Functional Theory; Diabetes Mellitus, Type 2; Diabetic Retinopathy; Dialysis Solutions; Disease Models, Animal; Dogs; Dopamine Agonists; Dose-Response Relationship, Drug; Doxorubicin; Drug Administration Schedule; Drug Resistance, Bacterial; Drug Therapy, Combination; Electrocardiography; Electrocardiography, Ambulatory; Electrolytes; Endocardium; Endocrine Disruptors; Endocytosis; Endoscopy, Gastrointestinal; Escherichia coli Proteins; Esters; Evolution, Molecular; Executive Function; Feasibility Studies; Female; Ferric Compounds; Fluorescence; Fluorescent Dyes; Fluorine Radioisotopes; Frailty; Free Radical Scavengers; Gabapentin; Geriatric Assessment; Glucaric Acid; Glucocorticoids; Glucose; Glucose Metabolism Disorders; Halogenated Diphenyl Ethers; Heart Rate; Heart Ventricles; HEK293 Cells; Helicobacter Infections; Helicobacter pylori; Hep G2 Cells; Hepatocytes; Humans; Hungary; Hydrogen Sulfide; Hydrogen-Ion Concentration; Immunologic Factors; Immunomodulation; Immunosuppressive Agents; Independent Living; Indocyanine Green; Infant; Infant Formula; Infant Mortality; Infant, Newborn; Infant, Newborn, Diseases; Inflorescence; Insulin Resistance; Insulins; International Agencies; Iron; Isotonic Solutions; Kidney Failure, Chronic; Kinetics; Lactones; Leukocytes, Mononuclear; Liver Neoplasms; Macular Edema; Magnetic Resonance Imaging; Magnetic Resonance Spectroscopy; Magnetosomes; Male; Medical Audit; Mesenchymal Stem Cells; Metabolic Syndrome; Metformin; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Mice, Nude; Middle Aged; Molecular Conformation; Molecular Targeted Therapy; Motor Activity; Multiple Sclerosis; Mycophenolic Acid; Netherlands; Neuropsychological Tests; Nuclear Energy; Organs at Risk; Osteoarthritis; Osteoarthritis, Hip; Oxidation-Reduction; Palladium; Pericardium; Perinatal Death; Peritoneal Dialysis; Phantoms, Imaging; Pharmaceutical Preparations; Phospholipids; Phosphorylation; Physical Conditioning, Human; Physical Endurance; Pilot Projects; Polyketides; Polymers; Positron-Emission Tomography; Postoperative Period; Potassium; Powders; Pramipexole; Predictive Value of Tests; Pregabalin; Pregnancy; Pregnancy Outcome; Protein Structure, Secondary; Proton Pump Inhibitors; Puberty; Pulmonary Circulation; Quality Assurance, Health Care; Quantum Dots; Radiometry; Radiotherapy Dosage; Radiotherapy Planning, Computer-Assisted; Radiotherapy, Intensity-Modulated; Rats, Sprague-Dawley; Receptors, CCR2; Receptors, Transferrin; Regeneration; Registries; Renal Insufficiency, Chronic; Reproducibility of Results; Research Design; Restless Legs Syndrome; Retina; Retinoid X Receptor alpha; Retrospective Studies; Rhenium; Risk Factors; RNA, Messenger; Severity of Illness Index; Sex Factors; Sodium; Sodium Fluoride; Solvents; Spectrometry, Fluorescence; Spectroscopy, Fourier Transform Infrared; Stereoisomerism; Stroke; Structure-Activity Relationship; Tachycardia, Ventricular; Tetracycline; Tetrahydrofolate Dehydrogenase; Tetrahydronaphthalenes; Thermodynamics; Thiophenes; Time Factors; Tinidazole; Tomography, Optical Coherence; Tomography, X-Ray Computed; Topiramate; Toxoplasma; Toxoplasmosis, Cerebral; Transferrin; Treatment Outcome; Up-Regulation; Upper Extremity; Uremia; Uveitis; Vascular Remodeling; Ventricular Fibrillation; Ventricular Function, Left; Ventricular Function, Right; Ventricular Remodeling; Verapamil; Veterans; Visual Acuity; Vitrectomy; Water Pollutants, Chemical; Zea mays; Zirconium	2019
High prevalence of clarithromycin resistance and effect on Helicobacter pylori eradication in a population from Santiago, Chile: cohort study and meta-analysis. Scientific reports, 2019, 12-27, Volume: 9, Issue:1 Topics: Adult; Anti-Bacterial Agents; Bismuth; Chile; Clarithromycin; Cohort Studies; Drug Resistance, Bacterial; Female; Helicobacter Infections; Helicobacter pylori; Humans; Male; Middle Aged; Prevalence; Prospective Studies	2019
Helicobacter pylori: A Review of Current Diagnostic and Management Strategies. Digestive diseases and sciences, 2020, Volume: 65, Issue:7 Topics: Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Antigens, Bacterial; Biopsy; Bismuth; Breath Tests; Clarithromycin; Culture Techniques; Doxycycline; Drug Resistance, Bacterial; Drug Therapy, Combination; Dyspepsia; Feces; Gastroscopy; Helicobacter Infections; Helicobacter pylori; Humans; Levofloxacin; Lymphoma, B-Cell, Marginal Zone; Metronidazole; Nitro Compounds; Organometallic Compounds; Peptic Ulcer; Polymerase Chain Reaction; Proton Pump Inhibitors; Rifabutin; Salicylates; Salvage Therapy; Serologic Tests; Stomach Neoplasms; Tetracycline; Thiazoles; Treatment Outcome; Urea	2020
Treatment of Helicobacter pylori infection: a clinical practice update. Minerva medica, 2021, Volume: 112, Issue:2 Topics: Antacids; Anti-Bacterial Agents; Bismuth; Clarithromycin; Drug Resistance, Bacterial; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans; Levofloxacin; Macrolides; Meta-Analysis as Topic; Practice Guidelines as Topic; Probiotics; Proton Pump Inhibitors; Salvage Therapy; Systematic Reviews as Topic	2021
Efficacy of second-line regimens for BMJ open gastroenterology, 2020, Volume: 7, Issue:1 Topics: Adult; Antacids; Anti-Bacterial Agents; Bismuth; Clarithromycin; Drug Resistance, Multiple; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Humans; Levofloxacin; Male; Metronidazole; Middle Aged; Network Meta-Analysis; Outcome Assessment, Health Care; Practice Guidelines as Topic; Proton Pump Inhibitors; Quinolones; Randomized Controlled Trials as Topic; Tetracycline	2020
Journal of biosciences, 2020, Volume: 45 Topics: Amoxicillin; Anti-Bacterial Agents; Biological Products; Bismuth; Clarithromycin; Drug Therapy, Combination; Dysbiosis; Gastrointestinal Microbiome; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Phytochemicals; Plant Extracts; Plants, Medicinal; Probiotics	2020
Treatment of Refractory Gut and liver, 2022, 01-15, Volume: 16, Issue:1 Topics: Amoxicillin; Anti-Bacterial Agents; Bismuth; Clarithromycin; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans; Metronidazole; Proton Pump Inhibitors	2022
V Spanish Consensus Conference on Helicobacter pylori infection treatment. Gastroenterologia y hepatologia, 2022, Volume: 45, Issue:5 Topics: Amoxicillin; Anti-Bacterial Agents; Bismuth; Clarithromycin; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans; Metronidazole; Peptic Ulcer; Proton Pump Inhibitors	2022
Impact of dexamethasone and tocilizumab on hematological parameters in COVID-19 patients with chronic disease. Medicina clinica (English ed.), 2022, Dec-23, Volume: 159, Issue:12 Topics: Acetaminophen; Acetylcarnitine; Acetylcholinesterase; Acids; Acinetobacter baumannii; Acinetobacter Infections; Adaptation, Psychological; Adolescent; Adsorption; Adult; Aged; Alcohol Drinking; Alzheimer Disease; Amikacin; Ammonia; Anaerobiosis; Animals; Anorexia; Anti-Bacterial Agents; Anti-Infective Agents; Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non-Steroidal; Antineoplastic Agents; Anxiety; Aptamers, Nucleotide; Asthenia; Attention Deficit Disorder with Hyperactivity; Bacterial Proteins; Beryllium; beta-Lactamases; Biofuels; Biomass; Biosensing Techniques; Bismuth; Blister; Body Mass Index; Body Surface Area; Boronic Acids; Brain; Breast Neoplasms; Butyrylcholinesterase; Cannabis; Carbapenems; Carbonyl Cyanide m-Chlorophenyl Hydrazone; Carboxylic Acids; Carcinoma, Hepatocellular; Cardiovascular Diseases; Carnitine; Case-Control Studies; Catalysis; Cell Cycle Proteins; Cell Line, Tumor; Cell Proliferation; Child; China; Cholinesterase Inhibitors; Clarithromycin; Clostridioides; Clostridioides difficile; Clostridium Infections; Cohort Studies; Colistin; Colitis; Colon; Coloring Agents; Coronary Artery Bypass; Creatinine; Crystalloid Solutions; Cytokines; Depression; Dextran Sulfate; Dextrans; Diabetes Mellitus, Type 2; Diabetic Retinopathy; Diarrhea; Dietary Supplements; Diphenhydramine; Disease Models, Animal; Disease Outbreaks; Double-Blind Method; Doxorubicin; Drosophila; Drug Tapering; Dysbiosis; Electrons; Escherichia coli; Extracellular Vesicles; Fatigue; Female; Fermentation; gamma-Cyclodextrins; Gastrointestinal Microbiome; Glucose; Graft Survival; Graft vs Host Disease; Head and Neck Neoplasms; Heart Arrest, Induced; Hematopoietic Stem Cell Transplantation; High-Intensity Interval Training; Hippocampus; Humans; Hydrogen-Ion Concentration; Hypertension; Incidence; Interferon-gamma; Italy; Kinetics; Klebsiella Infections; Klebsiella pneumoniae; Lab-On-A-Chip Devices; Lactoferrin; Larva; Length of Stay; Lignin; Liver; Liver Neoplasms; Liver Transplantation; Living Donors; Low Back Pain; Lung; Lung Volume Measurements; Macrophages; Male; Melphalan; Men; Mendelian Randomization Analysis; Meropenem; Methane; Mice; Mice, Inbred C57BL; Microbial Sensitivity Tests; Mitochondrial Proteins; Molecular Docking Simulation; Molecular Structure; Mothers; Motivation; Mycoplasma; Mycoplasma hominis; Mycoplasma Infections; NAD; Nanocomposites; Nanoparticles; Nanotubes, Carbon; Naproxen; Neovascularization, Pathologic; Neurons; Nitrates; Nucleolin; Opuntia; Paratyphoid Fever; Phenotype; Phosphatidylinositol 3-Kinases; Phytochemicals; Plant Extracts; Pregnancy; Prevalence; Prospective Studies; Proto-Oncogene Proteins c-akt; Pulmonary Disease, Chronic Obstructive; Rats; Rats, Wistar; Resveratrol; Retrospective Studies; Rifampin; Risk Factors; RNA, Messenger; Selenium; Sleep; Social Behavior; Soil; Soil Pollutants; Squamous Cell Carcinoma of Head and Neck; Staphylococcus aureus; Structure-Activity Relationship; Suicidal Ideation; Suicide; Superoxide Dismutase-1; Surveys and Questionnaires; Swimming; Syndrome; Tannins; Temperature; Transforming Growth Factor beta; Transplantation Conditioning; Treatment Outcome; Triple Negative Breast Neoplasms; Troponin T; Tumor Microenvironment; United Kingdom; Ureaplasma; Ureaplasma urealyticum; Urinary Tract Infections; Viscum; Waste Disposal Facilities; Wastewater; Water; Water Pollutants, Chemical; Wolfiporia; Young Adult	2022

Trials

142 trial(s) available for bismuth and clarithromycin

Article	Year
Impact of colloidal bismuth subnitrate in the eradication rates of Helicobacter pylori infection-associated duodenal ulcer using a short treatment regimen with omeprazole and clarithromycin: a randomized study. The American journal of gastroenterology, 1995, Volume: 90, Issue:5 Topics: Antacids; Bismuth; Clarithromycin; Drug Therapy, Combination; Duodenal Ulcer; Female; Gastritis; Helicobacter Infections; Helicobacter pylori; Humans; Male; Middle Aged; Omeprazole	1995
Omeprazole, bismuth and clarithromycin in the sequential treatment of Helicobacter pylori infection. Alimentary pharmacology & therapeutics, 1994, Volume: 8, Issue:4 Topics: Adult; Aged; Bismuth; Clarithromycin; Drug Administration Schedule; Female; Gastritis; Helicobacter Infections; Helicobacter pylori; Humans; Male; Middle Aged; Omeprazole	1994
Ranitidine bismuth citrate plus clarithromycin is effective for healing duodenal ulcers, eradicating H. pylori and reducing ulcer recurrence. RBC H. pylori Study Group. Alimentary pharmacology & therapeutics, 1996, Volume: 10, Issue:3 Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; Clarithromycin; Double-Blind Method; Drug Therapy, Combination; Duodenal Ulcer; Female; Helicobacter Infections; Helicobacter pylori; Histamine H2 Antagonists; Humans; Male; Middle Aged; Patient Compliance; Ranitidine; Recurrence	1996
Ranitidine bismuth citrate and clarithromycin twice daily in the eradication of Helicobacter pylori. Alimentary pharmacology & therapeutics, 1997, Volume: 11, Issue:1 Topics: Adult; Aged; Anti-Bacterial Agents; Bismuth; Breath Tests; Clarithromycin; Diarrhea; Double-Blind Method; Drug Therapy, Combination; Duodenal Ulcer; Duodenoscopy; Female; Helicobacter Infections; Helicobacter pylori; Histamine H2 Antagonists; Humans; Male; Middle Aged; Patient Compliance; Ranitidine	1997
One week treatment for Helicobacter pylori infection. Archives of disease in childhood, 1997, Volume: 76, Issue:4 Topics: Adolescent; Anti-Bacterial Agents; Antitrichomonal Agents; Bismuth; Breath Tests; Child; Child, Preschool; Clarithromycin; Drug Administration Schedule; Drug Therapy, Combination; Gastritis; Gastroscopy; Helicobacter Infections; Helicobacter pylori; Humans; Infant; Metronidazole; Organometallic Compounds	1997
Clarithromycin in the combination therapy for the eradication of Helicobacter pylori in peptic ulcer disease. Zhonghua yi xue za zhi = Chinese medical journal; Free China ed, 1997, Volume: 59, Issue:3 Topics: Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Bismuth; Clarithromycin; Drug Therapy, Combination; Duodenal Ulcer; Female; Helicobacter Infections; Helicobacter pylori; Histamine H2 Antagonists; Humans; Male; Metronidazole; Middle Aged; Nizatidine; Omeprazole; Organometallic Compounds; Penicillins; Ranitidine; Salicylates	1997
Helicobacter pylori eradication--comparison of three drug regimens and symptomatic assessment in duodenitis and antral gastritis. International journal of clinical practice, 1997, Volume: 51, Issue:4 Topics: Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Bismuth; Clarithromycin; Drug Therapy, Combination; Duodenal Ulcer; Duodenitis; Female; Gastritis; Helicobacter Infections; Helicobacter pylori; Humans; Male; Metronidazole; Middle Aged; Omeprazole; Organometallic Compounds; Penicillins; Treatment Outcome	1997
Ranitidine bismuth citrate with clarithromycin for the treatment of duodenal ulcer. Gut, 1997, Volume: 41, Issue:2 Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; Clarithromycin; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Combination; Duodenal Ulcer; Female; Helicobacter Infections; Helicobacter pylori; Humans; Life Tables; Male; Middle Aged; Ranitidine; Treatment Outcome; Wound Healing	1997
A new 1-week therapy for Helicobacter pylori eradication: ranitidine bismuth citrate plus two antibiotics. Alimentary pharmacology & therapeutics, 1997, Volume: 11, Issue:4 Topics: Anti-Bacterial Agents; Bismuth; Clarithromycin; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Histamine H2 Antagonists; Humans; Male; Metronidazole; Pyloric Antrum; Ranitidine	1997
Seven-day treatment for Helicobacter pylori infection: ranitidine bismuth citrate plus clarithromycin and tetracycline hydrochloride. Alimentary pharmacology & therapeutics, 1997, Volume: 11, Issue:4 Topics: Adult; Aged; Anti-Bacterial Agents; Bismuth; Clarithromycin; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Histamine H2 Antagonists; Humans; Male; Middle Aged; Ranitidine; Tetracycline	1997
Bismuth subsalicylate instead of metronidazole with lansoprazole and clarithromycin for Helicobacter pylori infection: a randomized trial. The American journal of gastroenterology, 1997, Volume: 92, Issue:9 Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Abdominal Pain; Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; Clarithromycin; Drug Administration Schedule; Drug Combinations; Drug Resistance, Microbial; Dyspepsia; Evaluation Studies as Topic; Feces; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Medical Records; Metronidazole; Middle Aged; Omeprazole; Organometallic Compounds; Patient Compliance; Peptic Ulcer; Proton Pump Inhibitors; Salicylates; Taste Disorders	1997
[Elimination of Helicobacter pylori in patients with recurrent abdominal pain with simultaneous administration of ranitidine, bismuth subsalicylate and clarithromycin]. Acta gastroenterologica Latinoamericana, 1996, Volume: 26, Issue:5 Topics: Abdominal Pain; Anti-Ulcer Agents; Bismuth; Child; Clarithromycin; Drug Therapy, Combination; Female; Gastritis; Helicobacter Infections; Helicobacter pylori; Histamine H2 Antagonists; Humans; Longitudinal Studies; Male; Prospective Studies; Ranitidine; Recurrence	1996
Randomized comparison of ranitidine bismuth citrate-based triple therapies for Helicobacter pylori. The American journal of gastroenterology, 1997, Volume: 92, Issue:12 Topics: Adult; Amoxicillin; Antacids; Anti-Bacterial Agents; Anti-Ulcer Agents; Biopsy; Bismuth; Breath Tests; Carbon Isotopes; Clarithromycin; Drug Combinations; Female; Follow-Up Studies; Gastroscopy; Helicobacter Infections; Helicobacter pylori; Histamine H2 Antagonists; Humans; Male; Metronidazole; Organometallic Compounds; Penicillins; Peptic Ulcer; Proton Pump Inhibitors; Ranitidine; Salicylates; Tetracycline; Urea	1997
Should we abandon metronidazole containing Helicobacter pylori treatment regimens? The clinical relevance of metronidazole resistance. The American journal of gastroenterology, 1998, Volume: 93, Issue:1 Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Antacids; Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; Clarithromycin; Clinical Trials as Topic; Drug Resistance, Microbial; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Histamine H2 Antagonists; Humans; Lansoprazole; Metronidazole; Omeprazole; Penicillins; Placebos; Proton Pump Inhibitors; Ranitidine; Tetracycline	1998
Ranitidine bismuth citrate with clarithromycin given twice daily effectively eradicates Helicobacter pylori and heals duodenal ulcers. The American journal of gastroenterology, 1998, Volume: 93, Issue:3 Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Antitrichomonal Agents; Bismuth; Clarithromycin; Double-Blind Method; Drug Therapy, Combination; Duodenal Ulcer; Female; Helicobacter Infections; Helicobacter pylori; Histamine H2 Antagonists; Humans; Male; Metronidazole; Middle Aged; Ranitidine; Treatment Outcome	1998
Bismuth-containing single-antibiotic 1-week triple therapy for Helicobacter pylori eradication. Alimentary pharmacology & therapeutics, 1998, Volume: 12, Issue:3 Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Abdominal Pain; Adolescent; Adult; Aged; Aged, 80 and over; Antacids; Anti-Bacterial Agents; Anus Diseases; Bismuth; Breath Tests; Carbon Isotopes; Clarithromycin; Diarrhea; Drug Therapy, Combination; Enzyme Inhibitors; Female; Hallucinations; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Male; Middle Aged; Nausea; Omeprazole; Peptic Ulcer; Pregnancy; Protein Synthesis Inhibitors; Proton Pump Inhibitors; Taste Disorders; Time Factors; Tongue Diseases; Treatment Outcome; Urea; Vomiting	1998
Ranitidine bismuth citrate plus clarithromycin 7-day regimen is effective in eradicating Helicobacter pylori in patients with duodenal ulcer. Alimentary pharmacology & therapeutics, 1998, Volume: 12, Issue:5 Topics: Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; Clarithromycin; Drug Therapy, Combination; Duodenal Ulcer; Female; Helicobacter Infections; Helicobacter pylori; Humans; Male; Middle Aged; Ranitidine	1998
Ranitidine bismuth citrate with clarithromycin versus omeprazole with amoxycillin in the cure of Helicobacter pylori infection. Alimentary pharmacology & therapeutics, 1997, Volume: 11, Issue:6 Topics: Adolescent; Adult; Aged; Amoxicillin; Anti-Ulcer Agents; Bismuth; Clarithromycin; Double-Blind Method; Drug Therapy, Combination; Duodenal Ulcer; Female; Helicobacter Infections; Helicobacter pylori; Humans; Male; Middle Aged; Omeprazole; Ranitidine; Wound Healing	1997
Optimal treatment of Helicobacter pylori with ranitidine bismuth citrate (RBC): a randomized comparison between two 7-day triple therapies and a 14-day dual therapy. The American journal of gastroenterology, 1998, Volume: 93, Issue:7 Topics: Adult; Aged; Aged, 80 and over; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; Clarithromycin; Drug Resistance, Microbial; Drug Therapy, Combination; Female; Gastroscopy; Helicobacter Infections; Helicobacter pylori; Histamine H2 Antagonists; Humans; Male; Metronidazole; Middle Aged; Penicillins; Ranitidine; Stomach Ulcer; Tetracycline; Treatment Outcome	1998
Efficacy and safety of three 7-day Helicobacter pylori eradication regimens containing ranitidine bismuth citrate. Alimentary pharmacology & therapeutics, 1998, Volume: 12, Issue:6 Topics: Adolescent; Adult; Aged; Aged, 80 and over; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; Clarithromycin; Double-Blind Method; Drug Therapy, Combination; Dyspepsia; Female; Gastritis; Gastroscopy; Helicobacter Infections; Helicobacter pylori; Humans; Male; Middle Aged; Penicillins; Ranitidine; Tinidazole	1998
One-week therapy for Helicobacter pylori eradication: ranitidine bismuth citrate plus medium-dose clarithromycin and either tinidazole or amoxycillin. Alimentary pharmacology & therapeutics, 1998, Volume: 12, Issue:6 Topics: Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; Clarithromycin; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Combination; Female; Gastroscopy; Helicobacter Infections; Helicobacter pylori; Humans; Male; Middle Aged; Prospective Studies; Ranitidine; Tinidazole	1998
Ranitidine bismuth citrate versus omeprazole triple therapy for the eradication of Helicobacter pylori and healing of duodenal ulcer. Alimentary pharmacology & therapeutics, 1998, Volume: 12, Issue:1 Topics: Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; Clarithromycin; Clinical Protocols; Drug Therapy, Combination; Duodenal Ulcer; Female; Helicobacter pylori; Histamine H2 Antagonists; Humans; Male; Middle Aged; Omeprazole; Penicillins; Prospective Studies; Ranitidine; Single-Blind Method	1998
Ranitidine bismuth citrate with either clarithromycin 1 g/day or 1.5 g/day is equally effective in the eradication of H. pylori and healing of duodenal ulcer. Alimentary pharmacology & therapeutics, 1998, Volume: 12, Issue:1 Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; Child; Child, Preschool; Clarithromycin; Dose-Response Relationship, Drug; Drug Therapy, Combination; Duodenal Ulcer; Female; Helicobacter pylori; Histamine H2 Antagonists; Humans; Male; Middle Aged; Ranitidine	1998
One-week triple therapy with ranitidine bismuth citrate, clarithromycin and metronidazole versus two-week dual therapy with ranitidine bismuth citrate and clarithromycin for Helicobacter pylori infection: a randomized, clinical trial. The American journal of gastroenterology, 1998, Volume: 93, Issue:8 Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; Clarithromycin; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Humans; Male; Metronidazole; Middle Aged; Peptic Ulcer; Ranitidine; Time Factors; Treatment Failure	1998
One-week use of ranitidine bismuth citrate, amoxycillin and clarithromycin for the treatment of Helicobacter pylori-related duodenal ulcer. Alimentary pharmacology & therapeutics, 1998, Volume: 12, Issue:8 Topics: Adolescent; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; Clarithromycin; Combined Modality Therapy; Duodenal Ulcer; Female; Helicobacter Infections; Helicobacter pylori; Humans; Male; Middle Aged; Omeprazole; Penicillins; Prospective Studies; Proton Pumps; Ranitidine; Single-Blind Method; Treatment Outcome	1998
Ranitidine bismuth citrate plus clarithromycin: a dual therapy regimen for patients with duodenal ulcer. Helicobacter, 1998, Volume: 3, Issue:3 Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; Clarithromycin; Double-Blind Method; Drug Therapy, Combination; Duodenal Ulcer; Female; Helicobacter Infections; Helicobacter pylori; Humans; Male; Middle Aged; Ranitidine; Recurrence; Treatment Outcome	1998
High Helicobacter pylori eradication rate with a 1-week regimen containing ranitidine bismuth citrate. Alimentary pharmacology & therapeutics, 1998, Volume: 12, Issue:11 Topics: Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; Clarithromycin; Confidence Intervals; Double-Blind Method; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Humans; Male; Metronidazole; Middle Aged; Ranitidine	1998
Optimal duration of therapy combining ranitidine bismuth citrate with clarithromycin and metronidazole in the eradication of Helicobacter pylori infection. Alimentary pharmacology & therapeutics, 1999, Volume: 13, Issue:1 Topics: Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; Breath Tests; Clarithromycin; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Histamine H2 Antagonists; Humans; Male; Metronidazole; Middle Aged; Ranitidine; Treatment Outcome; Urea	1999
The influence of metronidazole resistance on the efficacy of ranitidine bismuth citrate triple therapy regimens for Helicobacter pylori infection. Alimentary pharmacology & therapeutics, 1999, Volume: 13, Issue:3 Topics: Adult; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; Clarithromycin; Drug Resistance, Microbial; Drug Therapy, Combination; Duodenal Ulcer; Female; Gastritis; Gastroscopy; Helicobacter Infections; Helicobacter pylori; Humans; Male; Metronidazole; Penicillins; Ranitidine; Stomach Ulcer	1999
Effectiveness of ranitidine bismuth citrate, clarithromycin, and metronidazole therapy for treating Helicobacter pylori. The American journal of gastroenterology, 1999, Volume: 94, Issue:4 Topics: Adult; Bismuth; Clarithromycin; Drug Administration Schedule; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Histamine H2 Antagonists; Humans; Male; Metronidazole; Ranitidine; Time Factors	1999
Efficacy of a 1-week regimen of ranitidine bismuth citrate in combination with metronidazole and clarithromycin for Helicobacter pylori eradication. Alimentary pharmacology & therapeutics, 1999, Volume: 13, Issue:4 Topics: Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; Clarithromycin; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Humans; Male; Metronidazole; Middle Aged; Ranitidine	1999
Ten-day triple therapy with ranitidine bismuth citrate, amoxicillin, and clarithromycin in eradicating Helicobacter pylori. The American journal of gastroenterology, 1999, Volume: 94, Issue:5 Topics: Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; Breath Tests; Clarithromycin; Drug Administration Schedule; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Histamine H2 Antagonists; Humans; Male; Middle Aged; Penicillins; Ranitidine; Urea	1999
Twice-daily versus thrice-daily clarithromycin in combination with ranitidine bismuth citrate in the eradication of Helicobacter pylori. Helicobacter, 1999, Volume: 4, Issue:2 Topics: Adult; Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; Clarithromycin; Double-Blind Method; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Humans; Male; Microbial Sensitivity Tests; Middle Aged; Ranitidine	1999
Comparison of two 3-day Helicobacter pylori eradication regimens with a standard 1-week regimen. Alimentary pharmacology & therapeutics, 1999, Volume: 13, Issue:7 Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Aged, 80 and over; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Biopsy; Bismuth; Breath Tests; Clarithromycin; Drug Administration Schedule; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Male; Metronidazole; Middle Aged; Omeprazole; Penicillins; Peptic Ulcer; Ranitidine; Treatment Outcome	1999
Eradication of Helicobacter pylori infection with proton pump-based triple therapy in patients in whom bismuth-based triple therapy failed. Journal of clinical gastroenterology, 1999, Volume: 29, Issue:1 Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Bismuth; Clarithromycin; Drug Therapy, Combination; Enzyme Inhibitors; Female; Gastritis; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Male; Metronidazole; Middle Aged; Omeprazole; Organometallic Compounds; Penicillins; Proton Pump Inhibitors; Salicylates; Treatment Outcome	1999
Comparison of ranitidine bismuth citrate plus clarithromycin with omeprazole plus clarithromycin for the eradication of Helicobacter pylori. Alimentary pharmacology & therapeutics, 1999, Volume: 13, Issue:8 Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; Clarithromycin; Double-Blind Method; Drug Combinations; Enzyme Inhibitors; Female; Helicobacter Infections; Helicobacter pylori; Humans; Male; Middle Aged; Omeprazole; Patient Compliance; Proton Pump Inhibitors; Ranitidine	1999
One-week ranitidine bismuth citrate in combinations with metronidazole, amoxycillin and clarithromycin in the treatment of Helicobacter pylori infection: the RBC-MACH study. Alimentary pharmacology & therapeutics, 1999, Volume: 13, Issue:8 Topics: Adolescent; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; Clarithromycin; Double-Blind Method; Drug Combinations; Dyspepsia; Female; Helicobacter Infections; Helicobacter pylori; Humans; Male; Metronidazole; Microbial Sensitivity Tests; Middle Aged; Penicillins; Peptic Ulcer; Prospective Studies; Ranitidine; Treatment Outcome	1999
Low efficacy of ranitidine bismuth citrate plus clarithromycin combination on Helicobacter pylori in a Turkish population. The American journal of gastroenterology, 1999, Volume: 94, Issue:10 Topics: Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; Clarithromycin; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans; Ranitidine; Turkey	1999
Seven-day 'rescue' therapy after Helicobacter pylori treatment failure: omeprazole, bismuth, tetracycline and metronidazole vs. ranitidine bismuth citrate, tetracycline and metronidazole. Alimentary pharmacology & therapeutics, 1999, Volume: 13, Issue:10 Topics: Adult; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; Clarithromycin; Drug Administration Schedule; Drug Therapy, Combination; Female; Follow-Up Studies; Helicobacter Infections; Helicobacter pylori; Humans; Male; Metronidazole; Middle Aged; Omeprazole; Penicillins; Prospective Studies; Ranitidine; Tetracycline; Treatment Failure	1999
[Reinfection with Helicobacter pylori in patients with duodenal ulcer after successful eradication]. Przeglad lekarski, 1999, Volume: 56, Issue:7-8 Topics: Adult; Amoxicillin; Bismuth; Chronic Disease; Clarithromycin; Drug Therapy, Combination; Duodenal Ulcer; Duodenoscopy; Female; Follow-Up Studies; Helicobacter Infections; Helicobacter pylori; Humans; Male; Metronidazole; Middle Aged; Omeprazole; Recurrence; Wound Healing	1999
Six-day or seven-day regimens with ranitidine bismuth citrate plus high-dose clarithromycin and tinidazole are both effective against Helicobacter pylori infection. Digestive diseases and sciences, 1999, Volume: 44, Issue:12 Topics: Adolescent; Adult; Aged; Anti-Bacterial Agents; Anti-Ulcer Agents; Antitrichomonal Agents; Bismuth; Breath Tests; Clarithromycin; Drug Administration Schedule; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Histamine H2 Antagonists; Humans; Male; Middle Aged; Ranitidine; Tinidazole; Treatment Outcome; Urea	1999
Five-day regimens containing ranitidine bismuth citrate plus high-dose clarithromycin and either amoxycillin or tinidazole for Helicobacter pylori infection. Alimentary pharmacology & therapeutics, 2000, Volume: 14, Issue:1 Topics: Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; Breath Tests; Clarithromycin; Drug Therapy, Combination; Dyspepsia; Helicobacter Infections; Helicobacter pylori; Humans; Penicillins; Prospective Studies; Ranitidine; Tinidazole; Urea	2000
Efficacy of a multistep strategy for Helicobacter pylori eradication. Alimentary pharmacology & therapeutics, 2000, Volume: 14, Issue:1 Topics: Algorithms; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; Clarithromycin; Drug Resistance, Microbial; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Humans; Male; Middle Aged; Penicillins; Ranitidine; Tinidazole; Treatment Failure	2000
Salvage therapies after failure of Helicobacter pylori eradication with ranitidine bismuth citrate-based therapies. Alimentary pharmacology & therapeutics, 2000, Volume: 14, Issue:1 Topics: Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; Clarithromycin; Enzyme Inhibitors; Helicobacter Infections; Helicobacter pylori; Humans; Omeprazole; Penicillins; Prospective Studies; Proton Pump Inhibitors; Ranitidine; Salvage Therapy	2000
Seven-day triple therapy with ranitidine bismuth citrate or omeprazole and two antibiotics for eradication of Helicobacter pylori in duodenal ulcer: a multicentre, randomized, single-blind study. Alimentary pharmacology & therapeutics, 2000, Volume: 14, Issue:3 Topics: Adolescent; Adult; Aged; Aged, 80 and over; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; Clarithromycin; Duodenal Ulcer; Female; Helicobacter Infections; Helicobacter pylori; Humans; Male; Middle Aged; Omeprazole; Patient Compliance; Penicillins; Prospective Studies; Ranitidine; Single-Blind Method	2000
Efficacy of different Helicobacter pylori eradication regimens in patients affected by insulin-dependent diabetes mellitus. Scandinavian journal of gastroenterology, 2000, Volume: 35, Issue:3 Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Amoxicillin; Anti-Ulcer Agents; Benzimidazoles; Bismuth; Clarithromycin; Diabetes Mellitus, Type 1; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Humans; Male; Omeprazole; Pantoprazole; Ranitidine; Sulfoxides; Tinidazole	2000
Patients with dyspepsia benefit from eradication of Helicobacter pylori if other organic causes for dyspepsia were carefully ruled out. Zeitschrift fur Gastroenterologie, 2000, Volume: 38, Issue:3 Topics: Adult; Aged; Amoxicillin; Anti-Ulcer Agents; Bismuth; Clarithromycin; Diagnosis, Differential; Dose-Response Relationship, Drug; Drug Administration Schedule; Dyspepsia; Female; Follow-Up Studies; Gastritis; Gastroscopy; Helicobacter Infections; Helicobacter pylori; Humans; Male; Metronidazole; Middle Aged; Omeprazole; Organometallic Compounds; Salicylates; Tetracycline; Treatment Outcome	2000
Ranitidine bismuth citrate and clarithromycin, alone or in combination, for eradication of Helicobacter mustelae infection in ferrets. American journal of veterinary research, 1999, Volume: 60, Issue:10 Topics: Animals; Anti-Ulcer Agents; Bismuth; Clarithromycin; Drug Therapy, Combination; Female; Ferrets; Gastric Mucosa; Helicobacter; Helicobacter Infections; Ovariectomy; Ranitidine; Time Factors	1999
The impact of antibiotic resistance on the efficacy of three 7-day regimens against Helicobacter pylori. Alimentary pharmacology & therapeutics, 2000, Volume: 14, Issue:7 Topics: Adult; Anti-Bacterial Agents; Bismuth; Clarithromycin; Drug Resistance, Microbial; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Humans; Male; Metronidazole; Middle Aged; Ranitidine; Treatment Outcome	2000
[Combination of ranitidine and bismuth citrate plus 2 antibiotics in the eradication of Helicobacter pylori]. Medicina clinica, 2000, Jun-17, Volume: 115, Issue:3 Topics: Amoxicillin; Antacids; Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; Clarithromycin; Double-Blind Method; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans; Omeprazole; Organometallic Compounds; Penicillins; Prospective Studies; Ranitidine; Time Factors	2000
[Lansoprazole versus ranitidine bismuth citrate containing triple regimens for Helicobacter pylori eradication in patients with duodenal ulcer]. Orvosi hetilap, 2000, Jul-30, Volume: 141, Issue:31 Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; Clarithromycin; Drug Administration Schedule; Drug Therapy, Combination; Duodenal Ulcer; Female; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Male; Metronidazole; Middle Aged; Omeprazole; Prospective Studies; Ranitidine; Treatment Outcome	2000
Helicobacter pylori-positive duodenal ulcer: three-day antibiotic eradication regimen. Alimentary pharmacology & therapeutics, 2000, Volume: 14, Issue:10 Topics: Adolescent; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; Clarithromycin; Costs and Cost Analysis; Duodenal Ulcer; Enzyme Inhibitors; Female; Helicobacter Infections; Helicobacter pylori; Histamine H2 Antagonists; Humans; Male; Middle Aged; Omeprazole; Patient Compliance; Penicillins; Proton Pump Inhibitors; Ranitidine; Treatment Outcome	2000
Ranitidine bismuth citrate can help to overcome Helicobacter pylori resistance to clarithromycin in vivo. Helicobacter, 2000, Volume: 5, Issue:4 Topics: Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; Clarithromycin; Double-Blind Method; Drug Resistance, Microbial; Drug Synergism; Duodenal Ulcer; Female; Helicobacter Infections; Helicobacter pylori; Humans; Male; Microbial Sensitivity Tests; Middle Aged; Omeprazole; Ranitidine	2000
One-week ranitidine bismuth citrate-based triple therapy for the eradication of Helicobacter pylori in Hong Kong with high prevalence of metronidazole resistance. Alimentary pharmacology & therapeutics, 2001, Volume: 15, Issue:3 Topics: Adult; Aged; Anti-Bacterial Agents; Anti-Infective Agents; Anti-Ulcer Agents; Bismuth; Breath Tests; Carbon Isotopes; Clarithromycin; Drug Resistance; Drug Therapy, Combination; Female; Helicobacter Infections; Hong Kong; Humans; Male; Metronidazole; Middle Aged; Omeprazole; Prevalence; Ranitidine; Treatment Outcome; Urea	2001
Reduced symptoms and need for antisecretory therapy in veterans 3 years after Helicobacter pylori eradication with ranitidine bismuth citrate/amoxicillin/clarithromycin. The American journal of gastroenterology, 2001, Volume: 96, Issue:5 Topics: Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; Clarithromycin; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans; Male; Middle Aged; Patient Compliance; Penicillins; Ranitidine; Veterans	2001
Lansoprazole-based triple therapy versus ranitidine bismuth citrate-based dual therapy in the eradication of Helicobacter pylori in patients with duodenal ulcer: a multicenter, randomized, double-dummy study. Clinical therapeutics, 2001, Volume: 23, Issue:5 Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Anti-Ulcer Agents; Bismuth; Clarithromycin; Double-Blind Method; Drug Therapy, Combination; Duodenal Ulcer; Dyspepsia; Female; Headache; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Male; Middle Aged; Omeprazole; Pruritus; Ranitidine; Recurrence; Taste Disorders; Tinidazole; Treatment Outcome	2001
Ranitidine bismuth citrate-based triple therapies after failure of the standard 'Maastricht triple therapy': a promising alternative to the quadruple therapy? Alimentary pharmacology & therapeutics, 2001, Volume: 15, Issue:7 Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Administration, Oral; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Antitrichomonal Agents; Benzimidazoles; Bismuth; Breath Tests; Carbon Isotopes; Clarithromycin; Drug Administration Schedule; Drug Resistance; Drug Therapy, Combination; Female; Helicobacter Infections; Humans; Male; Middle Aged; Omeprazole; Pantoprazole; Penicillins; Proton Pump Inhibitors; Ranitidine; Recurrence; Sulfoxides; Tinidazole; Treatment Outcome; Urea	2001
High efficacy of ranitidine bismuth citrate, amoxicillin, clarithromycin and metronidazole twice daily for only five days in Helicobacter pylori Eradication. Helicobacter, 2001, Volume: 6, Issue:2 Topics: Adult; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; Clarithromycin; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Humans; Male; Metronidazole; Middle Aged; Ranitidine	2001
Ranitidine bismuth citrate with clarithromycin alone or with metronidazole for the eradication of Helicobacter pylori. Alimentary pharmacology & therapeutics, 2001, Volume: 15, Issue:8 Topics: Adult; Aged; Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; Breath Tests; Carbon Isotopes; Clarithromycin; Double-Blind Method; Drug Therapy, Combination; Dyspepsia; Female; Helicobacter Infections; Helicobacter pylori; Humans; Male; Metronidazole; Middle Aged; Peptic Ulcer; Ranitidine; Treatment Outcome; Urea; Urease	2001
[Comparative study of the eradication of Helicobacter pylori: ranitidine bismuth citrate versus omeprazole plus two antibiotics for seven days]. Anales de medicina interna (Madrid, Spain : 1984), 2001, Volume: 18, Issue:7 Topics: Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; Clarithromycin; Drug Therapy, Combination; Female; Gastrointestinal Diseases; Helicobacter Infections; Helicobacter pylori; Humans; Male; Middle Aged; Omeprazole; Prospective Studies; Ranitidine	2001
A randomized trial of lansoprazole, amoxycillin, and clarithromycin versus lansoprazole, bismuth, metronidazole and tetracycline in the retreatment of patients failing initial Helicobacter pylori therapy. Digestive diseases (Basel, Switzerland), 2001, Volume: 19, Issue:2 Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Aged, 80 and over; Amoxicillin; Antacids; Anti-Bacterial Agents; Bismuth; Breath Tests; Carbon Isotopes; Clarithromycin; Drug Resistance, Microbial; Drug Therapy, Combination; Enzyme Inhibitors; Female; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Male; Metronidazole; Middle Aged; Omeprazole; Penicillins; Proton Pump Inhibitors	2001
Comparison of 1-week vs. 2- or 4-week therapy regimens with ranitidine bismuth citrate plus two antibiotics for Helicobacter pylori eradication. Alimentary pharmacology & therapeutics, 2001, Volume: 15, Issue:9 Topics: Adult; Aged; Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; Clarithromycin; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Duodenal Ulcer; Female; Helicobacter Infections; Helicobacter pylori; Humans; Male; Metronidazole; Middle Aged; Ranitidine; Treatment Outcome	2001
Helicobacter pylori eradication therapy is more effective in peptic ulcer than in non-ulcer dyspepsia. European journal of gastroenterology & hepatology, 2001, Volume: 13, Issue:11 Topics: Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; Clarithromycin; Dyspepsia; Female; Helicobacter Infections; Helicobacter pylori; Histamine H2 Antagonists; Humans; Male; Metronidazole; Middle Aged; Penicillins; Peptic Ulcer; Ranitidine; Retrospective Studies	2001
Two new treatment regimens for Helicobacter pylori eradication: a randomised study. Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver, 2001, Volume: 33, Issue:8 Topics: Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Antitrichomonal Agents; Bismuth; Clarithromycin; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Humans; Male; Middle Aged; Omeprazole; Prospective Studies; Ranitidine; Tinidazole; Treatment Outcome	2001
Effectiveness of two quadruple, tetracycline- or clarithromycin-containing, second-line, Helicobacter pylori eradication therapies. Alimentary pharmacology & therapeutics, 2002, Volume: 16, Issue:3 Topics: Adolescent; Adult; Aged; Antacids; Anti-Bacterial Agents; Bismuth; Clarithromycin; Drug Interactions; Drug Resistance, Bacterial; Drug Therapy, Combination; Dyspepsia; Female; Helicobacter Infections; Helicobacter pylori; Humans; Male; Metronidazole; Microbial Sensitivity Tests; Middle Aged; Multivariate Analysis; Omeprazole; Tetracycline; Treatment Failure	2002
Comparison of azithromycin and clarithromycin in triple therapy regimens for the eradication of Helicobacter pylori. The American journal of gastroenterology, 2002, Volume: 97, Issue:10 Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Antacids; Anti-Bacterial Agents; Anti-Ulcer Agents; Azithromycin; Bismuth; Clarithromycin; Double-Blind Method; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Male; Omeprazole; Prospective Studies; Stomach Diseases	2002
The impact of primary antibiotic resistance on the efficacy of ranitidine bismuth citrate- vs. omeprazole-based one-week triple therapies in H. pylori eradication--a randomised controlled trial. Wiener klinische Wochenschrift, 2002, Jun-28, Volume: 114, Issue:12 Topics: Adult; Amoxicillin; Anti-Ulcer Agents; Bismuth; Clarithromycin; Drug Resistance; Drug Therapy, Combination; Dyspepsia; Female; Gastroscopy; Helicobacter Infections; Helicobacter pylori; Humans; Male; Metronidazole; Microbial Sensitivity Tests; Middle Aged; Omeprazole; Ranitidine; Treatment Outcome	2002
Effectiveness of ranitidine bismuth citrate based triple therapy for treating Helicobacter pylori. Journal of the Medical Association of Thailand = Chotmaihet thangphaet, 2002, Volume: 85, Issue:10 Topics: Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; Clarithromycin; Drug Therapy, Combination; Dyspepsia; Female; Gastroscopy; Helicobacter Infections; Helicobacter pylori; Humans; Male; Middle Aged; Peptic Ulcer; Prospective Studies; Ranitidine; Stomach; Thailand; Treatment Outcome	2002
Comparison of three triple regimens with omeprazole or ranitidine bismuth citrate for Helicobacter pylori eradication. Scandinavian journal of gastroenterology, 2002, Volume: 37, Issue:12 Topics: Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; Clarithromycin; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Humans; Male; Metronidazole; Middle Aged; Omeprazole; Patient Compliance; Ranitidine; Tetracycline	2002
A prospective, randomized study of quadruple therapy and high-dose dual therapy for treatment of Helicobacter pylori resistant to both metronidazole and clarithromycin. Helicobacter, 2003, Volume: 8, Issue:4 Topics: Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; Clarithromycin; Drug Resistance, Multiple, Bacterial; Drug Therapy, Combination; Female; Gastric Mucosa; Helicobacter Infections; Helicobacter pylori; Humans; Male; Metronidazole; Middle Aged; Omeprazole; Organometallic Compounds; Penicillins; Tetracycline; Urea	2003
A randomized trial comparing seven-day ranitidine bismuth citrate and clarithromycin dual therapy to seven-day omeprazole, clarithromycin and amoxicillin triple therapy for the eradication of Helicobacter pylori. Canadian journal of gastroenterology = Journal canadien de gastroenterologie, 2003, Volume: 17, Issue:9 Topics: Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; Breath Tests; Clarithromycin; Drug Administration Schedule; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Humans; Male; Middle Aged; Omeprazole; Patient Satisfaction; Ranitidine; Time Factors; Urea	2003
Role of antibiotic sensitivity testing before first-line Helicobacter pylori eradication treatments. Alimentary pharmacology & therapeutics, 2003, Oct-15, Volume: 18, Issue:8 Topics: Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; Clarithromycin; Drug Resistance, Bacterial; Drug Therapy, Combination; Dyspepsia; Female; Helicobacter Infections; Helicobacter pylori; Humans; Male; Microbial Sensitivity Tests; Middle Aged; Omeprazole; Ranitidine; Tinidazole; Treatment Outcome	2003
Eradication of Helicobacter pylori infection improves blood pressure values in patients affected by hypertension. Helicobacter, 2003, Volume: 8, Issue:6 Topics: Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Antibodies, Bacterial; Antigens, Bacterial; Bacterial Proteins; Bismuth; Blood Pressure; Clarithromycin; Female; Helicobacter Infections; Helicobacter pylori; Humans; Hypertension; Male; Middle Aged; Prevalence; Ranitidine	2003
Ranitidine-bismuth citrate, tetracycline and metronidazole followed by triple therapy as alternative strategy for Helicobacter pylori treatment: a pilot study. European journal of gastroenterology & hepatology, 2004, Volume: 16, Issue:10 Topics: Adult; Aged; Amoxicillin; Anti-Infective Agents; Bismuth; Clarithromycin; Drug Administration Schedule; Drug Resistance, Microbial; Drug Therapy, Combination; Female; Gastritis; Helicobacter Infections; Helicobacter pylori; Histamine H2 Antagonists; Humans; Male; Metronidazole; Middle Aged; Omeprazole; Pilot Projects; Ranitidine; Tetracycline; Treatment Outcome	2004
Ranitidine bismuth citrate-based triple therapies as a second-line therapy for Helicobacter pylori in Turkish patients. Journal of gastroenterology and hepatology, 2005, Volume: 20, Issue:4 Topics: Adult; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; Breath Tests; Chi-Square Distribution; Clarithromycin; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Humans; Male; Metronidazole; Middle Aged; Omeprazole; Prospective Studies; Ranitidine; Tetracycline; Treatment Outcome; Turkey	2005
One-week dual therapy with ranitidine bismuth citrate and clarithromycin for the treatment of Helicobacter pylori infection in Brazilian patients with peptic ulcer. World journal of gastroenterology, 2005, Jun-21, Volume: 11, Issue:23 Topics: Adult; Aged; Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; Brazil; Clarithromycin; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Humans; Male; Middle Aged; Peptic Ulcer; Ranitidine; Treatment Outcome	2005
Comparison of the efficacy of 1-day high-dose quadruple therapy versus 7-day triple therapy for treatment of Helicobacter pylori infection. Chinese journal of digestive diseases, 2005, Volume: 6, Issue:4 Topics: Adult; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; Breath Tests; Clarithromycin; Drug Administration Schedule; Drug Therapy, Combination; Dyspepsia; Esomeprazole; Female; Helicobacter Infections; Helicobacter pylori; Humans; Male; Metronidazole; Middle Aged; Organometallic Compounds; Proton Pump Inhibitors	2005
Impact of Helicobacter pylori eradication on dyspepsia, health resource use, and quality of life in the Bristol helicobacter project: randomised controlled trial. BMJ (Clinical research ed.), 2006, Jan-28, Volume: 332, Issue:7535 Topics: Adult; Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; Clarithromycin; Costs and Cost Analysis; Dyspepsia; Female; Helicobacter Infections; Helicobacter pylori; Humans; Male; Mass Screening; Middle Aged; Patient Acceptance of Health Care; Peptic Ulcer; Quality of Life; Ranitidine	2006
Third-line rescue therapy with levofloxacin after two H. pylori treatment failures. The American journal of gastroenterology, 2006, Volume: 101, Issue:2 Topics: Amoxicillin; Antacids; Anti-Bacterial Agents; Bismuth; Breath Tests; Clarithromycin; Drug Therapy, Combination; Enzyme Inhibitors; Female; Follow-Up Studies; Helicobacter Infections; Helicobacter pylori; Humans; Levofloxacin; Male; Metronidazole; Middle Aged; Ofloxacin; Omeprazole; Prospective Studies; Protein Synthesis Inhibitors; Tetracycline; Treatment Failure	2006
Seven-day is more effective than 4-day ranitidine bismuth citrate-based triple therapy in eradication of Helicobacter pylori in children: a prospective randomized study. Alimentary pharmacology & therapeutics, 2006, Jul-01, Volume: 24, Issue:1 Topics: Adolescent; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; Child; Clarithromycin; Drug Administration Schedule; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Humans; Male; Peptic Ulcer; Prospective Studies; Ranitidine	2006
Bismuth-based therapies for the first step eradication of Helicobacter pylori. The Turkish journal of gastroenterology : the official journal of Turkish Society of Gastroenterology, 2006, Volume: 17, Issue:2 Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Amoxicillin; Antacids; Anti-Infective Agents; Anti-Ulcer Agents; Bismuth; Breath Tests; Clarithromycin; Drug Therapy, Combination; Dyspepsia; Endoscopy, Gastrointestinal; Female; Helicobacter Infections; Helicobacter pylori; Humans; Male; Metronidazole; Middle Aged; Pantoprazole; Ranitidine; Tetracycline; Treatment Outcome; Urease; Young Adult	2006
The efficacy of bismuth containing quadruple therapy as a first-line treatment option for Helicobacter pylori. Journal of digestive diseases, 2007, Volume: 8, Issue:4 Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; Breath Tests; Clarithromycin; Drug Therapy, Combination; Dyspepsia; Gastroscopy; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Metronidazole; Middle Aged; Single-Blind Method; Statistics, Nonparametric; Tetracycline; Treatment Outcome	2007
Interpretation of the 13C-urea breath test in the choice of second- and third-line eradication of Helicobacter pylori infection. Journal of gastroenterology, 2008, Volume: 43, Issue:2 Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Anti-Infective Agents; Bismuth; Breath Tests; Clarithromycin; Cross-Over Studies; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Humans; Male; Metronidazole; Middle Aged; Pantoprazole; Proton Pump Inhibitors; Ranitidine; Urea	2008
Moxifloxacine plus amoxicillin and ranitidine bismuth citrate or esomeprazole triple therapies for Helicobacter pylori infection. Digestive diseases and sciences, 2008, Volume: 53, Issue:12 Topics: Adult; Aged; Aged, 80 and over; Amoxicillin; Anti-Infective Agents; Anti-Ulcer Agents; Aza Compounds; Bismuth; Breath Tests; Clarithromycin; Drug Therapy, Combination; Esomeprazole; Female; Fluoroquinolones; Helicobacter Infections; Humans; Male; Middle Aged; Moxifloxacin; Pilot Projects; Prospective Studies; Quinolines; Ranitidine; Treatment Outcome; Young Adult	2008
Triple or quadruple tetracycline-based therapies versus standard triple treatment for Helicobacter pylori treatment. The American journal of the medical sciences, 2009, Volume: 338, Issue:1 Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Aged, 80 and over; Amoxicillin; Anti-Bacterial Agents; Bismuth; Clarithromycin; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Male; Metronidazole; Middle Aged; Prospective Studies; Tetracycline; Treatment Outcome; Young Adult	2009
Efficacy of two different Helicobacter pylori eradication regimens in patients with type 2 diabetes and the effect of Helicobacter pylori eradication on dyspeptic symptoms in patients with diabetes: a randomized controlled study. The American journal of the medical sciences, 2009, Volume: 338, Issue:6 Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; Clarithromycin; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Dyspepsia; Female; Helicobacter Infections; Helicobacter pylori; Humans; Male; Middle Aged; Pantoprazole; Ranitidine	2009
Bismuth-based first-line therapy for Helicobacter pylori eradication in type 2 diabetes mellitus patients. Digestion, 2010, Volume: 82, Issue:1 Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Antacids; Anti-Bacterial Agents; Anti-Infective Agents; Bismuth; Case-Control Studies; Chi-Square Distribution; Clarithromycin; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Humans; Male; Metronidazole; Middle Aged; Pantoprazole; Proton Pump Inhibitors; Statistics, Nonparametric; Surveys and Questionnaires; Tetracycline; Treatment Outcome	2010
Standard triple, bismuth pectin quadruple and sequential therapies for Helicobacter pylori eradication. World journal of gastroenterology, 2010, Sep-14, Volume: 16, Issue:34 Topics: Adult; Aged; Amoxicillin; Bismuth; Clarithromycin; Double-Blind Method; Female; Helicobacter Infections; Helicobacter pylori; Humans; Male; Medication Adherence; Middle Aged; Omeprazole; Pectins; Prospective Studies	2010
A comparison between sequential therapy and a modified bismuth-based quadruple therapy for Helicobacter pylori eradication in Iran: a randomized clinical trial. Helicobacter, 2012, Volume: 17, Issue:1 Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Amoxicillin; Anti-Bacterial Agents; Bismuth; Clarithromycin; Drug Therapy, Combination; Duodenal Ulcer; Female; Furazolidone; Helicobacter Infections; Helicobacter pylori; Humans; Iran; Male; Middle Aged; Organometallic Compounds; Pantoprazole	2012
Efficacy of bismuth-containing quadruple therapies for clarithromycin-, metronidazole-, and fluoroquinolone-resistant Helicobacter pylori infections in a prospective study. Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association, 2013, Volume: 11, Issue:7 Topics: Adolescent; Adult; Aged; Anti-Bacterial Agents; Bismuth; Breath Tests; Clarithromycin; Drug Resistance, Bacterial; Drug Therapy, Combination; Female; Fluoroquinolones; Helicobacter Infections; Helicobacter pylori; Humans; Male; Metronidazole; Microbial Sensitivity Tests; Middle Aged; Prospective Studies; Treatment Outcome; Urea; Young Adult	2013
Risk of recurrent Helicobacter pylori infection 1 year after initial eradication therapy in 7 Latin American communities. JAMA, 2013, Feb-13, Volume: 309, Issue:6 Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Amoxicillin; Anti-Infective Agents; Bismuth; Breath Tests; Clarithromycin; Drug Administration Schedule; Drug Therapy, Combination; Enzyme Inhibitors; Female; Follow-Up Studies; Helicobacter Infections; Humans; Lansoprazole; Latin America; Male; Medication Adherence; Metronidazole; Middle Aged; Primary Prevention; Recurrence; Risk; Stomach Neoplasms; Young Adult	2013
The efficacy of two-week quadruple first-line therapy with bismuth, lansoprazole, amoxicillin, clarithromycin on Helicobacter pylori eradication: a prospective study. Helicobacter, 2013, Volume: 18, Issue:6 Topics: Adolescent; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Bismuth; Clarithromycin; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Male; Middle Aged; Prospective Studies; Young Adult	2013
A multicenter, randomized, prospective study of 14-day ranitidine bismuth citrate- vs. lansoprazole-based triple therapy for the eradication of Helicobacter pylori in dyspeptic patients. The Turkish journal of gastroenterology : the official journal of Turkish Society of Gastroenterology, 2013, Volume: 24, Issue:4 Topics: Adolescent; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Bismuth; Clarithromycin; Drug Administration Schedule; Drug Therapy, Combination; Dyspepsia; Endoscopy, Digestive System; Female; Helicobacter Infections; Helicobacter pylori; Histamine H2 Antagonists; Humans; Lansoprazole; Male; Middle Aged; Prospective Studies; Proton Pump Inhibitors; Ranitidine; Treatment Outcome; Young Adult	2013
Improved eradication rate of standard triple therapy by adding bismuth and probiotic supplement for Helicobacter pylori treatment in Thailand. Asian Pacific journal of cancer prevention : APJCP, 2014, Volume: 15, Issue:22 Topics: Amoxicillin; Anti-Bacterial Agents; Bismuth; Clarithromycin; Drug Therapy, Combination; Female; Follow-Up Studies; Gastritis; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Male; Middle Aged; Organometallic Compounds; Probiotics; Prognosis; Prospective Studies; Salicylates; Thailand	2014
High Efficacy of Levofloxacin-Dexlansoprazole-Based Quadruple Therapy as a First Line Treatment for Helicobacter pylori Eradication in Thailand. Asian Pacific journal of cancer prevention : APJCP, 2015, Volume: 16, Issue:10 Topics: Anti-Bacterial Agents; Antidiarrheals; Bismuth; Breath Tests; Clarithromycin; Cytochrome P-450 CYP2C19; Dexlansoprazole; Drug Therapy, Combination; Female; Genotype; Helicobacter Infections; Helicobacter pylori; Humans; Intention to Treat Analysis; Levofloxacin; Male; Microbial Sensitivity Tests; Middle Aged; Organometallic Compounds; Prospective Studies; Proton Pump Inhibitors; Salicylates; Thailand	2015
Tailored versus Triple plus Bismuth or Concomitant Therapy as Initial Helicobacter pylori Treatment: A Randomized Trial. Helicobacter, 2016, Volume: 21, Issue:2 Topics: Adolescent; Adult; Aged; Anti-Bacterial Agents; Bismuth; China; Clarithromycin; Cytochrome P-450 CYP2C19; Disk Diffusion Antimicrobial Tests; Drug Resistance, Bacterial; Drug Therapy, Combination; Female; Genotype; Helicobacter Infections; Helicobacter pylori; Humans; Male; Metronidazole; Middle Aged; Tertiary Care Centers; Treatment Outcome; Young Adult	2016
Bismuth, lansoprazole, amoxicillin and metronidazole or clarithromycin as first-line Helicobacter pylori therapy. Gut, 2015, Volume: 64, Issue:11 Topics: Adolescent; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Bismuth; Clarithromycin; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Male; Metronidazole; Middle Aged; Proton Pump Inhibitors; Young Adult	2015
Comparison of three different regimens against Helicobacter pylori as a first-line treatment: A randomized clinical trial. Bosnian journal of basic medical sciences, 2016, Jan-01, Volume: 16, Issue:1 Topics: Adolescent; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Biopsy; Bismuth; Clarithromycin; Cross-Over Studies; Drug Resistance, Bacterial; Drug Therapy, Combination; Female; Gastric Mucosa; Helicobacter pylori; Humans; Male; Metronidazole; Middle Aged; Potassium Citrate; Prospective Studies; Rabeprazole; Tetracycline; Time Factors; Young Adult	2016
Efficacy of 1st-line bismuth-containing quadruple therapies with levofloxacin or clarithromycin for the eradication of Helicobacter pylori infection: A 1-week, open-label, randomized trial. Medicine, 2017, Volume: 96, Issue:7 Topics: Adult; Antacids; Anti-Bacterial Agents; Bismuth; Clarithromycin; Cytochrome P-450 CYP2C19; Drug Resistance, Bacterial; Drug Therapy, Combination; Esomeprazole; Female; Helicobacter Infections; Helicobacter pylori; Humans; Levofloxacin; Male; Middle Aged; Proton Pump Inhibitors; Treatment Outcome	2017
Improving the standard sequential treatment of Helicobacter pylori with either extended treatment or by adding bismuth. Arab journal of gastroenterology : the official publication of the Pan-Arab Association of Gastroenterology, 2017, Volume: 18, Issue:2 Topics: Adult; Amoxicillin; Antacids; Anti-Bacterial Agents; Bismuth; Clarithromycin; Drug Administration Schedule; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Male; Metronidazole; Middle Aged; Proton Pump Inhibitors	2017
Berberine containing quadruple therapy for initial Helicobacter pylori eradication: An open-label randomized phase IV trial. Medicine, 2017, Volume: 96, Issue:32 Topics: Adult; Age Factors; Amoxicillin; Antacids; Anti-Bacterial Agents; Berberine; Bismuth; Body Mass Index; Breath Tests; Clarithromycin; Drug Therapy, Combination; Esomeprazole; Female; Helicobacter Infections; Helicobacter pylori; Humans; Male; Middle Aged; Proton Pump Inhibitors; Severity of Illness Index; Sex Factors	2017
Quadruple, sequential, and concomitant first-line therapies for H. pylori eradication: a prospective, randomized study. Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver, 2018, Volume: 50, Issue:2 Topics: Adult; Aged; Antacids; Anti-Bacterial Agents; Bismuth; Breath Tests; Clarithromycin; Drug Therapy, Combination; Esomeprazole; Female; Helicobacter Infections; Helicobacter pylori; Humans; Italy; Levofloxacin; Male; Middle Aged; Prospective Studies; Proton Pump Inhibitors	2018
A Prospective, randomized study comparing 7-day and 14-day quadruple therapies as first-line treatments for helicobacter pylori infection in patients with functional dyspepsia. Nigerian journal of clinical practice, 2018, Volume: 21, Issue:1 Topics: Adult; Amoxicillin; Anti-Bacterial Agents; Antidiarrheals; Bismuth; Clarithromycin; Drug Administration Schedule; Drug Therapy, Combination; Dyspepsia; Female; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Male; Middle Aged; Organometallic Compounds; Prospective Studies; Proton Pump Inhibitors; Salicylates	2018
New single capsule of bismuth, metronidazole and tetracycline given with omeprazole versus quadruple therapy consisting of bismuth, omeprazole, amoxicillin and clarithromycin for eradication of Helicobacter pylori in duodenal ulcer patients: a Chinese pro The Journal of antimicrobial chemotherapy, 2018, 06-01, Volume: 73, Issue:6 Topics: Adolescent; Adult; Aged; Amoxicillin; Antacids; Anti-Bacterial Agents; Bismuth; Capsules; China; Clarithromycin; Drug Therapy, Combination; Duodenal Ulcer; Female; Helicobacter Infections; Helicobacter pylori; Humans; Male; Metronidazole; Middle Aged; Omeprazole; Prospective Studies; Tetracycline; Young Adult	2018
Bismuth improves efficacy of proton-pump inhibitor clarithromycin, metronidazole triple Helicobacter pylori therapy despite a high prevalence of antimicrobial resistance. Helicobacter, 2018, Volume: 23, Issue:3 Topics: Adult; Aged; Anti-Bacterial Agents; Bismuth; Breath Tests; China; Clarithromycin; Drug Resistance, Bacterial; Drug Therapy, Combination; Esomeprazole; Female; Helicobacter Infections; Helicobacter pylori; Humans; Male; Metronidazole; Microbial Sensitivity Tests; Middle Aged; Proton Pump Inhibitors; Treatment Outcome	2018
Ten-Day Quadruple Therapy Comprising Low-Dose Rabeprazole, Bismuth, Amoxicillin, and Tetracycline Is an Effective and Safe First-Line Treatment for Helicobacter pylori Infection in a Population with High Antibiotic Resistance: a Prospective, Multicenter, Antimicrobial agents and chemotherapy, 2018, Volume: 62, Issue:9 Topics: Adolescent; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Bismuth; China; Clarithromycin; Drug Resistance, Microbial; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Humans; Male; Middle Aged; Prospective Studies; Protein Synthesis Inhibitors; Proton Pump Inhibitors; Rabeprazole; Tetracycline; Young Adult	2018
Optimizing first line 7-day standard triple therapy for Helicobacter pylori eradication: Prolonging treatment or adding bismuth: which is better? Journal of digestive diseases, 2018, Volume: 19, Issue:11 Topics: Adolescent; Adult; Aged; Aged, 80 and over; Amoxicillin; Anti-Bacterial Agents; Bismuth; Clarithromycin; Drug Administration Schedule; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Humans; Intention to Treat Analysis; Male; Middle Aged; Proton Pump Inhibitors; Rabeprazole; Treatment Outcome; Young Adult	2018
Bismuth-containing quadruple therapy versus concomitant quadruple therapy as first-line treatment for Helicobacter Pylori infection in an area of high resistance to clarithromycin: A prospective, cross-sectional, comparative, open trial. Helicobacter, 2019, Volume: 24, Issue:1 Topics: Anti-Bacterial Agents; Bismuth; Clarithromycin; Cross-Sectional Studies; Drug Administration Schedule; Drug Resistance, Bacterial; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Humans; Male; Middle Aged; Prospective Studies; Treatment Outcome	2019
Evaluation of the efficacy and safety of the hybrid scheme for eradication therapy of Helicobacter pylori infection. Terapevticheskii arkhiv, 2018, Aug-27, Volume: 90, Issue:8 Topics: Adult; Amoxicillin; Antacids; Anti-Infective Agents; Anti-Ulcer Agents; Bismuth; Clarithromycin; Drug Administration Schedule; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Humans; Male; Metronidazole; Omeprazole; Peptic Ulcer; Prospective Studies; Treatment Outcome	2018
Half-dose clarithromycin-containing bismuth quadruple therapy is effective and economical in treating Helicobacter pylori infection: A single-center, open-label, randomized trial. Helicobacter, 2019, Volume: 24, Issue:2 Topics: Adult; Amoxicillin; Antacids; Anti-Bacterial Agents; Bismuth; Breath Tests; China; Clarithromycin; Cost-Benefit Analysis; Drug Administration Schedule; Drug Therapy, Combination; Esomeprazole; Female; Helicobacter Infections; Helicobacter pylori; Humans; Male; Middle Aged; Treatment Outcome	2019
Twice daily short-message-based re-education could improve Helicobacter pylori eradication rate in young population: A prospective randomized controlled study. Helicobacter, 2019, Volume: 24, Issue:3 Topics: Adolescent; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Bismuth; Clarithromycin; Disease Eradication; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Male; Middle Aged; Patient Education as Topic; Pectins; Prospective Studies; Text Messaging; Young Adult	2019
Randomised controlled trial: susceptibility-guided therapy versus empiric bismuth quadruple therapy for first-line Helicobacter pylori treatment. Alimentary pharmacology & therapeutics, 2019, Volume: 49, Issue:11 Topics: Adolescent; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Bismuth; Clarithromycin; Drug Administration Schedule; Drug Therapy, Combination; Esomeprazole; Female; Helicobacter Infections; Helicobacter pylori; Humans; Levofloxacin; Male; Metronidazole; Middle Aged; Proton Pump Inhibitors; Treatment Outcome; Young Adult	2019
Effects of addition of probiotic and/or bismuth to triple therapy of H. pylori and analysis of genetic variation of 23S rRNA gene between patients with clarithromycin sensitivity and resistance. Pakistan journal of pharmaceutical sciences, 2019, Volume: 32, Issue:3 Special Topics: Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Asian People; Bismuth; Clarithromycin; Drug Resistance, Bacterial; Esomeprazole; Female; Gene Frequency; Helicobacter Infections; Helicobacter pylori; Humans; Male; Microbial Sensitivity Tests; Middle Aged; Polymorphism, Single Nucleotide; Probiotics; RNA, Ribosomal, 23S; Treatment Outcome	2019
Is tailored therapy based on antibiotic susceptibility effective ? a multicenter, open-label, randomized trial. Frontiers of medicine, 2020, Volume: 14, Issue:1 Topics: Adult; Amoxicillin; Anti-Bacterial Agents; Bismuth; Breath Tests; China; Clarithromycin; Drug Resistance, Bacterial; Drug Therapy, Combination; Esomeprazole; Female; Furazolidone; Helicobacter Infections; Helicobacter pylori; Humans; Intention to Treat Analysis; Levofloxacin; Male; Metronidazole; Middle Aged; Proton Pump Inhibitors; Treatment Outcome	2020
Addition of bismuth to standard triple therapy for Helicobacter pylori eradication: a randomised controlled trial. JPMA. The Journal of the Pakistan Medical Association, 2020, Volume: 70, Issue:8 Topics: Amoxicillin; Anti-Bacterial Agents; Bismuth; Clarithromycin; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Humans; Male; Metronidazole	2020
Susceptibility-guided quadruple therapy is not superior to medication history-guided therapy for the rescue treatment of Helicobacter pylori infection: A randomized controlled trial. Journal of digestive diseases, 2020, Volume: 21, Issue:10 Topics: Amoxicillin; Anti-Bacterial Agents; Bismuth; Clarithromycin; Cost-Benefit Analysis; Drug Therapy, Combination; Furazolidone; Helicobacter Infections; Helicobacter pylori; Humans; Levofloxacin; Metronidazole; Treatment Outcome	2020
A comparative study of 14-day dual therapy (esomeprazole and amoxicillin four times daily) and triple plus bismuth therapy for first-line Helicobacter pylori infection eradication: A randomized trial. Helicobacter, 2020, Volume: 25, Issue:6 Topics: Amoxicillin; Anti-Bacterial Agents; Bismuth; Clarithromycin; Drug Therapy, Combination; Esomeprazole; Helicobacter Infections; Helicobacter pylori; Humans; Treatment Outcome	2020
Empiric Versus Clarithromycin Resistance-Guided Therapy for Helicobacter pylori Based on Polymerase Chain Reaction Results in Patients With Gastric Neoplasms or Gastric Mucosa-Associated Lymphoid Tissue Lymphoma: A Randomized Controlled Trial. Clinical and translational gastroenterology, 2020, Volume: 11, Issue:9 Topics: Aged; Amoxicillin; Anti-Bacterial Agents; Biopsy; Bismuth; Clarithromycin; DNA, Bacterial; Drug Resistance, Bacterial; Drug Therapy, Combination; Esomeprazole; Female; Gastric Mucosa; Helicobacter Infections; Helicobacter pylori; Humans; Lymphoma, Non-Hodgkin; Male; Metronidazole; Middle Aged; Polymerase Chain Reaction; Prospective Studies; Republic of Korea; RNA, Ribosomal, 23S; Stomach Neoplasms; Tetracycline; Treatment Outcome	2020
Application of a semi-automatic, intensive follow-up for improving efficacy and adherence of Helicobacter pylori eradication therapy: A randomized controlled trial. MicrobiologyOpen, 2021, Volume: 10, Issue:1 Topics: Amoxicillin; Anti-Bacterial Agents; Bismuth; Clarithromycin; Esomeprazole; Helicobacter Infections; Helicobacter pylori; Humans; Medication Adherence; Proton Pump Inhibitors; Treatment Outcome	2021
Ten-day bismuth-containing quadruple therapy versus 7-day proton pump inhibitor-clarithromycin containing triple therapy as first-line empirical therapy for the Helicobacter pylori infection in Korea: a randomized open-label trial. BMC gastroenterology, 2021, Mar-02, Volume: 21, Issue:1 Topics: Amoxicillin; Anti-Bacterial Agents; Bismuth; Clarithromycin; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans; Metronidazole; Proton Pump Inhibitors; Republic of Korea	2021
Clarithromycin versus furazolidone for naïve Helicobacter pylori infected patients in a high clarithromycin resistance area. Journal of gastroenterology and hepatology, 2021, Volume: 36, Issue:9 Topics: Anti-Bacterial Agents; Bismuth; Clarithromycin; Cost-Benefit Analysis; Drug Therapy, Combination; Furazolidone; Helicobacter Infections; Helicobacter pylori; Humans; Treatment Outcome	2021
Evaluation of safety and pharmacokinetics of bismuth-containing quadruple therapy with either vonoprazan or lansoprazole for Helicobacter pylori eradication. British journal of clinical pharmacology, 2022, Volume: 88, Issue:1 Topics: Amoxicillin; Anti-Bacterial Agents; Bismuth; Clarithromycin; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Pyrroles; Sulfonamides; Treatment Outcome	2022
Pretreatment with Ranitidine Bismuth Citrate May Improve Success Rates of Helicobacter pylori Eradication: A Prospective, Randomized, Controlled and Open-Label Study. The Tohoku journal of experimental medicine, 2021, Volume: 255, Issue:1 Topics: Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Bacterial Load; Bismuth; Clarithromycin; Drug Administration Schedule; Drug Therapy, Combination; Esomeprazole; Female; Helicobacter Infections; Helicobacter pylori; Histamine H2 Antagonists; Humans; Male; Middle Aged; Prospective Studies; Ranitidine; Treatment Failure; Treatment Outcome	2021
Comparison of tailored Expert review of anti-infective therapy, 2022, Volume: 20, Issue:6 Topics: Amoxicillin; Anti-Bacterial Agents; Bismuth; Clarithromycin; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans; Metronidazole; Republic of Korea; Treatment Outcome	2022
Bismuth-Based Quadruple Therapy versus Metronidazole-Intensified Triple Therapy as a First-Line Treatment for Clarithromycin-Resistant Gut and liver, 2022, Sep-15, Volume: 16, Issue:5 Topics: Amoxicillin; Anti-Bacterial Agents; Bismuth; Clarithromycin; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans; Metronidazole; Treatment Outcome	2022
Randomised clinical trial: comparison of efficacy and adverse effects of a standard triple clarithromycin-containing regimen with high-dose amoxicillin and bismuth therapy in Helicobacter pylori eradication. European journal of cancer prevention : the official journal of the European Cancer Prevention Organisation (ECP), 2022, 07-01, Volume: 31, Issue:4 Topics: Amoxicillin; Anti-Bacterial Agents; Bismuth; Clarithromycin; Drug Therapy, Combination; Esomeprazole; Helicobacter Infections; Helicobacter pylori; Humans; Treatment Outcome	2022
High-dose amoxicillin-proton pump inhibitor dual therapy as first-line treatment for Helicobacter pylori infection in Northwest China: A prospective, randomised controlled trial. British journal of clinical pharmacology, 2023, Volume: 89, Issue:1 Topics: Amoxicillin; Anti-Bacterial Agents; Bismuth; China; Clarithromycin; Drug Therapy, Combination; Esomeprazole; Helicobacter Infections; Helicobacter pylori; Humans; Prospective Studies; Proton Pump Inhibitors; Treatment Outcome	2023
[A prospective randomized comparative study of the efficacy and safety of a two-week bismuth-based quadrotherapy of Terapevticheskii arkhiv, 2021, Aug-15, Volume: 93, Issue:8 Topics: Amoxicillin; Anti-Bacterial Agents; Bifidobacterium longum; Bismuth; Clarithromycin; Drug Therapy, Combination; Enterococcus faecium; Helicobacter Infections; Helicobacter pylori; Humans; Immunoglobulin A, Secretory; Omeprazole; Probiotics; Prospective Studies; Urease	2021
Comparison of 10 and 14 days of antofloxacin-based versus 14 days of clarithromycin-based bismuth quadruple therapy for Helicobacter pylori eradication: A randomized trial. Clinics and research in hepatology and gastroenterology, 2023, Volume: 47, Issue:1 Topics: Amoxicillin; Anti-Bacterial Agents; Bismuth; Clarithromycin; Drug Therapy, Combination; Esomeprazole; Helicobacter Infections; Helicobacter pylori; Humans; Nausea; Pectins; Proton Pump Inhibitors; Treatment Outcome	2023
Pharmacokinetic Interaction of Anaprazole, Amoxicillin and Clarithromycin after Single-Dose Simultaneous Administration and the Effect of Adding Bismuth on Their Pharmacokinetics in Healthy Male Chinese Subjects. European journal of drug metabolism and pharmacokinetics, 2023, Volume: 48, Issue:2 Topics: Amoxicillin; Anti-Bacterial Agents; Bismuth; Clarithromycin; Drug Combinations; East Asian People; Helicobacter Infections; Humans; Male; Proton Pump Inhibitors	2023
Impact of dexamethasone and tocilizumab on hematological parameters in COVID-19 patients with chronic disease. Medicina clinica (English ed.), 2022, Dec-23, Volume: 159, Issue:12 Topics: Acetaminophen; Acetylcarnitine; Acetylcholinesterase; Acids; Acinetobacter baumannii; Acinetobacter Infections; Adaptation, Psychological; Adolescent; Adsorption; Adult; Aged; Alcohol Drinking; Alzheimer Disease; Amikacin; Ammonia; Anaerobiosis; Animals; Anorexia; Anti-Bacterial Agents; Anti-Infective Agents; Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non-Steroidal; Antineoplastic Agents; Anxiety; Aptamers, Nucleotide; Asthenia; Attention Deficit Disorder with Hyperactivity; Bacterial Proteins; Beryllium; beta-Lactamases; Biofuels; Biomass; Biosensing Techniques; Bismuth; Blister; Body Mass Index; Body Surface Area; Boronic Acids; Brain; Breast Neoplasms; Butyrylcholinesterase; Cannabis; Carbapenems; Carbonyl Cyanide m-Chlorophenyl Hydrazone; Carboxylic Acids; Carcinoma, Hepatocellular; Cardiovascular Diseases; Carnitine; Case-Control Studies; Catalysis; Cell Cycle Proteins; Cell Line, Tumor; Cell Proliferation; Child; China; Cholinesterase Inhibitors; Clarithromycin; Clostridioides; Clostridioides difficile; Clostridium Infections; Cohort Studies; Colistin; Colitis; Colon; Coloring Agents; Coronary Artery Bypass; Creatinine; Crystalloid Solutions; Cytokines; Depression; Dextran Sulfate; Dextrans; Diabetes Mellitus, Type 2; Diabetic Retinopathy; Diarrhea; Dietary Supplements; Diphenhydramine; Disease Models, Animal; Disease Outbreaks; Double-Blind Method; Doxorubicin; Drosophila; Drug Tapering; Dysbiosis; Electrons; Escherichia coli; Extracellular Vesicles; Fatigue; Female; Fermentation; gamma-Cyclodextrins; Gastrointestinal Microbiome; Glucose; Graft Survival; Graft vs Host Disease; Head and Neck Neoplasms; Heart Arrest, Induced; Hematopoietic Stem Cell Transplantation; High-Intensity Interval Training; Hippocampus; Humans; Hydrogen-Ion Concentration; Hypertension; Incidence; Interferon-gamma; Italy; Kinetics; Klebsiella Infections; Klebsiella pneumoniae; Lab-On-A-Chip Devices; Lactoferrin; Larva; Length of Stay; Lignin; Liver; Liver Neoplasms; Liver Transplantation; Living Donors; Low Back Pain; Lung; Lung Volume Measurements; Macrophages; Male; Melphalan; Men; Mendelian Randomization Analysis; Meropenem; Methane; Mice; Mice, Inbred C57BL; Microbial Sensitivity Tests; Mitochondrial Proteins; Molecular Docking Simulation; Molecular Structure; Mothers; Motivation; Mycoplasma; Mycoplasma hominis; Mycoplasma Infections; NAD; Nanocomposites; Nanoparticles; Nanotubes, Carbon; Naproxen; Neovascularization, Pathologic; Neurons; Nitrates; Nucleolin; Opuntia; Paratyphoid Fever; Phenotype; Phosphatidylinositol 3-Kinases; Phytochemicals; Plant Extracts; Pregnancy; Prevalence; Prospective Studies; Proto-Oncogene Proteins c-akt; Pulmonary Disease, Chronic Obstructive; Rats; Rats, Wistar; Resveratrol; Retrospective Studies; Rifampin; Risk Factors; RNA, Messenger; Selenium; Sleep; Social Behavior; Soil; Soil Pollutants; Squamous Cell Carcinoma of Head and Neck; Staphylococcus aureus; Structure-Activity Relationship; Suicidal Ideation; Suicide; Superoxide Dismutase-1; Surveys and Questionnaires; Swimming; Syndrome; Tannins; Temperature; Transforming Growth Factor beta; Transplantation Conditioning; Treatment Outcome; Triple Negative Breast Neoplasms; Troponin T; Tumor Microenvironment; United Kingdom; Ureaplasma; Ureaplasma urealyticum; Urinary Tract Infections; Viscum; Waste Disposal Facilities; Wastewater; Water; Water Pollutants, Chemical; Wolfiporia; Young Adult	2022
Second-line levofloxacin-based quadruple therapy versus bismuth-based quadruple therapy for Helicobacter pylori eradication and long-term changes to the gut microbiota and antibiotic resistome: a multicentre, open-label, randomised controlled trial. The lancet. Gastroenterology & hepatology, 2023, Volume: 8, Issue:3 Topics: Adult; Anti-Bacterial Agents; Australia; Bismuth; Clarithromycin; Drug Therapy, Combination; Esomeprazole; Female; Gastrointestinal Microbiome; Helicobacter Infections; Helicobacter pylori; Humans; Levofloxacin; Male; Metronidazole; Middle Aged; Proton Pump Inhibitors; RNA, Ribosomal, 16S; Young Adult	2023
Tailored triple plus bismuth therapy based on previous antibiotic medication history for first-line Helicobacter pylori eradication: A randomized trial. Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver, 2023, Volume: 55, Issue:5 Topics: Amoxicillin; Anti-Bacterial Agents; Bismuth; Clarithromycin; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans; Levofloxacin; Macrolides; Metronidazole; Proton Pump Inhibitors; Quinolones; Treatment Outcome	2023
Ten-Day Vonoprazan-Amoxicillin Dual Therapy as a First-Line Treatment of Helicobacter pylori Infection Compared With Bismuth-Containing Quadruple Therapy. The American journal of gastroenterology, 2023, 04-01, Volume: 118, Issue:4 Topics: Amoxicillin; Anti-Bacterial Agents; Bismuth; Clarithromycin; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans; Proton Pump Inhibitors; Treatment Outcome	2023
Vonoprazan is noninferior to proton pump inhibitors in bismuth-containing quadruple therapy for the treatment of Helicobacter pylori infection: A propensity score matching analysis. Journal of digestive diseases, 2023, Volume: 24, Issue:1 Topics: Amoxicillin; Anti-Bacterial Agents; Bismuth; Clarithromycin; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans; Propensity Score; Proton Pump Inhibitors; Retrospective Studies; Treatment Outcome	2023
Quantitative PCR of string-test collected gastric material: A feasible approach to detect Helicobacter pylori and its resistance against clarithromycin and levofloxacin for susceptibility-guided therapy. Helicobacter, 2023, Volume: 28, Issue:4 Topics: Amoxicillin; Anti-Bacterial Agents; Bismuth; Clarithromycin; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans; Levofloxacin; Polymerase Chain Reaction; Retrospective Studies; Treatment Outcome	2023
Combination of vonoprazan and amoxicillin as the first-line Helicobacter pylori eradication therapy: a multicenter, prospective, randomized, parallel-controlled study. Clinical and experimental medicine, 2023, Volume: 23, Issue:7 Topics: Amoxicillin; Anti-Bacterial Agents; Bismuth; Clarithromycin; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans; Treatment Outcome	2023
Eradication rates of Helicobacter pylori in treatment-naive patients following 14-day vonoprazan-amoxicillin dual therapy: A multicenter randomized controlled trial in China. Helicobacter, 2023, Volume: 28, Issue:4 Topics: Amoxicillin; Anti-Bacterial Agents; Bismuth; Clarithromycin; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans; Proton Pump Inhibitors; Treatment Outcome	2023
Vonoprazan-based triple and dual therapy versus bismuth-based quadruple therapy for Helicobacter pylori infection in China: a three-arm, randomised clinical trial protocol. BMC gastroenterology, 2023, Jul-07, Volume: 23, Issue:1 Topics: Amoxicillin; Anti-Bacterial Agents; Bismuth; Clarithromycin; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans; Proton Pump Inhibitors; Randomized Controlled Trials as Topic; Stomach Neoplasms; Treatment Outcome	2023
Efficacy and safety of triple therapy containing berberine, amoxicillin, and vonoprazan for Helicobacter pylori initial treatment: A randomized controlled trial. Chinese medical journal, 2023, Jul-20, Volume: 136, Issue:14 Topics: Amoxicillin; Anti-Bacterial Agents; Berberine; Bismuth; Clarithromycin; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans; Proton Pump Inhibitors; Rabeprazole; Treatment Outcome	2023
Efficacy of quadruple therapy with clarithromycin based on faecal molecular antimicrobial susceptibility tests as first-line treatment for BMJ open, 2023, 07-21, Volume: 13, Issue:7 Topics: Amoxicillin; Anti-Infective Agents; Bismuth; China; Clarithromycin; Furazolidone; Helicobacter Infections; Helicobacter pylori; Humans; Rabeprazole; Randomized Controlled Trials as Topic; Single-Blind Method	2023
Pilot studies of vonoprazan-containing Helicobacter pylori eradication therapy suggest Thailand may be more similar to the US than Japan. Helicobacter, 2023, Volume: 28, Issue:6 Topics: Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Bismuth; Clarithromycin; Cytochrome P-450 CYP3A; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Humans; Japan; Male; Middle Aged; Pilot Projects; Proton Pump Inhibitors; Thailand	2023

Other Studies

98 other study(ies) available for bismuth and clarithromycin

Article	Year
Toward an optimal treatment of Helicobacter pylori-positive peptic ulcers. The American journal of gastroenterology, 1995, Volume: 90, Issue:5 Topics: Bismuth; Clarithromycin; Helicobacter Infections; Helicobacter pylori; Humans; Omeprazole; Peptic Ulcer	1995
Clarithromycin, tetracycline, and bismuth: a new non-metronidazole therapy for Helicobacter pylori infection. The American journal of gastroenterology, 1994, Volume: 89, Issue:8 Topics: Adult; Aged; Bismuth; Clarithromycin; Drug Administration Schedule; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans; Male; Middle Aged; Organometallic Compounds; Peptic Ulcer; Ranitidine; Salicylates; Tetracycline; Time Factors	1994
Response to article by Forné et al. The American journal of gastroenterology, 1996, Volume: 91, Issue:1 Topics: Anti-Bacterial Agents; Bismuth; Clarithromycin; Colloids; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans; Omeprazole; Remission Induction	1996
Cost-effectiveness of treatment regimens for the eradication of Helicobacter pylori in duodenal ulcer. The American journal of gastroenterology, 1996, Volume: 91, Issue:2 Topics: Amoxicillin; Antacids; Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; Clarithromycin; Cost-Benefit Analysis; Costs and Cost Analysis; Drug Therapy, Combination; Duodenal Ulcer; Endoscopy; Helicobacter Infections; Helicobacter pylori; Histamine H2 Antagonists; Humans; Metronidazole; Omeprazole; Patient Compliance; Penicillins; Recurrence; Tetracycline; Time Factors	1996
Practice guidelines for treatment of peptic ulcer disease. JAMA, 1996, Oct-09, Volume: 276, Issue:14 Topics: Anti-Bacterial Agents; Bismuth; Clarithromycin; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Histamine H2 Antagonists; Humans; Peptic Ulcer; Practice Guidelines as Topic; Ranitidine	1996
Reversal of long-standing iron deficiency anaemia after eradication of Helicobacter pylori infection. Scandinavian journal of gastroenterology, 1997, Volume: 32, Issue:6 Topics: Adult; Anemia, Iron-Deficiency; Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; Clarithromycin; Drug Therapy, Combination; Gastritis; Helicobacter Infections; Helicobacter pylori; Humans; Male; Metronidazole; Omeprazole; Organometallic Compounds; Salicylates; Tetracycline	1997
Serum 13C-bicarbonate assay for the diagnosis of gastric Helicobacter pylori infection and response to treatment. Gastroenterology, 1997, Volume: 113, Issue:1 Topics: Amoxicillin; Bicarbonates; Bismuth; Carbon Isotopes; Clarithromycin; Drug Therapy, Combination; Gastric Mucosa; Gastritis; Helicobacter Infections; Helicobacter pylori; Humans; Male; Mass Spectrometry; Metronidazole; Middle Aged; Omeprazole; Sensitivity and Specificity; Tetracycline	1997
In vitro synergy testing of clarithromycin and 14-hydroxyclarithromycin with amoxicillin or bismuth subsalicylate against Helicobacter pylori. Antimicrobial agents and chemotherapy, 1997, Volume: 41, Issue:7 Topics: Amoxicillin; Bismuth; Clarithromycin; Drug Synergism; Drug Therapy, Combination; Helicobacter pylori; Microbial Sensitivity Tests; Organometallic Compounds; Salicylates	1997
Pharmacological therapy of Helicobacter pylori infection. Seminars in gastrointestinal disease, 1997, Volume: 8, Issue:3 Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Antacids; Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; Clarithromycin; Drug Costs; Drug Resistance, Microbial; Drug Therapy, Combination; Guidelines as Topic; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Omeprazole; Patient Compliance; Penicillins; Proton Pump Inhibitors; Tetracycline; Treatment Outcome; Vaccination	1997
Treatment of Helicobacter pylori infection: summary of a meeting at the Fourth United European Gastroenterology Week, September 20, 1995. Helicobacter, 1996, Volume: 1, Issue:2 Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Antacids; Bismuth; Clarithromycin; Drug Resistance, Microbial; Drug Resistance, Multiple; Drug Therapy, Combination; Enzyme Inhibitors; Europe; Gastritis; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Metronidazole; Omeprazole; Proton Pump Inhibitors; Randomized Controlled Trials as Topic; Tetracycline; Tinidazole	1996
Cure of Helicobacter pylori: a hidden curse? The American journal of gastroenterology, 1997, Volume: 92, Issue:12 Topics: Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; Clarithromycin; Duodenal Ulcer; Esophagitis, Peptic; Female; Follow-Up Studies; Gastritis; Helicobacter Infections; Helicobacter pylori; Humans; Male; Omeprazole; Organometallic Compounds; Penicillins; Prospective Studies; Risk Factors; Salicylates; Sex Factors; Weight Gain	1997
The role of ranitidine bismuth citrate in significantly reducing the emergence of Helicobacter pylori strains resistant to antibiotics. Helicobacter, 1997, Volume: 2, Issue:1 Topics: Anti-Bacterial Agents; Bismuth; Clarithromycin; Drug Interactions; Drug Resistance, Microbial; Helicobacter pylori; Histamine H2 Antagonists; Metronidazole; Ranitidine; Streptomycin	1997
Cure of Helicobacter pylori infection by omeprazole-clarithromycin-based therapy in non-human primates. Journal of gastroenterology, 1998, Volume: 33, Issue:1 Topics: Amoxicillin; Animals; Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; Clarithromycin; Drug Therapy, Combination; Endoscopy, Gastrointestinal; Enzyme Inhibitors; Gastritis; Helicobacter Infections; Helicobacter pylori; Macaca mulatta; Male; Omeprazole; Organometallic Compounds; Penicillins; Salicylates	1998
[Drug clinics. The drug of the month. Ranitidine bismuth citrate (Pylorid)]. Revue medicale de Liege, 1998, Volume: 53, Issue:1 Topics: Amoxicillin; Antacids; Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; Clarithromycin; Drug Combinations; Duodenal Ulcer; Gastric Acid; Gastric Mucosa; Helicobacter pylori; Histamine H2 Antagonists; Humans; Nitroimidazoles; Penicillins; Proton Pump Inhibitors; Ranitidine; Receptors, Histamine H2; Stomach Ulcer	1998
Optimal PPI-based triple therapy for the cure of Helicobacter pylori infection: a single center comparison of four 14-day schedules. Helicobacter, 1998, Volume: 3, Issue:2 Topics: Adult; Aged; Aged, 80 and over; Antacids; Anti-Bacterial Agents; Bismuth; Clarithromycin; Drug Administration Schedule; Drug Therapy, Combination; Female; Follow-Up Studies; Helicobacter Infections; Helicobacter pylori; Humans; Male; Middle Aged; Proton Pump Inhibitors; Time Factors	1998
Helicobacter pylori eradication failure--'salvage' therapies needed. Italian journal of gastroenterology and hepatology, 1998, Volume: 30, Issue:4 Topics: Amoxicillin; Antacids; Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; Clarithromycin; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans; Omeprazole; Penicillins; Treatment Failure	1998
The bactericidal activity of clarithromycin versus ampicillin alone and in combination with omeprazole and/or bismuth against clarithromycin-susceptible and clarithromycin-resistant strains of Helicobacter pylori. Diagnostic microbiology and infectious disease, 1998, Volume: 32, Issue:1 Topics: Ampicillin; Anti-Bacterial Agents; Bismuth; Clarithromycin; Drug Interactions; Drug Resistance, Microbial; Helicobacter pylori; Humans; Microbial Sensitivity Tests; Omeprazole; Pyloric Antrum; Sensitivity and Specificity; Species Specificity	1998
Treating Helicobacter pylori. Archives of internal medicine, 1998, Nov-23, Volume: 158, Issue:21 Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; Clarithromycin; Drug Combinations; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Omeprazole; Organometallic Compounds; Penicillins; Peptic Ulcer; Ranitidine	1998
In-vitro evaluation of nitrofurantoin as an alternative agent for metronidazole in combination antimicrobial therapy against Helicobacter pylori. The Journal of antimicrobial chemotherapy, 1998, Volume: 42, Issue:5 Topics: Antacids; Anti-Bacterial Agents; Bismuth; Clarithromycin; Drug Resistance, Microbial; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans; Metronidazole; Nitrofurantoin; Tetracycline	1998
Optimal treatment for duodenal ulcer disease: a cost-decision analysis in Malaysian patients. Journal of gastroenterology and hepatology, 1999, Volume: 14, Issue:1 Topics: Amoxicillin; Anti-Bacterial Agents; Anti-Infective Agents; Anti-Ulcer Agents; Bismuth; Clarithromycin; Cost-Benefit Analysis; Decision Support Techniques; Drug Therapy, Combination; Duodenal Ulcer; Humans; Malaysia; Metronidazole; Models, Economic; Omeprazole; Tetracycline	1999
Ranitidine bismuth citrate, tetracycline, clarithromycin twice-a-day triple therapy for clarithromycin susceptible Helicobacter pylori infection. Alimentary pharmacology & therapeutics, 1999, Volume: 13, Issue:2 Topics: Adult; Aged; Bismuth; Clarithromycin; Drug Administration Schedule; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Humans; Male; Middle Aged; Prospective Studies; Ranitidine; Tetracycline	1999
Immunization with recombinant Helicobacter pylori urease decreases colonization levels following experimental infection of rhesus monkeys. Vaccine, 1999, Mar-17, Volume: 17, Issue:11-12 Topics: Adjuvants, Immunologic; Animals; Anti-Bacterial Agents; Antibodies, Bacterial; Bacterial Toxins; Bacterial Vaccines; Bismuth; Clarithromycin; Drug Therapy, Combination; Enterotoxins; Enzyme-Linked Immunosorbent Assay; Escherichia coli Proteins; Helicobacter Infections; Helicobacter pylori; Macaca mulatta; Metronidazole; Omeprazole; Organometallic Compounds; Recombinant Proteins; Salicylates; Saliva; Urease	1999
Use of a urea breath test to evaluate short-term treatments for cats naturally infected with Helicobacter heilmannii. American journal of veterinary research, 1999, Volume: 60, Issue:7 Topics: Animals; Antacids; Anti-Bacterial Agents; Anti-Ulcer Agents; Antitrichomonal Agents; Azithromycin; Biopsy; Bismuth; Breath Tests; Carbon Dioxide; Carbon Radioisotopes; Cat Diseases; Cats; Clarithromycin; Female; Gas Chromatography-Mass Spectrometry; Helicobacter; Helicobacter Infections; Male; Metronidazole; Polymerase Chain Reaction; Prospective Studies; Random Allocation; Ranitidine; Stomach Diseases; Tinidazole; Urea	1999
Re-treatment after Helicobacter pylori eradication failure. European journal of gastroenterology & hepatology, 1999, Volume: 11, Issue:9 Topics: Adult; Ampicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; Clarithromycin; Drug Resistance, Microbial; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Humans; Male; Metronidazole; Middle Aged; Omeprazole; Prospective Studies; Treatment Failure	1999
CYP2C19 genotype-related efficacy of omeprazole for the treatment of infection caused by Helicobacter pylori. Clinical pharmacology and therapeutics, 1999, Volume: 66, Issue:5 Topics: Amoxicillin; Antacids; Anti-Bacterial Agents; Anti-Ulcer Agents; Aryl Hydrocarbon Hydroxylases; Bismuth; Clarithromycin; Cytochrome P-450 CYP2C19; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Drug Therapy, Combination; Enzyme Inhibitors; Gastritis; Genotype; Helicobacter Infections; Helicobacter pylori; Histamine H2 Antagonists; Humans; Metronidazole; Mixed Function Oxygenases; Omeprazole; Penicillins; Peptic Ulcer; Polymerase Chain Reaction; Polymorphism, Restriction Fragment Length; Protein Synthesis Inhibitors; Treatment Outcome	1999
In vitro synergy between ranitidine bismuth citrate and tetracycline or clarithromycin against resistant strains of Helicobacter pylori. European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology, 1999, Volume: 18, Issue:11 Topics: Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; Clarithromycin; Drug Resistance, Microbial; Drug Synergism; Helicobacter pylori; Humans; Microbial Sensitivity Tests; Ranitidine; Tetracycline	1999
Treatment of Helicobacter pylori infection in clinical practice in the United States: results from 224 patients. Digestive diseases and sciences, 2000, Volume: 45, Issue:2 Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Bacterial Agents; Bismuth; Clarithromycin; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Male; Metronidazole; Middle Aged; Omeprazole; Organometallic Compounds; Proton Pump Inhibitors; Salicylates; Treatment Outcome; United States	2000
Effects of in vitro antibiotic resistance on treatment: bismuth-containing regimens. Canadian journal of gastroenterology = Journal canadien de gastroenterologie, 2000, Volume: 14, Issue:10 Topics: Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; Clarithromycin; Drug Resistance, Microbial; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans; Organometallic Compounds; Ranitidine; Salicylates	2000
Dual therapy with ranitidine bismuth citrate for Helicobacter pylori eradication. Journal of clinical gastroenterology, 2001, Volume: 32, Issue:1 Topics: Adolescent; Adult; Aged; Anti-Ulcer Agents; Bismuth; Clarithromycin; Drug Therapy, Combination; Gastritis; Helicobacter Infections; Helicobacter pylori; Humans; Middle Aged; Peptic Ulcer; Ranitidine	2001
A systematic comparison of triple therapies for treatment of Helicobacter pylori infection with proton pump inhibitor/ ranitidine bismuth citrate plus clarithromycin and either amoxicillin or a nitroimidazole. Alimentary pharmacology & therapeutics, 2001, Volume: 15, Issue:5 Topics: Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; Clarithromycin; Drug Costs; Drug Resistance; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans; Nitroimidazoles; Patient Care Planning; Penicillins; Proton Pump Inhibitors; Randomized Controlled Trials as Topic; Ranitidine; Treatment Outcome	2001
In search of the Holy Grail of Heliocobacter pylori remedies. Helicobacter, 2001, Volume: 6, Issue:2 Topics: Amoxicillin; Anti-Bacterial Agents; Anti-Infective Agents; Anti-Ulcer Agents; Bismuth; Clarithromycin; Clinical Trials as Topic; Drug Resistance; Drug Therapy, Combination; Duodenal Ulcer; Dyspepsia; Helicobacter Infections; Humans; Metronidazole; Pilot Projects; Ranitidine; Spain	2001
[In vitro antimicrobial susceptibility of Helicobacter pylori strains: isolation of strains resistant to clarithromycin]. Revista medica de Chile, 2001, Volume: 129, Issue:6 Topics: Amoxicillin; Antacids; Anti-Bacterial Agents; Bismuth; Clarithromycin; Drug Resistance, Microbial; Helicobacter pylori; Humans; Metronidazole; Microbial Sensitivity Tests; Penicillins	2001
Efficacy of Helicobacter pylori eradication therapies: a single centre observational study. BMC gastroenterology, 2001, Volume: 1 Topics: Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; Clarithromycin; Drug Resistance, Bacterial; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans; Metronidazole; Nitroimidazoles; Ranitidine; Treatment Outcome	2001
Helicobacter pylori. The New England journal of medicine, 2003, Jan-23, Volume: 348, Issue:4 Topics: Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; Clarithromycin; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans; Ranitidine	2003
Therapeutic efficacy of ranitidine bismuth citrate with clarithromycin for seven days in the eradication of Helicobacter pylori in Brazilian peptic ulcer patients. Sao Paulo medical journal = Revista paulista de medicina, 2003, Jan-02, Volume: 121, Issue:1 Topics: Adolescent; Adult; Aged; Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; Brazil; Clarithromycin; Cross-Sectional Studies; Drug Administration Schedule; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Humans; Male; Middle Aged; Peptic Ulcer; Ranitidine	2003
The efficacy of two-week therapy with ranitidine bismuth citrate, amoxicillin and clarithromycin on Helicobacter pylori eradication in clarithromycinresistant and- sensitive cases. The Turkish journal of gastroenterology : the official journal of Turkish Society of Gastroenterology, 2005, Volume: 16, Issue:4 Topics: Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; Clarithromycin; DNA, Bacterial; Drug Resistance, Bacterial; Endoscopy, Gastrointestinal; Female; Follow-Up Studies; Gastric Mucosa; Gastritis; Helicobacter Infections; Helicobacter pylori; Humans; Male; Middle Aged; Polymerase Chain Reaction; Ranitidine; Treatment Outcome	2005
Helicobacter pylori eradication in peptic dyspepsia. East African medical journal, 2005, Volume: 82, Issue:12 Topics: Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; Clarithromycin; Drug Administration Schedule; Drug Therapy, Combination; Dyspepsia; Helicobacter Infections; Helicobacter pylori; Humans; Omeprazole; Peptic Ulcer; Proton Pump Inhibitors; Ranitidine	2005
Triple levofloxacin-based rescue therapy is an accepted empirical third-line treatment. The American journal of gastroenterology, 2006, Volume: 101, Issue:8 Topics: Amoxicillin; Ampicillin; Antacids; Anti-Bacterial Agents; Bismuth; Breath Tests; Clarithromycin; Drug Therapy, Combination; Enzyme Inhibitors; Helicobacter Infections; Helicobacter pylori; Humans; Levofloxacin; Metronidazole; Ofloxacin; Omeprazole; Protein Synthesis Inhibitors; Tetracycline; Treatment Failure	2006
Efficacy of two triple eradication regimens in children with Helicobacter pylori infection. Journal of Korean medical science, 2006, Volume: 21, Issue:6 Topics: Adolescent; Amoxicillin; Anti-Bacterial Agents; Bismuth; Child; Child, Preschool; Clarithromycin; Drug Combinations; Female; Helicobacter Infections; Helicobacter pylori; Humans; Male; Metronidazole; Omeprazole; Organometallic Compounds; Retrospective Studies; Salicylates; Treatment Outcome	2006
Results from the pediatric European register for treatment of Helicobacter pylori (PERTH). Helicobacter, 2007, Volume: 12, Issue:2 Topics: Adolescent; Antacids; Bismuth; Child; Child, Preschool; Clarithromycin; Drug Therapy, Combination; Europe; Female; Helicobacter Infections; Helicobacter pylori; Humans; Infant; Male; Microbial Sensitivity Tests; Omeprazole; Registries; Treatment Outcome	2007
[Diagnosis and treatment guidelines for Helicobacter pylori infection in Korea]. The Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi, 2009, Volume: 54, Issue:5 Topics: Amoxicillin; Antacids; Anti-Infective Agents; Bismuth; Breath Tests; Clarithromycin; Enzyme-Linked Immunosorbent Assay; Gastroscopy; Helicobacter Infections; Helicobacter pylori; Humans; Metronidazole; Peptic Ulcer; Proton Pump Inhibitors; Stomach Neoplasms; Tetracycline	2009
Infection: Bismuth improves PPI-based triple therapy for H. pylori eradication. Nature reviews. Gastroenterology & hepatology, 2010, Volume: 7, Issue:10 Topics: Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; China; Clarithromycin; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans; Omeprazole; Treatment Outcome	2010
Ranitidine bismuth citrate in the first-line of Helicobacter pylori treatment. Panminerva medica, 2011, Volume: 53, Issue:2 Topics: Adult; Aged; Amoxicillin; Anti-Infective Agents; Bismuth; Clarithromycin; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Humans; Male; Metronidazole; Middle Aged; Proton Pump Inhibitors; Ranitidine; Treatment Outcome	2011
Rational Helicobacter pylori therapy: evidence-based medicine rather than medicine-based evidence. Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association, 2014, Volume: 12, Issue:2 Topics: Amoxicillin; Anti-Bacterial Agents; Bismuth; Clarithromycin; Drug Resistance, Bacterial; Drug Therapy, Combination; Evidence-Based Medicine; Helicobacter Infections; Helicobacter pylori; Humans; Metronidazole; Treatment Failure	2014
Comparison of antimicrobial activity of zinc chloride and bismuth subsalicylate against clinical isolates of Helicobacter pylori. Microbial drug resistance (Larchmont, N.Y.), 2014, Volume: 20, Issue:4 Topics: Adult; Aged; Anti-Bacterial Agents; Bismuth; Chlorides; Chronic Disease; Clarithromycin; Drug Resistance, Bacterial; Dyspepsia; Female; Gastric Juice; Gastritis; Helicobacter Infections; Helicobacter pylori; Humans; Hydrogen-Ion Concentration; Male; Microbial Sensitivity Tests; Middle Aged; Organometallic Compounds; Peptic Ulcer; Salicylates; Zinc Compounds	2014
[Guidelines for the diagnosis and treatment of Helicobacter pylori infection in Korea, 2013 revised edition]. The Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi, 2013, Volume: 62, Issue:1 Topics: Amoxicillin; Anti-Bacterial Agents; Aspirin; Bismuth; Breath Tests; Clarithromycin; Gastroesophageal Reflux; Gastroscopy; Helicobacter Infections; Helicobacter pylori; Humans; Lymphoma, B-Cell, Marginal Zone; Metaplasia; Metronidazole; Peptic Ulcer; Proton Pump Inhibitors; Republic of Korea; Stomach Neoplasms; Tetracycline	2013
Helicobacter pylori first-line and rescue treatments in the presence of penicillin allergy. Digestive diseases and sciences, 2015, Volume: 60, Issue:2 Topics: Antacids; Anti-Bacterial Agents; Bismuth; Breath Tests; Clarithromycin; Drug Administration Schedule; Drug Hypersensitivity; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Humans; Levofloxacin; Male; Medication Adherence; Metronidazole; Middle Aged; Omeprazole; Penicillins; Predictive Value of Tests; Prospective Studies; Proton Pump Inhibitors; Rifabutin; Salvage Therapy; Spain; Tetracycline; Time Factors; Treatment Outcome	2015
Guidelines for the management of Helicobacter pylori infection in Italy: The III Working Group Consensus Report 2015. Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver, 2015, Volume: 47, Issue:11 Topics: Amoxicillin; Antacids; Anti-Bacterial Agents; Anti-Inflammatory Agents, Non-Steroidal; Antigens, Bacterial; Barrett Esophagus; Bismuth; Breath Tests; Clarithromycin; Disease Management; Drug Therapy, Combination; Dyspepsia; Feces; Gastroesophageal Reflux; Helicobacter Infections; Helicobacter pylori; Italy; Levofloxacin; Metronidazole; Proton Pump Inhibitors; Stomach Neoplasms; Urea	2015
The impact of bismuth addition to sequential treatment on Helicobacter pylori eradication: A pilot study. Bosnian journal of basic medical sciences, 2015, Oct-25, Volume: 15, Issue:4 Topics: Adult; Amoxicillin; Antacids; Anti-Bacterial Agents; Bismuth; Breath Tests; Clarithromycin; Drug Resistance, Bacterial; Female; Gastric Mucosa; Helicobacter Infections; Helicobacter pylori; Humans; Male; Metronidazole; Middle Aged; Pilot Projects; Proton Pump Inhibitors; Treatment Outcome	2015
Levofloxacin, bismuth, amoxicillin and esomeprazole as second-line Helicobacter pylori therapy after failure of non-bismuth quadruple therapy. Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver, 2016, Volume: 48, Issue:5 Topics: Adult; Amoxicillin; Antacids; Anti-Bacterial Agents; Bismuth; Clarithromycin; Cytochrome P-450 CYP2C19; Drug Resistance, Multiple, Bacterial; Drug Therapy, Combination; Esomeprazole; Female; Helicobacter Infections; Helicobacter pylori; Humans; Levofloxacin; Male; Medication Adherence; Metronidazole; Microbial Sensitivity Tests; Middle Aged; Prospective Studies; Proton Pump Inhibitors; Retreatment; Treatment Outcome	2016
The relationship between the failure to eradicate Helicobacter pylori and previous antibiotics use. Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver, 2016, Volume: 48, Issue:4 Topics: Adult; Aged; Anti-Bacterial Agents; Bismuth; Breath Tests; Clarithromycin; Drug Resistance, Bacterial; Female; Helicobacter Infections; Helicobacter pylori; Hospitals, Teaching; Humans; Levofloxacin; Logistic Models; Macrolides; Male; Middle Aged; Multivariate Analysis; Republic of Korea; Retrospective Studies; Tertiary Care Centers	2016
Helicobacter pylori Clarithromycin Resistance and Treatment Failure Are Common in the USA. Digestive diseases and sciences, 2016, Volume: 61, Issue:8 Topics: Adolescent; Adult; Aged; Aged, 80 and over; Amoxicillin; Antacids; Anti-Bacterial Agents; Bismuth; Clarithromycin; Cohort Studies; Drug Resistance, Bacterial; Drug Therapy, Combination; Female; Gastric Mucosa; Gastritis; Helicobacter Infections; Helicobacter pylori; Humans; Male; Metronidazole; Middle Aged; Prevalence; Proton Pump Inhibitors; Retrospective Studies; RNA, Ribosomal, 23S; Treatment Failure; United States; Young Adult	2016
[Quadruple therapy is more effective against H. pylori]. MMW Fortschritte der Medizin, 2016, May-12, Volume: 158, Issue:9 Topics: Anti-Bacterial Agents; Bismuth; Clarithromycin; Drug Therapy, Combination; Gastritis; Helicobacter Infections; Helicobacter pylori; Humans; Peptic Ulcer; Proton Pump Inhibitors	2016
[Cuadruple concomitant non-bismuth therapy vs. classical triple therapy as first line therapy for Helicobacter pylori infection]. Medicina clinica, 2016, Sep-02, Volume: 147, Issue:5 Topics: Adult; Amoxicillin; Antacids; Anti-Bacterial Agents; Bismuth; Clarithromycin; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Humans; Male; Metronidazole; Middle Aged; Proton Pump Inhibitors; Retrospective Studies; Treatment Outcome	2016
Management of Helicobacter pylori infection-the Maastricht V/Florence Consensus Report. Gut, 2017, Volume: 66, Issue:1 Topics: Amoxicillin; Anti-Bacterial Agents; Bismuth; Clarithromycin; Drug Resistance, Bacterial; Drug Therapy, Combination; Dyspepsia; Early Detection of Cancer; Evidence-Based Medicine; Fluoroquinolones; Gastritis; Gastrointestinal Microbiome; Gastroscopy; Helicobacter Infections; Helicobacter pylori; Humans; Microbial Sensitivity Tests; Nitroimidazoles; Practice Guidelines as Topic; Proton Pump Inhibitors; Risk Factors; Stomach; Stomach Neoplasms	2017
ACG Clinical Guideline: Treatment of Helicobacter pylori Infection. The American journal of gastroenterology, 2017, Volume: 112, Issue:2 Topics: Amoxicillin; Antacids; Anti-Bacterial Agents; Anti-Infective Agents; Bismuth; Clarithromycin; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans; Levofloxacin; Metronidazole; Proton Pump Inhibitors; Salvage Therapy; Treatment Failure	2017
The Irish Helicobacter pylori Working Group consensus for the diagnosis and treatment of H. pylori infection in adult patients in Ireland. European journal of gastroenterology & hepatology, 2017, Volume: 29, Issue:5 Topics: Adult; Anti-Bacterial Agents; Anti-Ulcer Agents; Biopsy; Bismuth; Breath Tests; Clarithromycin; Drug Administration Schedule; Drug Therapy, Combination; Evidence-Based Medicine; Helicobacter Infections; Helicobacter pylori; Humans; Proton Pump Inhibitors; Pyloric Antrum; Stomach	2017
The diagnosis and management of H. pylori infection in Singapore. Singapore medical journal, 2017, Volume: 58, Issue:5 Topics: Antacids; Anti-Bacterial Agents; Bismuth; Breath Tests; Clarithromycin; Drug Therapy, Combination; Dyspepsia; Gastroscopy; Helicobacter Infections; Helicobacter pylori; Humans; Levofloxacin; Singapore	2017
Evaluation of first-line bismuth-containing 7-day concomitant quintuple therapy for Helicobacter pylori eradication. Journal of digestive diseases, 2017, Volume: 18, Issue:12 Topics: Adult; Amoxicillin; Bismuth; Clarithromycin; Drug Therapy, Combination; Esomeprazole; Female; Helicobacter Infections; Helicobacter pylori; Humans; Male; Prospective Studies	2017
Macrolide use in the previous years is associated with failure to eradicate Helicobacter pylori with clarithromycin-containing regimens. Helicobacter, 2018, Volume: 23, Issue:1 Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Bismuth; Clarithromycin; Drug Resistance, Bacterial; Electronic Health Records; Female; Helicobacter Infections; Helicobacter pylori; Hospitals; Humans; Macrolides; Male; Middle Aged; Retrospective Studies; Spain; Treatment Failure; Young Adult	2018
Effects of Helicobacter pylori Treatment on Incidence of Gastric Cancer in Older Individuals. Gastroenterology, 2018, Volume: 155, Issue:1 Topics: Adult; Aged; Amoxicillin; Antacids; Anti-Bacterial Agents; Bismuth; Clarithromycin; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Hong Kong; Humans; Incidence; Levofloxacin; Male; Middle Aged; Protective Factors; Proton Pump Inhibitors; Registries; Retrospective Studies; Risk Factors; Stomach Neoplasms	2018
Helicobacter pylori eradication may successfully treat primary cutaneous follicle center lymphoma. Helicobacter, 2018, Volume: 23, Issue:4 Topics: Amoxicillin; Anti-Bacterial Agents; Bismuth; Clarithromycin; Doxycycline; Female; Helicobacter Infections; Helicobacter pylori; Humans; Lansoprazole; Lymphoma, B-Cell; Metronidazole; Middle Aged; Organometallic Compounds; Rabeprazole; Salicylates	2018
[Efficacy of bismuth containing quadruple therapies on Helicobacter pylori eradication in patients with history of antibiotic treatment]. Zhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciences, 2018, Jul-28, Volume: 43, Issue:7 Topics: Amoxicillin; Anti-Bacterial Agents; Bismuth; Clarithromycin; Drug Therapy, Combination; Furazolidone; Helicobacter Infections; Helicobacter pylori; Humans; Metronidazole; Proton Pump Inhibitors; Tinidazole; Treatment Outcome	2018
Outcomes of furazolidone- and amoxicillin-based quadruple therapy for World journal of gastroenterology, 2018, Oct-28, Volume: 24, Issue:40 Topics: Adult; Alcohol Drinking; Amoxicillin; Antacids; Anti-Bacterial Agents; Anti-Infective Agents, Local; Bismuth; Breath Tests; Clarithromycin; Drug Resistance, Bacterial; Drug Therapy, Combination; Female; Furazolidone; Helicobacter Infections; Helicobacter pylori; Humans; Male; Medication Adherence; Middle Aged; Patient Education as Topic; Proton Pump Inhibitors; Treatment Failure	2018
[Amoxicillin-Clarithromycin-Containing Bismuth Quadruple Therapy for Primary Eradication of Helicobacter pylori]. Zhongguo yi xue ke xue yuan xue bao. Acta Academiae Medicinae Sinicae, 2019, Feb-28, Volume: 41, Issue:1 Topics: Amoxicillin; Anti-Bacterial Agents; Bismuth; Clarithromycin; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans; Treatment Outcome	2019
Combination of Bismuth and Standard Triple Therapy Eradicates Helicobacter pylori Infection in More than 90% of Patients. Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association, 2020, Volume: 18, Issue:1 Topics: Adolescent; Adult; Aged; Aged, 80 and over; Amoxicillin; Anti-Infective Agents; Bismuth; Clarithromycin; Drug Resistance, Multiple, Bacterial; Drug Therapy, Combination; Europe; Female; Helicobacter Infections; Helicobacter pylori; Humans; Male; Middle Aged; Proton Pump Inhibitors; Registries; Treatment Outcome; Young Adult	2020
Editorial: not yet time for universal susceptibility-guided first-line Helicobacter pylori treatment. Alimentary pharmacology & therapeutics, 2019, Volume: 50, Issue:3 Topics: Bismuth; Clarithromycin; Helicobacter Infections; Helicobacter pylori; Humans	2019
Tailored Helicobacter pylori eradication based on prior intake of macrolide antibiotics allows the use of triple therapy with optimal results in an area with high clarithromycin resistance. Revista espanola de enfermedades digestivas, 2019, Volume: 111, Issue:9 Topics: Adult; Aged; Aged, 80 and over; Amoxicillin; Anti-Bacterial Agents; Bismuth; Clarithromycin; Drug Resistance, Bacterial; Drug Therapy, Combination; Electronic Health Records; Female; Helicobacter Infections; Helicobacter pylori; Humans; Intention to Treat Analysis; Macrolides; Male; Metronidazole; Microbial Sensitivity Tests; Middle Aged; Omeprazole; Prospective Studies; Proton Pump Inhibitors; Quinolones; Tetracycline; Young Adult	2019
Comparison of four different regimens against Helicobacter pylori as a first-line treatment: A prospective, cross-sectional, comparative, open trial in Chinese children. Helicobacter, 2020, Volume: 25, Issue:2 Topics: Adolescent; Amoxicillin; Anti-Bacterial Agents; Bismuth; Breath Tests; Child; China; Clarithromycin; Cross-Sectional Studies; Cytochrome P-450 CYP3A Inhibitors; Drug Administration Schedule; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Humans; Male; Metronidazole; Omeprazole; Prospective Studies; Proton Pump Inhibitors	2020
Helicobacter pylori first-line and rescue treatments in patients allergic to penicillin: Experience from the European Registry on H pylori management (Hp-EuReg). Helicobacter, 2020, Volume: 25, Issue:3 Topics: Anti-Bacterial Agents; Bismuth; Clarithromycin; Drug Hypersensitivity; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans; Levofloxacin; Metronidazole; Penicillins; Prospective Studies; Proton Pump Inhibitors; Registries; Tetracycline	2020
Non-bismuth and bismuth quadruple therapies based on previous clarithromycin exposure are as effective and safe in an area of high clarithromycin resistance: A real-life study. Helicobacter, 2020, Volume: 25, Issue:4 Topics: Adult; Antacids; Anti-Bacterial Agents; Bismuth; Case-Control Studies; Clarithromycin; Drug Administration Schedule; Drug Resistance, Bacterial; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Humans; Male; Middle Aged; Patient Compliance; Treatment Outcome	2020
[European registry on Helicobacter pylori management (Hp-EuReg) as a tool to evaluate and improve clinical practice in Moscow]. Terapevticheskii arkhiv, 2020, Apr-27, Volume: 92, Issue:2 Topics: Amoxicillin; Anti-Bacterial Agents; Bismuth; Clarithromycin; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans; Moscow; Prospective Studies; Proton Pump Inhibitors; Registries; Russia	2020
Long-term changes in the gut microbiota after 14-day bismuth quadruple therapy in penicillin-allergic children. Helicobacter, 2020, Volume: 25, Issue:5 Topics: Adolescent; Anti-Bacterial Agents; Bismuth; Child; Clarithromycin; Cross-Sectional Studies; Drug Hypersensitivity; Dysbiosis; Gastrointestinal Microbiome; Helicobacter Infections; Helicobacter pylori; Humans; Metronidazole; Omeprazole; Penicillins; Prospective Studies; Proton Pump Inhibitors	2020
Helicobacter pylori and antibiotic resistance in the pediatric population: an update from Vietnam. Minerva medica, 2020, Volume: 111, Issue:5 Topics: Amoxicillin; Bismuth; Child; Clarithromycin; Drug Resistance, Bacterial; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans; Metronidazole; Omeprazole; Probiotics; Proton Pump Inhibitors; Vietnam	2020
Efficacy of Sucralfate-Combined Quadruple Therapy on Gastric Mucosal Injury Induced by BioMed research international, 2020, Volume: 2020 Topics: Amoxicillin; Animals; Bismuth; Clarithromycin; Drug Therapy, Combination; Gastric Mucosa; Gastritis; Gastrointestinal Microbiome; Helicobacter Infections; Helicobacter pylori; Humans; Mice; Proton Pump Inhibitors; Rabeprazole; Sucralfate	2020
Efficacy of a novel sequential treatment regimen containing bismuth for Helicobacter pylori eradication in Turkish children. Helicobacter, 2020, Volume: 25, Issue:6 Topics: Adolescent; Amoxicillin; Anti-Bacterial Agents; Bismuth; Child; Clarithromycin; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Humans; Metronidazole; Treatment Outcome; Turkey	2020
Helicobacter pylori Eradication Rates in Slovenia in the Period from 2017 to 2019: Data from the European Registry on H. pylori Management. Digestive diseases (Basel, Switzerland), 2021, Volume: 39, Issue:4 Topics: Adult; Amoxicillin; Anti-Bacterial Agents; Bismuth; Clarithromycin; Disease Eradication; Drug Therapy, Combination; Female; Health Plan Implementation; Helicobacter Infections; Helicobacter pylori; Humans; Intention to Treat Analysis; Levofloxacin; Male; Metronidazole; Middle Aged; Proton Pump Inhibitors; Registries; Slovenia	2021
Modified bismuth quadruple therapy with low-dose metronidazole as first-line therapy for Helicobacter pylori infection. Helicobacter, 2021, Volume: 26, Issue:1 Topics: Amoxicillin; Anti-Bacterial Agents; Bismuth; Clarithromycin; Drug Resistance, Bacterial; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans; Metronidazole; Pilot Projects; Prospective Studies	2021
Adherence to Maastricht V/Florence consensus report for the management of Helicobacter pylori infection among primary care physicians and medical students in Croatia: A cross-sectional study. Helicobacter, 2021, Volume: 26, Issue:2 Topics: Amoxicillin; Anti-Bacterial Agents; Bismuth; Clarithromycin; Croatia; Cross-Sectional Studies; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans; Physicians, Primary Care; Proton Pump Inhibitors; Students, Medical	2021
Recent Developments Pertaining to H. pylori Infection. The American journal of gastroenterology, 2021, 01-01, Volume: 116, Issue:1 Topics: Adenocarcinoma; Amoxicillin; Antacids; Anti-Bacterial Agents; Bismuth; Clarithromycin; Drug Resistance, Bacterial; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans; Metronidazole; Microbial Sensitivity Tests; Omeprazole; Practice Guidelines as Topic; Proton Pump Inhibitors; Pyrroles; Rifabutin; Stomach Neoplasms; Sulfonamides; Tetracycline; Treatment Outcome	2021
Dual Clarithromycin and Metronidazole Resistance Is the Main Cause of Failure in Ultimate Helicobacter pylori Eradication. Digestive diseases (Basel, Switzerland), 2021, Volume: 39, Issue:5 Topics: Anti-Bacterial Agents; Bismuth; Clarithromycin; Drug Resistance, Bacterial; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans; Metronidazole; Proton Pump Inhibitors	2021
Impact of Antimicrobial Resistance Rates on Eradication of Helicobacter pylori in a US Population. Gastroenterology, 2021, Volume: 160, Issue:6 Topics: Adolescent; Adult; Aged; Aged, 80 and over; Ampicillin; Bismuth; Child; Child, Preschool; Clarithromycin; Drug Resistance, Bacterial; Drug Therapy, Combination; Female; Fluoroquinolones; Helicobacter Infections; Helicobacter pylori; Humans; Male; Metronidazole; Middle Aged; Rhode Island; Rifabutin; Tetracycline; Young Adult	2021
Preliminary single-center experience of Helicobacter pylori eradication among the liver transplant recipients. Helicobacter, 2021, Volume: 26, Issue:3 Topics: Amoxicillin; Anti-Bacterial Agents; Bismuth; Case-Control Studies; Clarithromycin; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans; Liver Transplantation; Transplant Recipients	2021
Efficacy of bismuth added to standard triple therapy as the first-line eradication regimen for Helicobacter pylori infection. Helicobacter, 2021, Volume: 26, Issue:3 Topics: Amoxicillin; Anti-Bacterial Agents; Bismuth; Clarithromycin; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans; Prospective Studies; Treatment Outcome	2021
Cost-Effectiveness of Empirical Bismuth-Based Quadruple Therapy and Tailored Therapy After Clarithromycin Resistance Tests for Helicobacter pylori Eradication. Digestive diseases and sciences, 2022, Volume: 67, Issue:4 Topics: Amoxicillin; Anti-Bacterial Agents; Bismuth; Clarithromycin; Cost-Benefit Analysis; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans; Proton Pump Inhibitors; Retrospective Studies	2022
Clinical audit of current Singapore medical journal, 2022, Volume: 63, Issue:9 Topics: Amoxicillin; Anti-Bacterial Agents; Bismuth; Clarithromycin; Clinical Audit; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans; Metronidazole; Proton Pump Inhibitors; Singapore; Treatment Outcome	2022
Adherence to international guidelines for the management of Helicobacter pylori infection among gastroenterologists and gastroenterology fellows in Italy: A Survey of the Italian Federation of Digestive Diseases - FISMAD. Helicobacter, 2022, Volume: 27, Issue:1 Topics: Amoxicillin; Anti-Bacterial Agents; Bismuth; Clarithromycin; Drug Therapy, Combination; Gastroenterologists; Gastroenterology; Helicobacter Infections; Helicobacter pylori; Humans; Proton Pump Inhibitors; Surveys and Questionnaires	2022
Empirical Second-Line Therapy in 5000 Patients of the European Registry on Helicobacter pylori Management (Hp-EuReg). Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association, 2022, Volume: 20, Issue:10 Topics: Adult; Amoxicillin; Anti-Bacterial Agents; Bismuth; Clarithromycin; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans; Levofloxacin; Moxifloxacin; Penicillins; Prospective Studies; Proton Pump Inhibitors; Quinolones; Registries; Tetracycline	2022
Expert review of gastroenterology & hepatology, 2022, Volume: 16, Issue:4 Topics: Adult; Amoxicillin; Anti-Bacterial Agents; Bismuth; Clarithromycin; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans; Proton Pump Inhibitors; Stomach Neoplasms; Systematic Reviews as Topic; Treatment Failure	2022
Second-line Therapy for Helicobacter Pylori Eradication: State of the Art. Mini reviews in medicinal chemistry, 2022, Volume: 22, Issue:19 Topics: Amoxicillin; Anti-Bacterial Agents; Bismuth; Clarithromycin; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans; Levofloxacin; Metronidazole; Proton Pump Inhibitors; Tetracycline	2022
Helicobacter pylori eradication in elderly patients: can we assume that a bismuth-based therapy is effective as in young people? Panminerva medica, 2022, Volume: 64, Issue:2 Topics: Adolescent; Aged; Amoxicillin; Anti-Bacterial Agents; Bismuth; Clarithromycin; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans; Proton Pump Inhibitors; Treatment Outcome	2022
Effective Eradication Regimen and Duration According to the Clarithromycin Susceptibility of Gut and liver, 2023, 09-15, Volume: 17, Issue:5 Topics: Amoxicillin; Anti-Bacterial Agents; Bismuth; Clarithromycin; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans; Multiplex Polymerase Chain Reaction; Oligonucleotides; Retrospective Studies	2023
Bismuth-Based Quadruple Therapy for Clarithromycin-Resistant Gut and liver, 2022, 11-15, Volume: 16, Issue:6 Topics: Amoxicillin; Anti-Bacterial Agents; Bismuth; Clarithromycin; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans; Proton Pump Inhibitors; Treatment Outcome	2022
Cost-Effectiveness of Vonoprazan-Based and Rifabutin-Based vs Other Regimens as First-Line Treatment of Helicobacter pylori Infection in the United States. The American journal of gastroenterology, 2023, 04-01, Volume: 118, Issue:4 Topics: Amoxicillin; Anti-Bacterial Agents; Bismuth; Clarithromycin; Cost-Benefit Analysis; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans; Proton Pump Inhibitors; Rifabutin; Treatment Outcome; United States	2023
Can the optimal treatment duration be determined in bismuth-containing therapies for Helicobacter pylori eradication? Clinical and experimental medicine, 2023, Volume: 23, Issue:7 Topics: Anti-Bacterial Agents; Bismuth; Clarithromycin; Drug Therapy, Combination; Duration of Therapy; Helicobacter Infections; Helicobacter pylori; Humans; Treatment Outcome	2023
Efficacy of 7-day Tailored Therapy for The Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi, 2023, 07-25, Volume: 82, Issue:1 Topics: Bismuth; Clarithromycin; Helicobacter pylori; Humans	2023
Real-world practice of Helicobacter pylori management: A survey among physicians in Southeast Asia. Helicobacter, 2023, Volume: 28, Issue:6 Topics: Amoxicillin; Anti-Bacterial Agents; Asia, Southeastern; Bismuth; Clarithromycin; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans; Metronidazole; Physicians; Proton Pump Inhibitors; Surveys and Questionnaires	2023
Helicobacter pylori Empirical and Tailored Eradication Therapy and Factors Influencing Eradication Rate: a 4-Year Single-Center Study. Clinical laboratory, 2023, Oct-01, Volume: 69, Issue:10 Topics: Anti-Bacterial Agents; Bismuth; Clarithromycin; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans; Retrospective Studies; Treatment Outcome	2023